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SUMMARY 
An association between breast cancer (BC) and thyroid autoimmunity (TA) has 
been frequently observed and several small-scale studies correlated the presence 
of thyroid peroxidase (TPO) autoantibodies (TPOAb) with an improved BC 
outcome. The presence of an immune response to shared thyroid/breast antigens 
has been hypothesized: both tissues express the sodium iodide symporter (NIS) and 
have a peroxidase activity: TPO in thyroid and lactoperoxidase (LPO) in breast. I 
have identified 3 possibilities: i) BC patients with TPOAb may also have 
autoantibodies to NIS (NISAb) ii) BC may express TPO iii) TPOAb may cross-react 
with LPO in BC. This thesis aimed to identify the TA/BC shared antigen(s) and also 
investigated the prognostic role of TPOAb in a large cohort of BC patients. 
The presence of NISAb was investigated by flow cytometry using CHO cells stably 
transfected with human NIS. No positive response was obtained in 42 patients with 
BC and/or TA, therefore NIS is unlikely to be an antigen. 
TPO transcripts (RT-PCR, QPCR, LongRange PCR) and protein (western blot, 
immunohistochemistry, immunofluorescence) were detected in BC tissues but at 
levels 104 times less than in thyroid tissue. TPO was also expressed in adipose 
tissue and different cancers. Some potentially BC specific TPO isoforms were 
identified. 
The observational large-scale study conducted on 1974 women affected with BC 
did not reveal any evidence for a significant impact of TPOAb and/or thyroid 
function on BC prognosis. 
In conclusion, BC and thyroid tissues share similar properties and could be 
common targets of TA, with TPO being the most likely common antigen; further 
studies are needed to clarify the role of tissue-specific TPO isoforms. The roles of 
TPOAb and thyroid function on BC prognosis have to be reconsidered, maybe 
focusing on different TA aspects (e.g. goitre, different autoantibodies). 
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1 GENERAL INTRODUCTION 
1.1 THE THYROID GLAND 
1.1.1 Anatomy and histology 
The thyroid is one of the largest endocrine glands and is located in the 
neck, just below the larynx. It is made of two lateral lobes, right and left, 
connected by a central isthmus, with occasionally an accessory pyramidal lobe 
discernible as a finger-like projection directed upward from the isthmus. Behind 
the thyroid are located the parathyroid glands, different endocrine glands 
involved in calcium metabolism (1) (Figure 1-1). 
Figure 1-1. Thyroid anatomy 
 
Adapted from © 2012 Terese Winslow LLC. Panel A: localization of the thyroid in the neck. 
Panel B: details of thyroid gland 
 
The structure of the gland is composed of closely packed follicles, 
spherical units characterized by a lumen containing proteinaceous colloid 
surrounded by a continuous single layer of thyroid epithelial cells, named 
thyrocytes or follicular cells (Figure 1-2). The diameter of the follicles varies 
considerably, even within a single gland, but averages about 200 nm. The 
follicular cells vary in height with the degree of glandular stimulation, becoming 
columnar when active and cuboidal when inactive. The epithelium rests on a 
basement membrane that is rich in glycoproteins and separates the follicular cells 
from the surrounding capillaries. Between 20 and 40 follicles are demarcated by 
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connective tissue septa to form a lobule supplied by a single artery. The 
functional activity of a given lobule may differ from that of its neighbors. The 
thyroid gland contains also calcitonin-producing parafollicular cells (C cells), 
usually localized along the basement membrane of the thyroid epithelium (1). 
Figure 1-2: Thyroid histology  
 
Panel A, adapted from (2): schematic representation of thyroid histology. Panel B, 
adapted from (3): cross-section of thyroid tissue with hematoxylin and eosin stain (H&E 
stain).  
1.1.2 Physiology and synthesis of thyroid hormones 
The thyrocytes’ main function is producing thyroid hormones thyroxine 
(T4) and triiodothyronine (T3), homodimer peptides deriving from the iodination 
and coupling of the amino acid L-tyrosine (Figure 1-3). 
Figure 1-3: Structures of thyroid hormones and their precursors 
 
Adapted from NEUROtiker, Brenton, Hoffmeier (https://commons.wikimedia.org). MIT= 
3-monoiodo-L-tyrosine; DIT= 3,5-diiodo-L-tyrosine; T3= triiodothyronine; T4= thyroxine. 
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The synthesis of thyroid hormones is a complex process involving different 
and polarized activities of the thyrocytes (1) (Figure 1-4): 
v The basolateral cell membrane is in contact with the blood circulation, from 
where it takes up the necessary elements to synthetize T3 and T4: amino acids 
and iodide ion (I-) by the sodium iodide symporter (NIS), a transmembrane 
glycoprotein. 
v Inside the thyrocytes two of the main thyroid proteins implicated in thyroid 
hormone production are thyroglobulin (Tg) and thyroid peroxidase (TPO). Tg is 
secreted through the apical membrane inside the follicular lumen and it 
represents the major component of colloid. TPO is a transmembrane protein 
and is located on the apical membrane of thyrocytes.  
v The apical border is the key site where T3 and T4 are synthetized. I- is 
transported into the follicular lumen by a transporter called Pendrin situated 
on the apical membrane. In the follicular lumen specific tyrosine residues of 
Tg homodimers are iodinated to form 3-monoiodo-L-tyrosine (MIT) and 3,5-
diiodo-L-tyrosine (DIT), the precursors of thyroid hormones. TPO catalyzes the 
oxidation of I- and its transfer to tyrosine; this process requires the formation 
of hydrogen peroxide (H2O2) that is produced by the transmembrane enzymes 
dual oxidase 1 (DUOX1) and DUOX2. TPO also catalyzes the fusion of two DIT 
molecules in order to synthetize T4 and of one MIT and one DIT to produce T3. 
At this stage MIT, DIT, T3 and T4 are still attached to Tg protein and stored in 
the colloid. 
When the thyroid has to release T3 and T4, a multi-step process is activated: 
v Apical membrane of thyrocytes: endocytosis of colloid from the follicular 
lumen through both macropinocytosis (pseudopods) and micropinocytosis 
(small coated vescicles). 
v Inside the thyrocytes: endocytic vescicles fuse with lysosomes and proteolysis 
determines the release of iodotyrosines (MIT, DIT, T3, T4) from Tg. MIT and 
DIT are then deiodinated by the iodotyrosine dehalogenase (IYD),encoded by 
the IYD gene, to allow recycling of the iodide together with Tg. 
v On the basolateral side of thyrocytes, T3 and T4 are secreted into the blood 
stream through transmembrane protein transporters, including the 
monocarboxylate transporter 8 (MCT8), specific for the transport of thyroid 
hormones (4).  
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Figure 1-4: Thyrocyte structure and thyroid hormone synthesis 
 
DIT= 3,5-diiodo-L-tyrosine; DUOX1= dual oxidase 1; DUOX2= dual oxidase 2; H2O2= hydrogen 
peroxide; IYD= iodotyrosine dehalogenase; I-= iodide; MCT8= monocarboxylate transporter 
8; MIT= 3-monoiodo-L-tyrosine; Na+= sodium; NIS= sodium iodide symporter; Tg= 
thyroglobulin; TPO= thyroid peroxidase; T3 = triiodothyronine; T4= thyroxine. 
1.1.3 Hypothalamic – Pituitary –Thyroid Axis 
The thyroidal secretion of T3 and T4 is controlled by the thyroid-stimulating 
hormone or thyrotropin (TSH), a peptide produced by endocrine cells in the 
anterior pituitary named thyrotrophs (5). TSH production is regulated by two 
interacting systems (Figure 1-5): 
1) open-loop neural control by hypothalamic hypophysiotropic factors 
2) negative feedback by thyroid hormones 
The neural control is mainly exerted by the thyrotropin-releasing hormone 
(TRH), a peptide produced by the paraventricular neurons of the hypothalamus 
that binds to specific receptors on the plasma membrane of the thyrotrophs, 
stimulating their production of TSH (5). TSH secretion is also influenced by other 
hormones including oestrogens, glucocorticoids and possibly growth hormone 
(GH), while it is inhibited by cytokines in the pituitary and hypothalamus (6).  
Thyroid hormones, both T3 and T4, exert their negative feedback control 
on both the pituitary and the hypothalamus, determining a reduction in TRH and 
TSH release. Circulating T3 and T4 are transported inside the brain, where T4 is 
converted into T3 by type II deiodinase and then T3 interacts with thyroid 
hormone receptors (7). 
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Figure 1-5: Hypothalamic – Pituitary – Thyroid Axis 
 
Modified from Hiller-Sturmhöfel S et al. (8). TSH = thyroid-stimulating hormone; TRH = 
thyrotropin-releasing hormone; T3 = triiodothyronine; T4 = thyroxine; += activation; -= 
inhibition. 
 
TSH binds to its specific receptor (TSHR) located on the basolateral 
membrane of thyrocytes and exerts several functions acting via different 
intracellular signaling cascades. TSH main actions include: 1) induction of thyroid 
hormone synthesis 2) stimulation of endocytosis on the apical membrane, causing 
internalization and digestion of colloid with consequent thyroid hormone release 
into the blood from the basolateral membrane 3) maintenance of trophic thyroid 
cell integrity and tropism (9). In particular, two main aspects of thyroid hormone 
synthesis induction are: A) Tg/TPO/NIS genes transcription induction via adenylate 
cyclase (AC), an enzyme that catalyzes the conversion of adenosine triphosphate 
(ATP) to 3',5'-cyclic adenosine monophosphate (cAMP) and pyrophosphate B) H2O2 
generation via Gq–phospholipase C cascade leading to increased intracellular 
levels of diacylglycerol  and calcium ion (Ca2+) (10). 
TSH is a glycoprotein hormone composed by two subunits: α and β. The β 
subunit is unique to TSH and therefore determines its receptor specificity. The α 
subunit contains the effector region and it is nearly identical to other hormones, 
such as the human chorionic gonadotropin (hCG), luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) (5). 
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1.1.4 Transport and metabolism of thyroid hormones 
T4 and T3 are released by the thyroid gland with a 10:1 ratio. They are 
both poorly soluble in water and therefore bind reversibly to plasma proteins, 
principally thyroxine-binding globulin (TBG) and less to transthyretin and albumin. 
The small amount of hormones that is not bound to such proteins, respectively 
0.02% for T4 and 0.3% for T3, is that available for uptake by peripheral tissues. 
This fraction is called free-T4 (FT4) and free-T3 (FT3) and is determined by the 
concentration and degree of saturation of these proteins, especially TBG (1).  
For this reason in clinical practice the thyroid status correlates with FT4 
and FT3, not with T4 and T3. The normal serum concentrations are usually within 
the range of respectively 9 to 30 pmol/L (0.7 to 2.5 ng/dL) for FT4 and 3 to 8 
pmol/L (0.2 to 0.5 ng/dL) for FT3 (1). There is a linear inverse relationship 
between the serum FT4 concentration and the logarithm (log) of the TSH, making 
the serum TSH concentration an exquisitely sensitive indicator of the thyroid state 
of patients with an intact hypothalamic-pituitary axis (1). As will be better 
explained in paragraph 1.2.4, the term “euthyroidism” defines the situation when 
FT4, FT3 and TSH are within the normal range, while the terms “hypothyroidism” 
and “hyperthyroidism” define a situation of reduced FT4,FT3/increased TSH and 
increased FT4,FT3/decreased TSH levels, respectively.  
The transport of T3 and T4 across the cell membrane of peripheral target 
organs is mainly mediated by transporter proteins, including MCT8 (4).   
Despite T4 being the most abundant hormone produced by the thyroid 
gland, the principal effector in the target cells is T3, 80% of which is derived from 
T4 by deiodinases in the peripheral tissues that catalyze the removal of a single 5’ 
iodine atom from T4 (11). In particular there are 3 types of deiodinases: 
deiodinase 1 (D1), deiodinase 2 (D2) and deiodinase 3 (D3). Both D1 and D2 
produce T3 from T4 but they differ in terms of tissue location and regulation. In 
particular D1 is mainly present in liver and kidney, while D2 is mainly located in 
the central nervous system, pituitary, skeletal muscle, brown adipose tissue, 
placenta and heart. D3 has a different function in deactivating both T3 and T4 and 
it is mainly located in the central nervous system, placenta, liver and skeletal 
muscle (1). 
T3 and T4 are partly degraded intracellularly before exit by peripheral 
deiodinases (12). Another pathway involved in T4 metabolism is the hepatic 
glucuronidation of the phenolic hydroxyl group by the uridine diphosphate 
glucuronyl transferases (UDPGT) in the liver, but only minimal amounts of T3 
undergo this process (13).  
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1.1.5 Actions of thyroid hormones 
Thyroid hormones act by binding to a specific nuclear thyroid hormone 
receptor (TR); T3 has a 15-fold higher binding affinity for TRs than does T4, 
explaining its function as the active thyroid hormone. When bound to T3, TR binds 
to DNA usually as heterodimer with retinoid X receptor at specific sequences 
called thyroid hormone response elements (TREs) (1). There are two TR genes, α 
and β, that are subjected to alternative splicing forming both active and inactive 
gene products. The active proteins are TRα1, TRβ1, TRβ2 and TRβ3 (14) and there 
are tissue-specific preferences in expression of the various TRs, suggesting that 
they serve different functions in different tissues (15). In general, TRα, 
particularly TRα2, is thought to be important in the hypothalamus and pituitary 
where regulation of thyroid function occurs (16).  
T3 and T4 exert several physiological actions on many different target 
organs and systems, including the control of metabolic rate, regulation of growth, 
positive chronotropic and inotropic cardiac effects and development of the 
central nervous system (17). Thyroid hormones are essential during organogenesis 
and after birth during infancy and childhood. However thyroid hormones are very 
important also in adult life and the principal effects of thyroid hormones on target 
organs are summarized in Table 1-1 (1, 17). 
Table 1-1: Actions of thyroid hormones on target organs 
CARDIOVASCULAR SYSTEM § ê peripheral vascular resistance 
§ Positive chronotropic and inotropic cardiac effects 
METABOLISM § é basal metabolic rate  
§ é heat production  
§ é both protein synthesis/degradation 
§ é both lipogenesis and lipolysis 
CENTRAL AND PERIPHERAL 
NERVOUS SYSTEM 
§ é sensitivity to catecholamines  
§ Cortical and cerebellar development 
§ Myelination 
SKELETAL SYSTEM § Regulation of bone turnover 
KIDNEY  § é renal blood flow, glomerular filtration and tubular 
reabsorptive and secretory maxima 
HEMATOPOIETIC SYSTEM § é erythropoiesis 
REPRODUCTIVE SYSTEM § Regulation of amplitude and frequency of LH/FSH pulses 
§ é liver production of sex-hormone-binding globulin (SHBG)  
§ é conversion of androgens to oestrogenic products 
PITUITARY AND 
HYPOTHALAMUS 
§ ê TSH and TRH secretion 
FSH= follicle-stimulating hormone; LH= luteinizing hormone; SHBG= sex-hormone-binding 
globulin; TSH= thyroid-stimulating hormone; TRH= thyrotropin-releasing hormone; é= 
increase; ê= decrease. 
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1.2 THYROID DISORDERS 
Benign thyroid disorders are very common and have a clear female 
preponderance (1). In this thesis they have been subdivided into distinct topics 
such as thyroiditis, thyroid autoimmunity, goitre and alterations of thyroid 
function, and they will be discussed separately in the next paragraphs. In a final 
paragraph a brief overview of thyroid cancer will be also described.  
1.2.1 Thyroiditis  
The term thyroiditis indicates the presence of thyroid inflammation and 
comprises a very large group of inflammatory conditions summarized in Table 1-2, 
including autoimmune, infectious (viral, bacterial, fungal), sclerosing (Riedel’s 
thyroiditis) or granulomatous (sarcoidosis) etiopathogenesis.  
Table 1-2: Classification of thyroiditis 
 
 
Thyroiditis does not affect thyroid function directly but may cause 
hypothyroidism by the damage to the thyroid gland. In the early stages of 
thyroiditis, a transient excessive release of thyroid hormones by the damaged 
thyroid gland can result in a condition of excessive serum levels of thyroid 
hormones, called “thyrotoxicosis” (1).  
Acute thyroiditis is very rare and usually caused by bacterial or fungal 
infections. It is characterized by local pain and tenderness and difficulty in 
swallowing is often present. It is usually accompanied by general malaise and 
fever and increased erythrocyte sedimentation rate (ESR) (18).  
Subacute thyroiditis has different clinical manifestations according to its 
pathogenesis. If it has an infectious (viral) origin it is called De Quervain’s 
thyroiditis and usually is characterized by clinical and biochemical features similar 
to acute thyroiditis. However De Quervain’s thyroiditis is usually diffuse, while 
acute thyroiditis is usually more localized as a painful isolated nodular 
enlargement of the thyroid. Postpartum thyroiditis is a different form of subacute 
thyroiditis, with a classical onset during the first months after delivery. In 
contrast to De Quervain’s, postpartum thyroiditis is not usually associated with 
ACUTE Suppurative thyroiditis Bacterial, fungal 
SUBACUTE 
De Quervain’s  Viral 
Postpartum (silent) Autoimmune 
CHRONIC 
Autoimmune thyroiditis (AITD) Autoimmune 
Post irradiation Iatrogenic (radioiodine, radiations) 
Riedel’s thyroiditis Sclerosis 
Sarcoidosis Granulomatous 
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general symptoms or ESR alterations but with positivity for anti-thyroid 
autoantibodies (TAb), as will be better explained in the next paragraph 1.2.2 (18). 
The most common form of chronic thyroiditis has autoimmune origins and 
it will be better discussed in the next paragraph 1.2.2. A second important group 
is related to iatrogenic chronic thyroiditis induced by radioiodine treatment or 
external radiation therapy. Finally, rare forms of chronic thyroiditis include 
Riedel’s thyroiditis, characterized by fibrosis of the thyroid gland and adjacent 
structures but its origin remains uncertain, (19) or granulomatous diseases such as 
sarcoidosis (1).   
1.2.2 Thyroid autoimmunity 
Thyroid autoimmunity (TA) is the most common autoimmune disease in 
humans and accounts for two main types of disease: autoimmune thyroiditis 
(AITD) and Graves’ disease (GD) (20). Early post-mortem studies confirmed 
histological evidence of chronic AITD in 27% of adult women and 7% of adult men 
with an increase in frequency in the past 50 years. GD is also the principal cause 
of hyperthyroidism (21).    
1.2.2.1 Brief overview of immunology and immunological synapse  
Our immune system consists of innate and adaptive immune responses 
against a wide range of pathogens (bacteria, viruses, etc.). In the present thesis a 
brief overview of the adaptive immune responses, mediated mainly by B and T-
lymphocytes, will be provided, based on (22). 
Both B and T-lymphocytes, through their surface receptors, recognize a 
specific and short sequence (usually amino acidic; called “epitope”) of a molecule 
(usually a protein; called “antigen”) that triggers the immune reaction. Both B 
and T-lymphocytes’ receptors consist of variable and constant regions; the 
variable region is the part recognizing the antigen, while the constant region has 
other functional activities. The variable regions are generated through a process 
of intense gene rearrangements leading to a great variability, therefore 
generating receptors recognizing a multitude of different antigens.     
Both B and T-lymphocytes originate from precursors in the bone marrow 
and then undergo a process called “central tolerance”, where B and T-
lymphocytes strongly recognizing self-antigens (antigens expressed by our own 
body), are inactivated and eliminated; this process happens in bone marrow and 
thymus respectively for B and T-lymphocytes.  
B-lymphocytes’ antigen-receptor consists of surface immunoglobulins (Igs) 
directed versus specific antigens. Igs are complex proteins characterized by a 
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total of 4 different amino acidic chains, two heavy and two light, both types 
containing constant (Fc) as well as variable (Fab) regions.  
T-lymphocytes, in addition to their antigen-receptor (TCR), express surface 
molecules with crucial roles for the adaptive immune response, as shown in Figure 
1-6. In particular, CD4 and CD8 are co-receptor molecules identifying 2 subtypes 
of effector T-lymphocytes with different tasks, as explained later. 
In order to be recognized by T-lymphocytes, antigens need to be presented 
by antigen-presenting cells (APC) through particular transmembrane glycoproteins 
belonging to the mammalian major histocompatibility complex (MHC) family, and 
referred to also as the human leukocyte antigen (HLA) system in humans. Briefly, 
intracellular antigens (e.g. virus) are expressed on APC’s surface through MHC 
class I (MHC-I), while extracellular antigens (e.g. secreted bacterial toxins) are 
internalized by APCs and then expressed on their surface through MHC class II 
(MHC-II). There are different MHC proteins in humans: the major subtypes of MHC-
I and MHC-II molecules are respectively HLA-A, HLA-B, HLA-C (type I) and HLA-DP, 
HLA-DQ, HLA-DR (type II).  
T-lymphocytes require two different signals from APC to be activated. The 
first signal is antigen-specific and provided by the interaction of TCR with antigen-
MHC complex expressed on APC’s membrane. The second signal is not antigen 
specific and called “co-stimulatory signal”; it is provided by the interaction 
between additional co-stimulatory molecules expressed on the membrane of both 
T-lymphocytes and APC. The interface between APCs and T-lymphocytes is called 
the immunological synapse and comprises the interaction between surface 
molecules expressed by APC and T-lymphocytes leading to activation of both cells 
and is the basis of the adaptive immune response (Figure 1-6). The description of 
such molecules’ function is beyond the aim of the present thesis. Briefly, in 
addition to TCR and CD4/CD8, T-lymphocytes’ surface proteins may be adhesion 
molecules such as CD44, important activating/co-stimulatory molecules such as 
CD3 or inhibitory molecules such as cytotoxic T lymphocyte-associated molecule-4 
(CTLA4). T-lymphocytes depend from co-stimulatory signals for their 
differentiation, proliferation and survival; absence of co-stimulation may lead to 
T-lymphocytes’ anergy (impossibility to respond to their specific antigen) and 
depletion or the development of immune tolerance. APC use the same co-
stimulatory molecules to be activated as well; e.g. APC express the CD40, a co-
stimulatory protein that, after binding with the correspondent ligand on T-
lymphocytes surface (CD40L), activates APCs. Both stimulating and inhibitory 
molecules, as well as HLAs, are likely to be involved in the pathogenesis of thyroid 
autoimmunity (TA), as explained in the next paragraph.  
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Figure 1-6: Immunological synapse 
 
Adapted from (23). Profile view of a T-lymphocyte (T-lymph) and an antigen-presenting 
cell (APC) and some of the key signaling molecules and ligand pairs involved in the T-
lymph/APC interaction. The antigen(peptide)-MHC complex is shown in red; in blue 
activating/co-stimulatory molecules; in yellow inhibitory molecules; in grey molecules not 
contributing to signaling. The arrow indicates converging signals leading to T-lymphocyte 
activation.  
 
As a consequence of the interaction between APCs and T-lymphocytes, two 
main kinds of adaptive immunity may arise: humoral or cell-mediated, more 
effective against extracellular and intracellular pathogens respectively. In 
summary, the humoral immunity consists in antigen-MHC-II APC’s complex 
triggering CD4 T-lymphocytes type II (Th2) that activate B-lymphocytes. Activated 
B-cells differentiate into “plasma cells” that secrete Igs against a specific antigen, 
called antibodies (Abs), in order to eliminate the extracellular bacteria or toxins. 
The cell-mediated immunity is composed by 2 main mechanisms: 1) antigen-MHC-II 
APC’s complex triggers CD4 T-lymphocytes type I (Th1) with consequent activation 
of the bactericidal activity of macrophages; 2) APC’s antigen-MHC-I complex 
triggers CD8 T-lymphocytes that directly kill the APC (and therefore also the 
intracellular pathogen infecting the cell).   
Another important class of T-lymphocytes are the regulatory T-cells (Treg), 
involved in the “peripheral tolerance”. As previously described, the process of 
central tolerance in bone marrow (B-lymphocytes) and thymus (T-lymphocytes) is 
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essential in order to suppress self-reactive immune cells. However, some of them 
may escape this process and the peripheral tolerance operated by Tregs, which 
act to eliminate self-reactive peripheral auto-reactive lymphocytes, is essential in 
order to maintain the immunological self-tolerance (24, 25).   
1.2.2.2 Etiopathogenesis of thyroid autoimmunity (TA) 
TA results from the breaking of tolerance to self-antigens of the thyroid 
and different mechanisms are involved: mainly cell-mediated for AITD and 
antibody-mediated for GD  (26).  
Thyroid autoimmune diseases are characterized by increased lymphocytic 
infiltration into the thyroid (27, 28) and thyrocytes have been described 
expressing CD40 under stressful conditions, therefore, as briefly explained in the 
previous paragraph, potentially acting as APCs and participating in the immune 
activation (29).  
Several possible mechanisms have been postulated to explain the rise of 
TA, from genetic predisposition (30) to environmental factors including infections, 
iodine excess, selenium deficiency, stress, allergy, female hormones, foetal 
microchimerism, smoking, irradiation and drugs (31, 32).  
v Genetic predisposition.  
1) HLA system is crucial for the antigen presentation process and therefore 
very often involved in genetic predisposition for autoimmunity in general. Both 
HLA class I and II genes have been consistently associated with TA, especially 
with GD (33, 34). In particular, HLA-DR is a class II HLA gene that plays a 
critical role in antigen presentation and HLA-DR3 allele has a well-established 
association with GD but it may be also involved in AITD (35).  
2) Signaling molecules involved in the immunological synapse between T-
lymphocytes and APCs may represent another important source of genetic 
predisposition to autoimmunity (36, 37). In particular, CTLA-4 is associated 
with both GD and AITD, while CD40 is GD specific (30). The protein tyrosine 
phosphatase non-receptor type 22 (PTPN22) is a gene encoding the cell 
signaling molecule lymphoid tyrosine phosphatase (LYP), which inhibits the 
activation of T cells by interacting with other signal transduction molecules. 
Initial studies demonstrated an association between certain PTPN22 alleles and 
TA susceptibility, in particular GD (38).  
3) Treg and peripheral tolerance are logically another important possible 
cause of general predisposition to autoimmunity. The forkhead box P3 (FOXP3) 
is a known crucial regulator of the differentiation and function of Treg and 
various FOXP3 polymorphisms have been reported to be associated with AITD 
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(30). Similarly, CD25 is the α-chain of interleukin-2 (IL-2) receptor and is 
involved in the regulation of T cell function and mediates IL-2 signaling, 
indispensable for Treg survival and growth (39). Genetic variants of CD25 gene 
have been found to predispose mainly to GD (40, 41).   
4) Finally, thyroid specific genes may be involved in loss of central 
tolerance leading specifically to TA. The target antigens for autoreactive 
lymphocytes in TA are Tg and TPO proteins for AITD and the TSHR for GD. The 
role of these antigens and their correspondent genes will be described in more 
detail in the paragraphs below (1.2.2.3 and 1.2.2.4).  
v Epigenetic mechanisms. There are different controversial definitions for 
epigenetic mechanisms and effects; they generally indicate non-coding effects 
on gene expression and function that are mitotically stable, thus long lasting. 
They include DNA methylation, histone modifications and ribonucleic acid 
(RNA) interference by microRNA (miRNA) (42). This is a relatively recent 
research field and an increasing number of studies suggest a crucial role of 
genetic-epigenetic interactions in the cases where one of the above mentioned 
genetic susceptibility variants is present. This would explain why the genetic 
risk factors alone cannot trigger the disease without other non-genetic 
modifier and epigenetics is one of the major ones. Epigenetics could also 
represent the mechanism of interaction between an environmental factor and 
genetic susceptibility variants (43).  
v Environmental factors 
1) Infections. The precise mechanisms involved in this association are 
unknown and the two main hypothesis are I) molecular mimicry: antigen 
sharing homology between bacterial pathogens and self-antigens, with 
consequent cross-reactive immune response towards bacterial antigens on one 
side and autoimmunity on the other side II) the local infection and 
inflammation against the bacteria create tissue damage and consequent 
release of sequestered antigens triggering an autoimmune response (31). An 
additional theory of “bystander effects” proposes that viral infection of a 
certain tissue can induce local inflammation, resulting in activation of 
autoreactive T-cells that were dormant or suppressed by peripheral regulatory 
mechanisms (44).  
Several infections are known to be associated with thyroid autoimmunity: A) 
Bacteria, including Yersinia enterocolitica, Bifidobacterium and lactobacillis 
species, Helicobacter pylori and Clostridium botulinum neurotoxin A (26); B) 
Viruses: Coxsackie B virus, retroviruses, enterovirus, rubella, mumps virus, 
herpes simplex virus (HSV), EBV, Parvovirus, HCV (45, 46).  
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2) Excessive iodine intake is a risk factor for thyroid autoimmunity and the 
incidence of TA has risen concomitantly with increased iodine consumption 
(47). The etiopathogenic hypothesis is that an excess of iodine may lead to 
some thyroid destruction and hence presentation of thyroidal antigens to the 
immune system leading to an autoimmune reaction (31). An alternative 
explanation involves Tg iodination and Tg iodine-induced conformational 
changes affecting its uptake and processing by antigen presenting cells (48).  
3) Sex differences. Organ specific autoimmune diseases and thyroid 
disorders in general have a strong female preponderance. The reasons for this 
phenomenon are unknown, but the influence of the X chromosome seems to be 
limited, considering that AITD is very prevalent among girls with Turner’s 
syndrome (X0 karyotype), but not in men with Klinefelter’s syndrome (XXY 
karyotype) (49). Therefore hormonal influences are more likely to be operative 
in the induction of TA (31), as suggested by the presence of oestrogen 
receptor (ER) in both neoplastic and non-neoplastic thyroid tissue, where 
17βestradiol exerts a growth-promoting effect on thyroid cells (50). Recently 
Merril et al. proposed a crucial role of leptin-induced inflammation to explain 
the female preponderance of TA (26), considering that leptin is involved in 
inflammation (51) and rises in both young girls and boys as they approach 
puberty but in boys the leptin declines along with testosterone levels (52). 
4) Pregnancy. During pregnancy the immune system is suppressed with a 
fall in the T-helper/suppressor-cell ratio, whereas in the first post-partum 
months T-cell activation occurs and autoantibody production rises (53). As 
consequence several types of autoimmune disorders abate during pregnancy 
but often worsen or arise de novo after the delivery when T-cells reactivate 
(31). 
The transfer of foetal cells into the maternal circulation is called foetal 
microchimerism and these foetal cells can persist for a long time. Some 
authors proposed that foetal microchimerism could be one possible mechanism 
for the etiopathogenesis of postpartum thyroiditis (54-56). 
5) Irradiation. Both external and internal irradiation by radioactive iodine 
expose thyroidal antigens to the immune system and thus induce TA. Indeed, 
an increased prevalence of TA has been clearly demonstrated after nuclear 
disasters (e.g. Chernobyl nuclear plant accident) (31).    
6) Cigarette smoking has an influence on the immune system, inducing a 
polyclonal activation of both B and T cells and cytokines production; it also 
causes cell damage and therefore may also increase the presentation of 
antigens. Smoking is linked to several autoimmune diseases including 
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rheumatoid arthritis and GD, in particular with Graves’ orbitopathy (GO); the 
reasons for this strong association are still largely unknown (31).  
7) Several drugs acting on the immune system towards different 
mechanisms are associated with an increased incidence of TA, including 
antiretroviral therapy, interferon-alpha, IL-2 and alemtuzumab (31). In 
particular, alemtuzumab (Campath) is a humanized anti-CD52 monoclonal 
antibody used for the treatment of multiple sclerosis and it triggers TA, in 
particular GD, in about one third of treated patients (57). 
8) Stress has been found driving the immune system towards a Th2 
response, therefore suppressing cellular immunity and enhancing humoral 
immunity (31). This differential action on T-lymphocytes would explain why 
stress has been repeatedly associated to GD (humoral immunity), while only 
very few reports support an association between stress and AITD (cellular 
immunity) (58).  
9) Allergic conditions are Th2 disorders, therefore they have been found to 
be associated with Th2-driven autoimmune diseases such as GD and lupus 
erythematosus (59). 
10) Selenium is a trace mineral and exerts a marked influence on the 
immune system, acts as anti-oxidant reducing free radical formation and plays 
an essential role in thyroid hormone synthesis. Low selenium blood levels are 
associated with increased thyroid volume and thyroid hypoechogenicity, a 
marker for lymphocytic infiltration (31).  
1.2.2.3 Autoimmune thyroiditis (AITD) and role of thyroid autoantibodies 
The term AITD refers to the presence of thyroid gland damage, 
inflammation or lymphocytic infiltration, usually detectable as a hypoechoic and 
non-homogeneous pattern at the ultrasonography (US) scan examination of the 
thyroid gland. The definition of AITD covers different clinical entities, such as: 
chronic thyroiditis, painless sporadic thyroiditis or postpartum thyroiditis with a 
typical onset in the early months after delivery. Chronic thyroiditis is called 
Hashimoto’s thyroiditis when characterized by the presence of both goitre and 
hypothyroidism. Alternatively, when the volume of the thyroid gland is greatly 
reduced, it is named atrophic thyroiditis (60).  
The first event in AITD etiopathogenesis is the activation of thyroid 
antigen-specific helper T cells (60). Tg has been recognized as the potential 
earliest trigger of AITD (61) and linkage studies indicated Tg as a susceptibility 
gene for TA (43). The role of TPO as autoimmune antigen in TA will be extensively 
explained in chapter 3. There are different theories explaining the possible causes 
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of T-cell activation: 1) result from a viral infection with common properties 
between viral and thyroid proteins (62); 2) thyrocytes present their own 
intracellular proteins to T cells (29); 3) foetal microchimerism (56).  
Once helper T cells are activated, they induce B cells to secrete TAb. The 
main two antigens involved in AITD are Tg and TPO, therefore anti-Tg 
autoantibodies (TgAb) and anti-TPO autoantibodies (TPOAb) are the main thyroid 
autoantibodies (TAb) and they are both considered typical serum biomarkers of 
TA, AITD in particular. Autoantibodies to colloid antigen, thyroid hormones and 
NIS have also been detected in patients with AITD, even if they are rare and 
therefore much less important compared with TgAb and TPOAb (60). However 
both TgAb and TPOAb are also largely present in the general population, without 
being associated with the presence of thyroiditis, thyroidal damage or thyroid 
dysfunction. In particular Hollowell et al. estimated a TPOAb and TgAb prevalence 
among general population of respectively 13% (8.7% males, 17% females) and 
11.5% (7.6% males, 15.2% females) (63). Vanderpump et al. described an even 
higher TAb prevalence of 26.4%, considering together TPOAb and TgAb (64). The 
great majority of authors in this field agree that TAb prevalence increases with 
age (63-67) and varies with ethnicity, noticing a major TAb prevalence among 
whites compared with blacks or Mexican Americans (63). An increase of TAb 
prevalence has also been registered after iodization programs and the generation 
of autoantibodies seems to be related to a sudden increase of iodine intake, more 
than to exposure to a constant but high iodine level (68). Possible mechanisms 
may be 1) free radical-mediated damage of thyroid tissue induced by the sudden 
shift from low to high iodine intake (69) and 2) major changes in Tg 
stereochemical configuration caused by its increased iodization with consequent 
changes in its immunoreactivity and induction of TgAb production (48, 70). TPOAb 
are the most valid clinical biomarker for the detection of early TA, considering 
that they are present in 90% of patients affected with autoimmune thyroiditis 
(AITD) (71). However, it is currently unknown why such a high percentage of 
individuals from the general population develop TPOAb; it is also unclear why 
many individuals positive for TAb do not develop clinical thyroid disease (63, 72).  
The mechanisms for autoimmune destruction of thyroid tissue probably 
involves both cellular and humoral immunity, in fact in AITD the lymphocytic 
infiltration of the thyroid gland is characterized by equal numbers of B cells and 
cytotoxic T cells (60). Furthermore, thyrocytes of AITD patients express the Fas 
gene, a member of the closely linked group of tumour necrosis factor genes, 
therefore apoptosis could represent an additional cause of thyrocyte destruction 
(73). In particular, the proposal for a causative role of TPOAb in the pathogenesis 
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of Hashimoto’s thyroiditis remains controversial (74-76). Some authors consider 
TPOAb as secondary to the thyroid damage inflicted by T cells (71), while others 
proposed a role of TPOAb in AITD antibody-dependent cell cytotoxicity (77), 
considering that TPOAb are complement-fixing and thus directly cytotoxic to 
thyrocytes (78). It has also been repeatedly noticed that TPOAb positive women 
have an increased risk of developing pregnancy complications such as miscarriage 
and pre-term delivery (79, 80).  
The obvious consequence of thyroid tissue destruction is a reduced thyroid 
function (hypothyroidism). However an alternative cause of hypothyroidism could 
be the presence of autoantibodies blocking the TSHR, that has been reported in 
up to 10% of patients with AITD and they could have a role in both development 
and severity of hypothyroidism (81).   
The principal clinical manifestation of AITD is hypothyroidism, however the 
majority of patients with measurable TAb have normal thyroid function (60). A 
goitre may be present and this is typical of Hashimoto’s thyroiditis. 
Epidemiological studies estimated that 10% and 0.5% of postmenopausal women 
with high serum TAb had respectively subclinical hypothyroidism and overt 
hypothyroidism, although euthyroid individuals with high serum TAb titre had a 
progression to overt hypothyroidism at a rate of 2 to 4 percent a year (64, 82). 
1.2.2.4 Graves’ disease (GD) 
GD has an estimated incidence of 80/100’000/year in women and 
8/100’000/year in Western countries (83) 
GD is a Th2-driven disorder and therefore involves humoral autoimmunity.  
GD etiopathogenesis involves the presence of stimulating TRAb causing a 
persistent activation of the TSHR and therefore hyperthyroidism (84).   
A popular hypothesis regarding the pathogenesis of GD involves a defect in 
negative selection of autoreactive T cells to the TSHR, either in the thymus or the 
peripheral immune system, supported by the existence of autoantibodies to TSHR 
(TRAb) (30).  
Many different single nucleotide polymorphisms (SNPs) of TSHR have been 
found to be associated with GD (30, 38), with the 10 principal SNPs spread across 
a 340 kb region encompassing the gene upstream of the TSHR (85). Interestingly, 
although TPOAb are not involved in GD etiopathogenesis, TPOAb positive persons 
have an increased risk of developing GD (86). A likely explanation is that the 
genetic susceptibility of AITD and GD involves shared genes, as well as unique 
genes (87).  
 18 
The main clinical manifestations of GD include hyperthyroidism and goitre. 
In rare cases it can be associated with Graves’ orbitopathy (GO) and very rarely 
with an infiltrative dermopathy of the legs called pretibial myxedema. The 
pathogenesis of GO is complex and involves several mechanisms, including the 
accumulation in the extracellular matrix of glycosaminoglycans that are secreted 
by fibroblasts under the influence of cytokines, with consequent functional 
disruption and impairment of ocular muscles. Extraocular muscles have also been 
found to be infiltrated with T cells, mainly TSHR-reactive. Less is known about the 
etiopathogenesis of the rare pretibial mixedema, characterized by the 
accumulation of hyaluronic acid and chondroitin sulfates in the dermis, probably 
secondary to cytokine activation of fibroblasts, with consequent compression of 
the dermal lymphatics and edema (1). However, the expression of 
immunoreactive TSHR mRNA and protein has been found in orbital pre-adipocytes, 
fibroblasts and other cells, therefore it is probable that an immune response to 
the TSHR plays a direct role in the development of all 3 these manifestations: GD, 
GO and pretibial mixedema (88). 
1.2.3 Goitre and iodine deficiency  
The term goitre means the enlargement of the thyroid gland and it can be 
diffuse or nodular, endemic or sporadic. Endemic goitre affects more than 12% of 
the world’s population; the World Health Organisation (WHO) defined the goitre 
“endemic” when present in 5% or more of schoolchildren aged 6-12 years (89). 
Considering that iodine is an essential component of thyroid hormones, one of the 
major causes of goitre is iodine deficiency and the prevalence of goitre varies 
widely depending on the iodine intake of the referred population (1). Formation of 
normal quantities of thyroid hormone requires a daily thyroidal uptake of 
approximately 60 to 75 µg of iodine. Considering a fecal loss of about 10 to 20 µg, 
at least 100 µg of iodine per day is required in order to ensure the availability of 
adequate quantities of exogenous iodide for thyroid hormone synthesis (90). The 
daily dietary intake of iodine varies widely throughout the world, depending on 
the iodine content of soil and water and on dietary practice; in particular, iodine 
deficiency is common especially in mountainous and formerly glaciated regions of 
the earth (91). The level of iodine availability in a population is usually 
established measuring the urinary iodine excretion and a level of 100 to 150 µg as 
urinary iodine is considered for iodine-sufficient populations (90). 
Similarly to the rest of thyroid diseases, the goitre has a female 
preponderance and its overall prevalence among the general population according 
to the Framingham survey and the Wickham study is estimated respectively as 
 19 
4.6% (6.4% in women, 1.5% in men) and 3.2% (female to male ratio = 6.6:1) (82, 
92). When ultrasonography (US) scan is applied as the screening method instead of 
palpation, the prevalence of goitre increases to 30% to 50% in an unselected adult 
population and even higher in iodine-deficient areas and among older people (82, 
92-95). Thyroid nodules, associated or not with goitre, are also very common and 
a prevalence of up to 50% has been described in autopsy series (93) and greater 
than 60% in healthy adults screened with US scan of the thyroid gland (94). 
The pathophysiological mechanisms of goitre involve an adaptive response 
of the thyroid follicular cell to any factor that impairs the synthesis of thyroid 
hormones. As previously introduced, iodine deficiency is one of the major causes 
of goitre, but considering that not all the inhabitants of iodine deficient 
geographic areas develop the goitre, other factors, both genetic and 
environmental, are likely to be involved. By studying families affected with goitre, 
several gene abnormalities involving proteins related to thyroid hormone synthesis 
have been detected, including Tg, NIS, TPO, DUOX2, pendrin and TSHR (1). 
Environmental factors include cigarette smoking, infections, drugs and goitrogens 
(95) and a role for oestrogens in goitre formation has been proposed, considering 
its female preponderance (21, 96).  
The hyperplasia of thyroid follicular cells leading to the goitre is mainly 
driven by increased TSH levels as response to decreased thyroid hormone synthesis 
(97). However, the serum TSH concentration is normal in most patients with 
nontoxic goitre, therefore any factor that impairs thyroid hormone synthesis, 
especially iodine deficiency, may lead to gradual development of goitre in 
response to normal concentrations of TSH (95). Indeed, a complex network of both 
TSH–dependent and TSH–independent pathways plays a role in the goitrogenic 
process, including a variety of autocrine or paracrine growth factors (97).  
As clinical manifestation, the nontoxic goitre is usually palpable and 
sometimes may be seen as a visible lump in the neck in correspondence of the 
thyroid gland. Large goitres, which may displace or compress the trachea, 
esophagus and neck vessels, can be associated with symptoms and signs including 
inspiratory stridor, dysphagia and a choking sensation. Vocal cord paralysis can 
occasionally result from benign nodular goitres, even if the compression of the 
recurrent laryngeal nerve, with resulting hoarseness, suggests carcinoma rather 
than nontoxic goitre. Finally, an acute local painful enlargement with 
enhancement or induction of obstructive symptoms can suddenly manifest in case 
of hemorrhage into a nodule or cyst (95). In case of toxic goitre, symptoms of 
thyrotoxicosis are also present and they will be discussed in the next paragraph 
1.2.4.  
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1.2.4 Hypothyroidism and hyperthyroidism 
As previously introduced in paragraph 1.1.4, a reduced level of thyroid 
hormones is termed hypothyroidism and biochemically defined by FT4 levels below 
the lower normal limit accompanied by raised TSH. On the contrary, an increased 
production of thyroid hormone is termed hyperthyroidism and biochemically 
corresponds to FT4 levels above the normal limit, accompanied by decreased or 
undetectable TSH. The condition of abnormality of TSH levels with FT4 levels still 
within the normal range is called subclinical hypothyroidism or subclinical 
hyperthyroidism when TSH levels are respectively raised or reduced. The term 
thyrotoxicosis means elevated plasma levels of thyroid hormones and includes not 
only hyperthyroidism but also different conditions where the excess of thyroid 
hormone is not related to an increased thyroid production. 
Table 1-3 summarizes the possible different causes of hypothyroidism: the 
principal main distinction of hypothyroidism is between primary, when the thyroid 
dysfunction is the consequence of a disease primarily affecting the thyroid gland, 
or central, when the thyroid dysfunction is secondary to an altered pituitary 
secretion of TSH (secondary) or an altered hypothalamic secretion of TRH 
(tertiary). The prevalence of hypothyroidism is 10 times higher among women, the 
elderly and in some racial and ethnic groups, with a prevalence in iodine-replete 
communities between 1 and 2% (21, 63). The two most common causes of 
hypothyroidism are iodine deficiency and, in iodine sufficient areas, AITD (83). 
Congenital hypothyroidism affects about one newborn in 3500–4000 births and is 
the most treatable cause of mental retardation (98).  
Table 1-3: Causes of hypothyroidism  
PRIMARY 
CONGENITAL 
§ Reduced thyroid mass (agenesis or dysplasia) 
§ Reduced thyroid function: iodide transport or utilization defect (NIS or pendrin 
mutations), iodotyrosine dehalogenase deficiency, organification disorders 
(TPO deficiency or disfunction), defectes in Tg synthesis or processing, TSHR 
defects, thyroidal Gs protein abnormalities, idiopathic TSH unresponsiveness 
ACQUIRED 
§ Iodine deficiency 
§ Autoimmune 
§ Inflammatory/Degenerative: De Quervain thyroiditis, Riedel’s thyroiditis, 
amyloidosis, hemochromatosis, sarcoidosis, cystinosis, sclerodermia 
§ Iatrogenic: thyroidectomy, radioiodine treatment 
§ Drugs blocking synthesis or release of thyroid hormones: carbimazole, 
methimazole, propylthiouracil, potassium perchlorate, lithium, ethionamide, 
sulfonamides, amiodarone, interferon α, iodine 
CENTRAL 
§ Secondary: isolate TSH deficit, panhypopituitarism, resistance of pituitary 
receptor for TRH 
§ Tertiary: reduced TRSH biological activity  
§ Refetoff syndrome (generalized resistance to thyroid hormones) 
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Tg= thyroglobulin; TPO= thyroid peroxidase; TRH= thyrotropin-releasing hormone; TSH= 
thyroid-stimulating hormone. 
 
The possible causes of thyrotoxicosis are summarized Table 1-4: in this 
classification it is important to distinguish between true hyperthyroidism caused 
by an increased thyroid activity or thyrotoxicosis associated with a decreased 
thyroid activity. The most common causes of hyperthyroidism are GD, followed by 
toxic multinodular goitre, whilst rarer causes include an autonomously functioning 
thyroid adenoma or thyroiditis. The prevalence of hyperthyroidism in women is 
between 0.5 and 2%, and is 10 times more common in women than in men in 
iodine-replete communities (21).  
Table 1-4: Causes of hyperthyroidism and thyrotoxicosis 
HYPERTHYROIDISM 
AUTOIMMUNE 
§ Graves’ disease (GD) 
NOT AUTOIMMUNE 
§ Toxic multinodular goitre 
§ Toxic adenoma 
§ Gestational hyperthyroidism 
§ Trophoblastic tumours secerning excess of serum human chorionic 
gonadotropin hormone 
§ Struma ovarii (monodermal teratoma containing mostly thyroid 
tissue) 
§ Excess of iodine (e.g. amiodarone) 
§ Metastatic functioning thyroid carcinoma 
§ TSH receptor or G protein mutations 
§ TSH-secreting pituitary tumours 
§ Thyroid hormone resistance with pituitary predominance 
THYROTOXICOSIS 
ENDOGENOUS 
§ Transient thyroid hormones release due to thyroid gland 
damaging in Hashimoto thyroiditis (Hashitoxicosis) or subacute 
thyroiditis  
§ Drug induced: amiodarone, lithium, IFN- α, IL-2 
EXOGENOUS 
§ Iatrogenic overreplacement 
§ Thyroxicosis factitia 
§ Ingestion of natural products containing thyroid hormone (e.g. 
“hamburger thyrotoxicosis, natural foodstuffs) 
IFN-α = interferon alpha ; IL-2 = interleukin-2 ; TSH= thyroid-stimulating hormone. 
 
Hypothyroidism and thyrotoxicosis/hyperthyroidism have many clinical 
manifestations involving different organs and systems and they are summarized in 
Table 1-5. The severity of the clinical manifestations depends from the grade of 
thyroid hormone deficiency/excess and from the duration of the disease. 
Hyperthyroidism caused by GD is usually more severe compared to that of toxic 
goitre or adenoma and usually symptoms are more evident in young patients 
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compared to elderly (1). One of the clinical features of full-blown hypothyroidism 
is a mucinous edema (myxedema) caused by an accumulation of hyaluronic acid 
that alters the composition of the ground substance in the dermis and other 
tissues (99).  
Table 1-5: Clinical manifestations of hypo- and hyper-thyroidism in adults 
 HTPOTHYROIDISM HYPERTHYROIDISM 
CARDIOVASCULAR 
system 
§ Bradycardia 
§ Peripheral vasoconstriction è Pallor 
and intolerance to cold 
§ Tachycardia, palpitations 
§ Blood pressure: ê 
diastolic and é systolic 
§ Cardiac arrhythmias, e.g. 
atrial fibrillation 
METABOLISM § ê appetite 
§ Weight gain 
§ é LDL cholesterol 
§ é appetite 
§ Heat intolerance 
§ Weight loss 
§ é plasma free fatty acids 
§ ê cholesterol levels 
§ Slight ê triglyceride 
levels 
CENTRAL AND 
PERIPHERAL 
NERVOUS SYSTEM 
§ Slowing of all intellectual functions 
§ Loss of initiative 
§ Memory defects 
§ Lethargy and somnolence 
§ Paranoid and depression 
§ Nervousness 
§ Emotional lability 
§ Hyperkinesia 
§ Insomnia 
MUSCLE § Weakness and fatigue 
§ é creatine kinase levels 
§ Weakness and fatigue 
§ Muscle wasting 
EYES  § Retraction of upper lower 
eyelids è typical “stare” 
SKIN AND HAIR § Dry skin 
§ Mucinous edema (myxedema) 
especially around the eyes, on 
supraclavicular fossa, hands, feet, 
tongue, pharyngeal and laryngeal 
mucous membranes 
§ Slow wounds healing 
§ Hair dry and brittle, é hair loss 
§ Excessive sweating  
§ Palmar erythema 
§ Hair fine and friable and 
é hair loss 
§ Nails soft and friable 
§ Plummer’s nails 
(onycholysis) 
RESPIRATORY 
SYSTEM 
§ Dyspnea: myxedematous involvement 
of respiratory muscles; depression of 
hypoxic/hypercapnic ventilator 
drives 
§ Obstructive sleep apnea  
§ Dyspnea: weakness of 
respiratory muscles 
BONE, CALCIUM 
METABOLISM 
§ Bone frailty and osteoporosis § Osteoporosis 
§ Hypercalcemia 
RENAL FUNCTION § Edema and fluid retention § Mild polyuria 
HEMATOPOIETIC 
SYSTEM 
§ Mild normocytic normochromic 
anemia 
§ Anemia 
G-I SYSTEM § Constipation § Diarrhea 
REPRODUCTIVE 
FUNCTION 
§ Anovulatory cycles 
§ ê libido 
§ Anovulatory cycles 
§ Gynecomastia 
G-I = gastro-intestinal; LDL = low density lipoproteins. 
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1.2.5 Thyroid neoplasms  
Thyroid tumours are the most common endocrine neoplasms and they are for 
the great majority (about 95%) benign, presenting as thyroid nodules. The 
follicular adenoma results from a genetic mutation in a single precursor cell, 
usually affecting the TSHR and causing its continuous activation. Thyroid 
adenomas can be both functioning and not functioning and in the first case they 
usually determine a clinical condition of hyperthyroidism. The thyroid adenoma is 
typically solitary and it has to be distinguished from nodules in the multinodular 
goitre, where they are the result of a hyperplastic response to a certain stimulus, 
e.g. iodine deficiency, as previously discussed (100).  
Thyroid malignant neoplasms account for about 0.5% of cancers in men and 
1.5% in women and may be secondary (thyroid metastasis from different primary 
carcinoma) or primary (101). Primary thyroid cancers are classified according to 
the cell of origin, as summarized in Table 1-6: rare mixed follicular and medullary 
carcinoma have also been described (1). 
Table 1-6: Classification of thyroid primary malignant neoplasms 
CELL OF ORIGIN NAME OF CANCER FREQUENCY 
THYROCYTES 
Differentiated  
§ Papillary (PTC) 
§ Follicular (FTC) 
90% 
Poorly differentiated 1% 
Undifferentiated (anaplastic) 2% 
C CELLS Medullary carcinoma (MTC) 5% 
NON EPITHELIAL 
§ Malignant lymphomas 
§ Sarcomas 
§ Others 
2% 
 
Papillary thyroid carcinoma (PTC) is the most common, accounting for the 
80-85% of total thyroid cancers in iodine-sufficient areas and has a very good 
prognosis, with a 10-year survival rate of 93-94%, versus 84-85% of follicular 
variant (FTC) (102). Medullary thyroid carcinoma (MTC) has an intermediate 
prognosis with a 10-year survival of 50%-75%, while anaplastic carcinoma has the 
absolute worse prognosis, with a disease-specific mortality of almost 100% (101).   
Thyroid cancer may be sporadic and familial. In particular, differentiated 
thyroid cancer may be present in (102): 
v Cowden syndrome (hamartomas, breast, colon and lung tumours) 
v Gardner syndrome (intestinal polyps, osteomas, fibromas and lipomas) 
v Carney complex (pigmented adrenal nodules, pituitary tumours, skin 
pigmentation and myxomas) 
v Turcot syndrome (large intestinal polyps and brain tumours) 
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MTC may be associated with hereditary multiple endocrine neoplasias (MEN) type 
2A and 2B, associated respectively with parathyroid hyperplasia/adenomas and 
pheochromocytoma (MEN2A) and with pheochromocytoma, marfanoid body 
habitus and multiple intestinal and mucosal ganglioneuromas (MEN2B) (103).  
Thyroid cell tumourigenesis can develop along several paths, sometimes 
specific and sometimes common to other solid tumours. The RET (abbreviation for 
“rearranged during transfection”) proto-oncogene encodes for a receptor tyrosine 
kinase and its activating mutations are involved in the development of various 
types of cancer, especially MTC, MEN2A and MEN2B (104). RET/PTC mutations 
leading to unregulated tyrosine kinase activation, together with B-RAF and RAS 
genes mutations, have been found in about 70% of patients affected with PTC. 
Finally, translocations of the DNA-binding domain of paired box gene 8 (PAX-8) to 
the peroxisome proliferator-activated receptor γ (PPAR-γ1) gene have been 
identified in some FTC (102). 
1.3 BREAST CANCER 
Breast cancer (BC) is the most frequent malignant disease and the leading 
cause of cancer death among women in both economically developed and 
developing countries. Worldwide, 1.4 million new BC cases are diagnosed each 
year, with a related mortality in about one third (105).  
BC mortality rates have declined in recent years thanks to several factors, 
including increased awareness leading to early detection and the availability of 
better treatment options (106). However, despite current efforts to prevent the 
disease, BC incidence is rising in most countries mainly as a consequence of 
increasing numbers of women with major risk factors for breast cancer, especially 
obesity, sedentary life and alcohol consumption but also cultural and reproductive 
changes in women’s lives (107). 
1.3.1 Breast anatomy and physiology  
Both males and females have breasts, but normally they are well 
developed only in women. Mammary glands in females are accessory to 
reproduction, while in men they are functionless, consisting of only a few small 
ducts or cords (108).   
1.3.1.1 Breast anatomy 
The breasts or mammary glands are located in the thorax region and are modified 
sweat glands and therefore have no special capsule or sheath (Figure 1-7). The 
contour and volume of the breasts are produced by subcutaneous fat except 
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during pregnancy, when the mammary glands enlarge and new glandular tissue 
forms. Breast size and shape result from genetic, racial and dietary factors (108).  
Between the breast and the deep pectoral fascia is a loose connective 
tissue plane or potential space, called “retromammary space” or “bursa”; it 
contains a small amount of fat, that allows the breast some degree of movement 
on the deep pectoral fascia. At the greatest prominence of the breast is the 
nipple, surrounded by a circular pigmented area (the areola) (108). 
The lymphatic drainage of the breast is important because of its role in the 
metastasis of cancer cells. The lymph passes from lobules of the gland, nipple and 
areola to the subareolar lymphatic plessus and from it to the axillary lymph nodes 
(>75%), pectoral (anterior) nodes, parasternal lymph nodes, abdominal lymph 
nodes (inferior phrenic nodes) (108).  
The breast contains 15 to 20 lobes of glandular tissue, which constitute the 
parenchyma of the mammary gland (108): 
v Each mammary lobe consists of a system of draining ever-branching ducts that 
penetrate deep into the breast fibro-adipose tissue. The duct system finally 
converges into a unique lactiferous duct that opens independently on the 
nipple; just deep to the areola, each lactiferous duct has a dilated portion, 
the lactiferous sinus (108). Each duct is lined by columnar or cuboidal 
epithelium, with a continuous surface layer of epithelial cells and an outer 
discontinuous layer of myoepithelial cells. Each duct is surrounded by loose 
fibrocollagenous support tissue containing rich capillary network (109). 
v The branching duct system ends in a cluster of blind-ending terminal ductules, 
each cluster and its feeding duct comprising a mammary lobule. The terminal 
ducts and lobules are embedded in a loose fibrous support tissue, which is rich 
in capillaries and also contains a few lymphocytes, macrophages and mast 
cells. The tissue is surrounded by a more dense fibrocollagenous support tissue 
intermingled with adipose tissue (109).  
v Each lobule is composed by alveolar cells, secretory units responsible for milk 
production that during lactation become columnar and look like exocrine cells. 
Myoepithelial cells are located in the basement membrane of the lobule and 
along the intralobular ducts (110). 
 
 
 
 
 
 26 
Figure 1-7: Mammary gland and its associated structures 
 
Adapted from © Pearson Education, Inc. 
1.3.1.2 Breast physiology  
The structure, size, form and function of breast tissue result from an 
intricate combination of hormone signals and ratios. Lactation is indeed the 
primary function of the breast and it serves two equally important functions: it 
supplies the newborn with adequate nutrients and it lengthens the interval 
between births. The postpuberal breast is mature but inactive; a proliferative 
phase occurs during pregnancy, followed by regression after lactation ceases 
(110).   
The maternal breast milk contains all the nutrients that an infant needs in 
the first 6 months of life, including fat, carbohydrates, proteins, vitamins, 
minerals, growth factors and water. In particular, the main carbohydrate is 
lactose, a disaccharide and the main proteins are casein and alpha-lactalbumin, 
together with a balance of various amino acids. One important function of the 
maternal milk is to protect the newborn from infections, therefore it contains 
immunoglobulins (Ig), white blood cells, special proteins that can kill bacteria, 
viruses and fungi (lysozyme and lactoferrin) and oligosaccharides which prevent 
bacteria from attaching the mucosal surfaces (111).    
The breast function is regulated by many different hormones and growth 
factors (110). In this thesis only a brief overview of their actions on the mammary 
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gland will be provided, without mentioning their complex mechanisms of 
regulation and secretion that are beyond the scope of the present thesis. 
v Pregnancy-related hormones, oxytocin, prolactin (PRL), human placental 
lactogen (hPL), have the major role of stimulating milk production and release 
during lactation (Figure 1-8). 
1) Oxytocin is synthetized in the neurons of the supraoptic and paraventricular 
nucleus of the hypothalamus, transported into the posterior pituitary gland 
and then released into the circulation. Oxytocin determines the contraction of 
the myoepithelial cells of the mammary lobules, promoting milk ejection.  
2) PRL is synthetized and secreted by the lactotrophs cells of the anterior 
pituitary gland. PRL is an obligate regulator of mammary organogenesis, 
lobular and alveolar growth and functional differentiation. It is also the 
hormone primarily responsible for the induction and maintenance of milk 
protein, lactose and lipid production.  
3) hPL is synthetized by the syncytiotrophoblasts of the placenta and its main 
role is related to breast growth and differentiation during pregnancy. A role 
similar to PRL in lactation has also been described. 
v Steroid hormones: oestrogens, progesterone, glucorticoids.  
1) Oestrogens are secreted by ovaries and act via nuclear oestrogen receptor 
(ER). They are responsible for the proliferation of mammary epithelium, 
especially the ductal portions of the gland. They have complex actions on 
lactation, since they directly inhibit milk secretion but at the same time they 
promote PRL secretion by the anterior pituitary gland.   
2) Progesterone is mainly synthetized in the ovaries and placenta and acts via 
a nuclear receptor whose expression is induced by oestrogens. Progesterone 
synergizes with oestrogen and prolactin to produce full lobuloalveolar 
development of the mammary gland. Similarly to oestrogens, it prevents milk 
protein synthesis and inhibits milk secretion during pregnancy.   
3) Glucocorticoids are mainly secreted by the adrenal glands and act via 
nuclear receptors. They are essential for the process of lactation and act in 
synergism with the other hormones involved. 
v Other hormones: GH, insulin, thyroid hormones 
1) GH is produced by the anterior pituitary gland and it is important for the 
function and development of the breast in concert with the other hormones, 
where it has a substantial lactogenic activity.  
2) Insulin is produced by β-cells of pancreatic isles and its main function on the 
breast is regulating the transport of glucose into the mammary acinar cells, 
essential requisite for synthesis of lipids for milk fat. 
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3) Thyroid hormones are involved in mammary growth and lactation and have a 
permissive role, more than regulatory. The interactions between thyroid 
hormones and breast cell will be further described in paragraph 1.4.2. 
v Growth factors: several growth factors are involved in normal growth and 
development of the breast and with its function: 
1) The fibroblast growth factor (FGF) family is composed of several heparin-
binding structurally related polypeptides acting via tyrosine kinase receptors 
and they are important in mammary development during sexual maturity.  
2) The epidermal growth factor (EGF) family comprises several different 
proteins that act via a set of transmembrane receptors and are mitogens for 
mammary epithelial cells.  
3) The transforming growth factor beta family (TGFβ) is composed of several 
related multifunctional proteins that modulate a wide variety of cellular 
functions. In the mammary gland they are important for ductal morphogenesis 
and regulation of the onset of lactation.  
4) Insulin-like growth factors (IGFs) are structurally homologous peptides 
involved in many biological processes and they primarily have a proliferative 
effect. 
5) Other growth factors. Platelet-derived growth factor (PDGF) is a potent 
mitogen stimulating the proliferation of mesenchymal cells, thought to act 
principally via mammary stromal cells. Another growth factor that may act 
indirectly on the breast is colony stimulating factor-1 (CSF-1). 
Figure 1-8: Breast lobule and maternal milk production 
 
Mammary lobule and main hormones involved in lactation. Adapted from (112).  
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1.3.2 Risk factors 
Many different risk factors for BC have been identified and they can be 
classified as genetic, environmental/lifestyle and medical conditions. 
1.3.2.1 Genetic factors 
It is currently estimated that 5-10% of all BC are hereditary and due to 
mutations in high-penetrance susceptibility genes. Only two of these genes have 
been identified so far: BRCA1, associated with families having BC and ovarian 
cancer, and BRCA2, associated with families having male breast tumours (113). 
BRCA1 and BRCA2 genes are classified as tumour suppressors and linked with key 
metabolic processes, including deoxyribonucleic acid (DNA)-damage repair, 
regulation of gene expression and cell-cycle control (114, 115). About 85% of all 
alterations in BRCA1 and BRCA2 tumours are frameshift or nonsense mutations and 
yield a truncated protein product (113).  
Several other less known mutations related to BC exist and they include 
high penetrance lower frequency mutations leading to neoplasias in multiple 
organs, such as p53 (Li-Fraumeni syndrome), PTEN (Cowden syndrome) and STK11 
(Peutz-Jeghers syndrome). Other genetic mutations have only more recently been 
identified and are characterized as high frequency but lesser penetrance 
mutations, such as CHEK2, ATM, BRIP1 and PALB2 (116).   
1.3.2.2 Environmental and lifestyle factors 
The fraction of BC cases attributable to lifestyle and environmental factors 
in the UK was estimated to be 26.8% in 2010 (117).  The major lifestyle and 
environmental risk factors for BC are: 
v Hormonal factors. Hormones, oestrogens in particular, are believed to be the 
most important risk factor for BC. Oestrogens are considered weak 
carcinogens, as a consequence of their stimulatory activity on breast 
epithelium by increasing the rate of cell division and proliferation, thereby 
allowing for an increase in the accumulation of random genetic errors (118). In 
particular, a high exposure to oestrogens and therefore an increased risk of BC 
is a consequence of the following situations (119): 
1) Endogenous oestrogens: early menarche, late menopause. 
2) Exogenous oestrogens. The two main sources of exogenous oestrogens are 
oral contraception in pre-menopausal women and hormonal replacement 
therapy in post-menopausal women. Numerous studies examining the 
association between exogenous hormones and BC risk have been published but 
they report contrasting results and must be interpreted cautiously as a 
consequence of changes in hormonal dose over time and methods of delivery 
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(e.g. sequential versus combination) (119). As an example, hormonal birth 
control has been associated to an increased development of premenopausal BC 
(120) but other meta-analyses and studies did not confirm these findings 
among general population (121, 122) or even among high-risk women BRCA1 
and BRCA2 mutation carriers (123).  
v Other reproductive factors. Breast cells that have never undergone 
differentiation to produce milk divide 20 times more often than cells that have 
acquired the terminal phenotype (124). Therefore the following situation are 
considered risk factors for BC:   
1) Low parity and late pregnancy 
2) Abbreviated breast feeding 
v Obesity. Strong observational data indicate that weight gain in the 
premenopausal period and being overweight or obese after menopause 
increase the risk of BC. Obesity is in general related to an increased risk of 
different types of cancer and the involved mechanisms are not yet fully 
understood, but likely to involve three different hormonal systems: 1) the 
insulin and insulin-like growth factor (IGF) axis, 2) sex steroids, and 3) 
adipokines. In particular, the specific link between increased body weight and 
postmenopausal BC could be explained by an increased aromatase activity 
(present in the adipose tissue, therefore overexpressed in obese people), with 
consequent increased oestrogen production from androgen precursors (125).  
v Diet and iodine. The impact of dietary components such as the amount of 
saturated fat, fruit and vegetables on the risk of BC has been analyzed in 
different studies, mainly leading to contrasting or inconclusive results (107). 
However, a recent systematic review of dietary patterns and BC concluded 
that a Mediterranean dietary pattern and diets composed largely of 
vegetables, fruit, fish and soy are associated with a decreased risk of BC (126). 
Iodine plays an important role in the mammary gland and iodine deficiency has 
been associated with an increased risk of BC. Milk, seafood and seaweeds are 
very rich in iodine; Japanese women, having a diet rich in seafood/seaweeds, 
have one of the lowest incidence of both benign and malignant breast diseases 
(127). The topic of iodine and BC will be further discussed in paragraph 1.4.4. 
v Alcohol. It is estimated that BC cancer risk is increased by 7% to 10% for each 
one-unit increase in intake of alcohol per day (a unit is half pint of 4% strength 
beer or cider or 25 milliliters (mL) of 40% strength spirits; one small 125 mL 
glass of 12% strength wine is 1.5 unit). Several studies suggest that women who 
want to minimize their BC risk should not be drinking more than one alcohol 
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unit daily and they are recommended to include a period of at least 2 alcohol-
free days weekly (107).  
v Physical activity. A recent review of 73 observational studies indicated that  
moderate to vigorous physical activity reduces the risk of BC by an average of 
25% in pre- and post-menopausal women compared with inactive women. 
However, the optimal level of physical activity for BC cancer risk reduction is 
unclear and may be greater than current recommendations (128). 
Furthermore, these kind of observational studies conducted so far have major 
limitations, such as the heterogeneity of self-reported questionnaires used to 
measure the amount of physical activity (107).   
v Radiations. The increased neoplastic risk, including BC, after exposure to 
ionizing radiations is well known and dose dependent (129). Although the 
radiation from mammography is a low dose, it is estimated that yearly 
screening from 40 to 80 years of age can cause approximately 225 cases of 
fatal BC per million of screened women (130). 
v Chemicals. The exposure to several chemicals has been associated with an 
increased risk of BC, including polychlorinated biphenyls, polycyclic aromatic 
hydrocarbons, organic solvents (131) and a number of pesticides (132). 
1.3.2.3 Medical conditions 
Type II diabetes mellitus (DM) has been associated with an increased risk of 
developing many different types of cancer. A recent extensive review of existing 
meta-analysis and observational studies confirmed a significant association of type 
II DM only with 4 different types of cancer and BC was one of them (133). 
The precise mechanisms involved are not fully known, but several 
hypotheses have been postulated, considering that DM and cancer share several 
common mechanisms, including increased insulin and IGF signaling, dysregulation 
of ovarian steroid hormones and chronic inflammation (134).     
1.3.3 Classification 
BC cannot be viewed as a single clinical-pathological entity and it must be 
necessarily dissected into a number of more homogeneous entities, therefore its 
classification is complex and taking into account histological, biological and 
molecular factors. Despite all the efforts, the “perfect” classification of BC has 
not been written yet (135). 
1.3.3.1 Histopathological classification 
The histopathological classification of breast tumours is based on the different 
morphological features of mammary lesions and the World Health Organization 
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(WHO) classification, recently updated in 2012 and published by the International 
Agency for Research on Cancer (IARC), is adopted worldwide. The whole WHO 
classification is very complex and takes into account all the existing benign and 
malignant breast tumours; its integral report is beyond the scope of the present 
thesis. Malignant breast lesions may be primary, originating from breast 
epithelium, mesenchymal cells or breast lymphocytes, and secondary (metastatic 
tumours). In particular, malignant mesenchymal tumours include liposarcoma, 
angiosarcoma, rhabdomyosarcoma, osteosarcoma, leiomyoma and leiomyosarcoma 
(136).  
In the present thesis the term BC refers to invasive malignant lesions derived from 
the breast epithelium, summarized in Table 1-7. The most common form of BC is 
adenocarcinoma arising from the epithelial cells of the lactiferous ducts in the 
mammary gland lobes (108) and traditionally BC takes a different name according 
to the different part of the mammary gland it originates from (109):  
v Ductal carcinomas: originating from the epithelial components of the 
mammary ducts, both extralobular or intralobular 
v Lobular carcinomas: originating from the epithelial components of the 
terminal ductules  
The last version of WHO classification replaced the term “ductal carcinoma” 
(adopted until the previous 2003 version), with the more general “carcinoma of no 
special type”, referring to all tumours without the specific differentiating features 
that characterize the other categories of BC (exclusion diagnosis based on 
histopathological criteria). The rationale for this is that the term “ductal” conveys 
unproven histogenetic assumptions (derivation of the tumours from the ductal 
system) and also invasive ductal carcinoma does not comprise a uniform group of 
carcinomas (137). Invasive carcinoma of no special type (ex “ductal”) is the most 
common form of invasive BC, comprising between 40% and 75% of cases, followed 
by invasive lobular carcinoma (5-15%) (136). 
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Table 1-7: BC WHO histopathological classification of malignant lesions of the breast 
epithelium 
INVASIVE 
BREAST 
CARCINOMA 
Invasive carcinoma of no special type (ex invasive ductal carcinoma) 
§ Several subtypes 
40-75 % 
Invasive lobular carcinoma 
§ Several subtypes 
5-15 % 
Tubular carcinoma 2 % 
Cribriform carcinoma 0.3-0.8 % 
Mucinous carcinoma 2 % 
Carcinoma with medullary features 
§ Several subtypes 
<1 % 
Carcinoma with apocrine differentiation 4 % 
Carcinoma with signet-ring-cell differentiation NA (rare) 
Invasive micropapillary carcinoma 0.9-2 % 
Metaplastic carcinoma of no special type 
§ Several subtypes 
0.2-5 % 
Carcinoma with neuroendocrine features 
§ Several subtypes 
<1 % 
Other rare types 
§ Several subtypes 
<1 % 
TUMOURS 
EPITHELIAL-
MYOEPITHELIAL 
Adenomyoepithelioma with carcinoma NA (rare) 
Adenoid cystic carcinoma <0.1 % 
PRECUSOR 
LESIONS 
Ductal carcinoma in situ 20-25 % 
Lobular carcinoma in situ 
§ Several subtypes 
NA 
PAPILLARY 
LESIONS 
Intraductal papillary carcinoma NA (rare) 
Solid papillary carcinoma <1 % 
NA = Not available. Adapted from (136). 
1.3.3.2 Molecular classification 
Molecular classification of BC is essential for both BC prognostic assessment 
and choice of therapies, therefore mandatory in all BC cases. It is based on the 
following molecular biomarkers: oestrogen receptor (ER), progesterone receptor 
(PR), human epidermal growth factor receptor type 2 (HER2) and proliferation 
index Ki67. (135).  
v ER and PR are nuclear transcription factors that stimulate the growth of both 
normal and neoplastic breast cells (136, 138). They are routinely detected by 
immunohistochemistry (IHC) on primarily formalin-fixed paraffin-embedded 
(FFPE) tissue sections of BC and their expression is defined as a continuum 
ranging from 0% to 100% of positive cells (136). Both ER and PR are considered 
positive in the presence of ≥1% positive-staining tumour cells (139) and ER and 
PR positive expression is reported in respectively 80% and 60-70% of invasive 
BC, with PR expression highly correlated with ER expression (136). In fact PR 
expression is regulated by ER, therefore PR positivity indicates that the 
oestrogen-ER pathway is intact and functional. However, ER-PR correlation is 
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imperfect and 4 possible phenotypes of combined expression are possible, 
although it is debatable whether ER-negative/PR-positive tumours exist (136).  
v HER2 oncogene and oncoprotein. The HER2 gene encodes for a growth factor 
receptor on the surface of normal breast epithelial cells. This gene is 
amplified in approximately 15% of BC and its amplification is highly correlated 
with elevated protein expression. HER2 gene amplification and protein 
expression status are mainly determined on FFPE samples respectively by 
fluorescence in situ hybridization (FISH) and IHC (136).  In addition, other 
chromogenic methods that can accurately determine gene copy number using 
routine bright-field microscopy are becoming popular (140). HER2 expression is 
considered positive when an amplification of HER2 gene is detectable by FISH 
and/or >30% of tumoural cells show IHC staining of HER2 protein that can be 
classified as strong (3+) or moderately strong (2+). When tumours show little 
(1+ staining) or no (0 staining) protein expression by IHC, usually FISH reports a 
normal number of gene copies and the tumours are classified as HER2-negative 
(136, 141).  
v Proliferative fraction (Ki67). Tumour proliferation is an important BC 
prognostic factor and in clinical practice is usually determined by the 
immunohistochemical staining of Ki67 antigen. In particular, the Ki67 mouse 
monoclonal antibody recognizes a nuclear antigen present only in proliferating 
cells and not in resting cells (142). Proliferative fraction, by Ki67 detection, 
can be classified as low or high and is essential for a complete molecular 
classification of BC (135). 
 
Several different approaches have been attempted to unveil the molecular 
basis for heterogeneity of BC. Perou et al. used a hierarchical clustering analysis 
of gene expression profiling, including keratins, to identify molecularly defined 
classes of BC (luminal, HER2-enriched, basal-like, normal-like). They found that 
basal and luminal cells of breast epithelium were respectively ER-negative and ER-
positive and since then the terms “basal” and “luminal” have been introduced in 
BC molecular classification to describe ER-expression state (143). This 
classification has been shown to have prognostic value and predictive of the 
response to chemotherapy (135). However, it was derived from investigations on 
frozen tissue and therefore not applicable to formalin-fixed and paraffin-
embedded (FFPE) material routinely used.  
Consequently, new classifications based on surrogate protein markers 
detectable using the more familiar IHC have been applied and they are based on 
the combined evaluation of HER2, ER, PR and Ki-67 (144). The different BC 
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molecular categories are frequently updated and modified and one of the latest 
versions is reported in Table 1-8, according to the 2011 St. Gallen International 
Consensus. Despite the lack of complete overlap among BC molecular classes 
determined by gene expression profiling and protein expression by IHC, the 
molecular classification of BC based on IHC staining of proteinaceous markers has 
been endorsed to determine the choice of systemic treatments for BC (145).     
Table 1-8: BC molecular classification based on IHC staining 
 ER and/or PR HER2 Ki67 
Luminal A Pos Neg Low 
Luminal B – HER2 negative Pos Neg High 
Luminal B – HER2 positive Pos Pos Any 
HER-2 positive Neg Pos NA 
Basal-like (Triple negative) Neg Neg NA 
BC molecular classification according to the 2011 St. Gallen International Consensus, 
modified from (145). ER= oestrogen receptor; HER2= human epidermal growth factor 
receptor type 2; low Ki67 = <14%; NA = not assessed; Neg = negative; Pos = positive; PR= 
progesterone receptor. 
1.3.4 Clinical manifestations 
Usually BC presents as a firm lump in the breast, but can have additional 
local manifestations, including lymphedema (excess fluid in the subcutaneous 
tissue), nipple retraction or deviation or a thickened, leather-like appearance of 
the skin and abnormal contours of the breast because of traction on the 
suspensory ligaments (108). 
The BC cell can spread outside the breast and this process is called 
metastasization; the spread BC cells then produce nests of tumoural cells called 
metastases. There are two types of metastasization: via lymphatic system to the 
lymph nodes (lymphogenic metastasis) or via veins to different organs (distant 
metastasis). The most common site of BC metastases are axillary lymph nodes, but 
other different nodes may be involved, including cervical, parasternal, 
infraclavicular, supraclavicular and abdominal and both sides of the body may be 
involved (e.g. presence of contralateral lymph node metastases). The major sites 
of distant metastases of BC through the hematic route include bone, brain, lung 
and liver (108).  
1.3.5 Blood biomarkers 
In contrast to markers detected in the primary tumour tissue, blood tumour 
markers reflect a dynamic situation and their measurement can be repeated as 
required. A large number of blood tumour markers have been proposed for BC and 
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the most widely used in clinical practice are carcinoembryonic antigen (CEA) and 
cancer antigen 15.3 (CA15.3) (146).  
v CEA is an oncofoetal protein and its increased levels have been detected not 
only in BC but in several other different types of cancers, especially primary 
colorectal cancer (146). 
v The mucin MUC1 is a glycoprotein expressed by most “wet” epithelia, 
including mammary epithelial cells, and both aberrant and up-regulated 
expression of MUC1 are features of malignancy. MUC1 is highly heterogeneous 
and a large number of distinct monoclonal antibodies have been raised against 
different epitopes; a specific monoclonal antibody recognizing the antigen 
CA15.3 is the gold standard for MUC1 assessment in BC (146).  
CA15.3 has a higher sensitivity compared with CEA, considering that they are 
positive in respectively 54-80% and 30-50% of metastatic BC. Unfortunately, they 
have low specificity, since they may both be positive in many different malignant 
and benign (especially inflammatory) conditions (146).  
Although CA15.3 is more sensitive than CEA, CA15.3 is positive only in less than 
10% of early stage BC, therefore it is not recommended for screening or diagnosis 
of BC onset (147). Therefore, both CEA and CA15.3 have clinical utility only in 
advanced and metastatic BC, especially to monitor the response to treatments 
(146). Additional clinical tools include the assessment of distant metastasis at BC 
diagnosis and screening or early diagnosis of BC recurrence (148).    
Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) released 
by tumoural cells have been identified as very promising blood tumoural markers 
with great and important potentialities in clinical practice. In particular, they may 
be applied to assess cancer diagnosis, prognosis, treatment choice and prediction 
of tumoural response to it. In fact solid tumours exhibit both spatial and temporal 
heterogeneity; tumoural cells are affected with clonal and subclonal diversity, 
therefore two different cells are likely to be genetically different with a different 
behavior, especially when comparing primary tumour and its distant metastases. 
Furthermore, tumoural cells evolve over time under selection pressure from 
cancer specific treatments. CTCs and ctDNA therefore have the great potentiality 
of a non-invasive real-time assessment of tumour molecular profiles during the 
course of disease, considered as “liquid biopsy technologies”. However, further 
studies are still needed in order to validate and routinely use them in clinical 
practice (149, 150). 
MicroRNAs (miRNAs) are a group of small non-coding RNAs able to regulate 
gene expression at the post-transcriptional level by binding to the 3’ un-translated 
region of target messenger RNAs (mRNAs) (151). They have been proposed as well 
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as potential prognostic and predictive biomarkers in BC management, however 
they are still in a premature phase of investigation and further studies are needed 
in order to propose their assessment in clinical practice (152). 
1.4 THYROID DISEASES AND BREAST CANCER 
1.4.1 Benign thyroid diseases and breast cancer: an overview 
The relationship between benign thyroid disorders (BTD) and breast 
pathology has been studied since 1896, when Beatson reported that the use of 
oophorectomy and thyroid extract was useful in the treatment of metastatic BC 
(153). Subsequently, many studies addressed the connection between BC and 
thyroid diseases, in particular BTD and so far, after more than one century, this 
topic is still debated and rich in conflicting and contradictory results. Some 
authors support the presence of an association between BTD and BC (154-158) but 
others do not (159-163). The possible causes of this discrepancy are many, 
including the use of different diagnostic criteria for the existing BTD, the 
predominant retrospective or cross-sectional nature of existing studies, the high 
heterogeneity of BC and its subtypes and the fact that both BTD and breast 
pathology are two of the most common diseases among women, therefore a high 
number of studied subjects is required in order to obtain significant results.  
The association between BTD and BC seems to be bilateral, in the sense that 
a higher prevalence of BTD has been found among patients with BC, as well as a 
higher risk of BC among patients with BTD. In fact in 2003 Turken found a higher 
prevalence of both autoimmune and non-autoimmune BTD in 150 patients affected 
with BC compared with 100 controls (156). Many other authors confirmed a higher 
prevalence of BTD, in particular thyroid autoimmunity (TA), among patients with 
BC compared to controls, even if not confirmed by other studies. This will be 
described in more detail in the following paragraph 1.4.3. 
Regarding the opposite relationship, 2 cross-sectional studies from the same 
research group and 1 independent retrospective study showed about three-fold 
increased risk of BC in patients affected with any kind of BTD, both autoimmune 
or not, compared with the expected BC prevalence among age-matched general 
population calculated from national cancer registries (158, 164, 165). 
Interestingly, in studies from Prinzi et al. patients negative for anti-thyroid 
autoantibodies (TAb) had a higher BC prevalence compared with TAb positive, 
suggesting a protective role of TAb (158, 164). The impact on BC prognosis 
exerted by TAb, TPOAb in particular, will be introduced in the next paragraph 
1.4.3 and further discussed in paragraph 4.1.1. 
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1.4.2 Thyroid function and breast cancer 
The relationship between thyroid function and BC has been debated for a 
long time and contrasting results have been generated, with some authors 
claiming hypothyroidism associated with an increased (166) or reduced (167, 168) 
risk of developing BC, while others did not find any correlation at all (155, 159, 
160, 169). 
In particular, an increased risk of BC among hyperthyroid patients is a 
recurrent finding and Hellevik et al. in a prospective population study involving 
almost 30’000 participants found that individuals with a TSH below the normal 
range had a generalized increased risk to develop different types of cancers, with 
a Hazard Ratio (HR) for BC of 1.20 (170). Similarly, other population-based case-
control studies confirmed that hyperthyroidism seems to be associated with an 
increased risk of different types of cancer (171).   
The epidemiological finding of increased risk of BC among hyperthyroid 
patients and protective effect exerted by hypothyroidism is supported by in vitro 
experiments showing a tumour-promoting effect of thyroid hormones. In fact 
normal mammary epithelial cells express thyroid hormone receptors, therefore 
mammary gland development and gene expression are responsive to T3 (172, 173). 
Furthermore, in contrast to other hormone receptors, BC cells also express thyroid 
hormone receptors (174, 175). The activation of thyroid hormone receptors of the 
mammary gland induces differentiation and lobular growth in an oestrogen-like 
manner (175-177). In tumour transplant rodent models, thyroid hormones appear 
to stimulate tumour growth and metastasis, whereas treatment-induced 
hypothyroidism has opposite effects with favorable outcome not just in BC but in 
several other cancer types (171). 
During recent decades it has been debated whether an increased risk of 
cancer among hyperthyroid patients could be possibly due to the treatment with 
radioiodine. A recent Finnish long-term follow-up study conducted on a total of 
6148 patients affected with hyperthyroidism and treated with thyroidectomy or 
radioiodine seems to have definitively solved this debate, concluding that the type 
of treatment (thyroid surgery versus radioiodine) did not affect the overall risk of 
cancer and therefore radioiodine can be considered a safe treatment (178).      
1.4.3 Thyroid autoimmunity and breast cancer 
A relatively recent extensive meta-analysis published in 2012 confirmed the 
presence of a strong association between thyroid autoimmunity (TA) and BC (157), 
in total contrast with a previous meta-analysis published in 2002, that failed in 
confirming such association (161). A possible explanation is the use in the 2012 
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meta-analysis of more specific and appropriate definition of TA and the inclusion 
of additional studies that were not available in 2002.   
Several authors found an increased prevalence of anti-thyroid 
autoantibodies (TAb), especially anti-thyroid peroxidase (TPO) autoantibodies 
(TPOAb), among patients with BC compared with healthy controls (166, 179-181). 
In particular TPOAb prevalence in BC patients compared with healthy controls was 
respectively 36% and 19% according to Shering et al. (179), 23.5% and 8% according 
to Giani et al. (180) and 15% and 9.8% according to Kuijpens et al. (166). However, 
these findings have not been confirmed by other authors (163).     
According to two recent extensive cross-sectional studies, patients affected 
with non-autoimmune BTD had a higher prevalence of BC compared with TAb 
positive patients, suggesting a protective role of TAb (158, 164). In particular, 
several small-scale studies described a better BC outcome among women positive 
for serum TPOAb compared with TPOAb negative (182-184), even if not confirmed 
by all authors (185); this topic will be further discussed in paragraph 4.1.1. 
1.4.4 Iodine deficiency, goitre and breast cancer 
The mammary gland during pregnancy and lactation is highly effective in 
capturing I-, essential to form iodoproteins (e.g. iodocasein) and provide the 
neonate with iodine to make his/her own thyroid hormones necessary to normal 
neural development (127). This is possible through the expression by the 
mammary gland of NIS and lactoperoxidase (LPO), that will be better discussed in 
the next paragraph 1.5.1 and in chapters 2 (NIS) and 3 (LPO). 
Iodine also exerts an anti-oxidant effect in iodide-concentrating cells, e.g. 
thyroid and breast cells, therefore iodine deficiency may cause a decrease in 
antioxidant defenses and therefore an increase of oxidative stress and cell 
damage (186-188). Accordingly, Eskin and co-workers showed that iodine 
deficiency may cause evident dysplasia and cell atypia in mammary tissue of rats 
and that iodine replacement was able to reverse these changes (189). The same 
authors also demonstrated that the block of I- uptake with perclorate was 
associated with the presence of mammary gland atypia in rats (190).  
A possible role of iodine in human breast pathology is provided by the 
study of Kilbane et al., showing a reduced content of tissue iodine in BC tissue 
compared to breast benign tumours, e.g. fibroadenomas (187).  
Iodine deficiency as a common risk factor for BC and BTD is further 
supported by the evidence of an increased prevalence of goitre among patients 
affected with BC, as first reported by Smyth et al. (191) and then confirmed in 
other independent studies (156). 
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1.4.5 Thyroid cancer and breast cancer 
According to Surveillance, Epidemiology and End Results (SEER) program of 
U.S. cancer registry data, the cumulative incidence of developing any second 
cancer after thyroid cancer is 16% at 25 years, with BC being the most common 
(36%) (192). A reciprocal association between thyroid cancer and BC has been 
described (193) but still the subject of controversy. Accordingly, some authors 
observed an increased prevalence of BC among patients with thyroid cancer (192), 
while others reported an increase of thyroid cancer cases among BC patients 
(194), not confirmed in a different large retrospective cohort study (195).      
Although still a matter for debate, the possible explanations for an 
association between BC and thyroid cancer are several and involve common 
genetic, endocrine or environmental risk factors. The increased prevalence of BC 
after thyroid cancer could be also due to a combination of several elements, 
including 1) the excellent 10-year overall survival of thyroid cancer (up to 94%) 
(102); 2) the increased medical surveillance of neoplastic patients and consequent 
screening bias (196); 3) BC is the most common neoplastic disease among women 
(197), therefore it is not surprising if also the most common neoplastic disease 
among patients with thyroid cancer.  
Regarding the opposite relationship, an increased prevalence of thyroid 
cancer after BC could also be due to the involvement of thyroid gland within the 
radiation field during radiotherapy for BC, however the adult thyroid is much less 
susceptible to the carcinogenic effects of medical radiation compared with the 
thyroid of a child. Accordingly, the National Surgical Adjuvant Breast and Bowel 
Project involving 818 women with BC found that only 2 cases of thyroid cancer 
occurred after breast irradiation (198). Similarly, no increased risk of thyroid 
cancer after radiation therapy for BC has been found in a large retrospective 
cohort study (195). 
Regarding the genetic factors, BC and thyroid cancer are surely associated 
in Cowden’s syndrome, one rare autosomal dominant genetic condition 
characterized by a germline mutation of tumour suppressor PTEN gene, 
determining an increased predisposition to different cancer types. However, 
Cowden’s syndrome is quite rare, therefore responsible for only a small proportion 
of associated BC and thyroid cancer (193).   
Regarding the endocrine factors, sex hormones are likely to be involved, 
considering that oestrogens are fundamental for BC progression and ER has been 
found also in both neoplastic and non-neoplastic thyroid tissue (50).  
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1.5 THESIS AIMS 
The present thesis has two main aims: 
1) To identify hypothetical common antigens between thyroid and breast cancer 
(BC) tissue 
2) To verify the prognostic role of TPOAb in a large cohort of women with BC 
1.5.1 Common antigens between thyroid and breast cancer tissues 
It is known that thyroid and tumoural mammary glands share similar 
physiological properties and activities (199), as summarized in Figure 1-9: 
v They both express NIS and iodine has a crucial role for both glands 
v They both have a peroxidase activity: TPO in thyroid and lactoperoxidase 
(LPO) in breast 
Figure 1-9: Schematic representation of thyroid/tumoural breast cells’ similar 
properties 
 
H2O2 = hydrogen peroxide; I
- = iodide; I2 = iodine; LPO = lactoperoxidase; Na
+ = sodium; NIS 
= sodium iodide transporter; TPO = thyroid peroxidase.  
 
The epidemiological suggestion of an association between thyroid 
autoimmunity (TA) and BC and in particular the suggested protective role of 
TPOAb among patients with BC led us to hypothesize the presence of a common 
immune response against a shared antigen between thyroid and BC cells, leading 
to thyroid tissue damaging on one side and BC growth control on the other side. 
As previously introduced in paragraph 1.1.2, NIS is a transmembrane 
glycoprotein involved in active transport of iodide into follicular thyroid cells. 
Tazebay et al. demonstrated by immunohistochemistry that both lactating breast 
cells and BC cells express NIS, while no NIS activity was shown in normal non-
lactating samples from reductive mammoplasties in humans (200). Therefore, 
considering that NIS is expressed by both thyroid and BC tissues, we hypothesized 
NIS as putative common antigen between BC and thyroid cells and we searched for 
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autoantibodies to NIS (NISAb) as possible epiphenomenon of this shared immune 
reaction. This will be discussed further in chapter 2.  
As alternative possible antigen, considering that TPOAb are more prevalent 
among patients affected with BC, we hypothesized that TPO itself is expressed not 
only in thyroid tissue but also in BC tissue. As third possibility, since TPO and LPO 
belong to the same family of proteins (peroxidases) and have considerable 
homology, we hypothesized that TPOAb could cross-react with shared or similar 
epitopes present in both TPO and LPO. Both hypotheses will be discussed in 
chapter 3 (TPO) and chapter 5, paragraph 5.2.1 (TPOAb cross-reactivity). 
1.5.2 Prognostic role of TPOAb in a large cohort of women with breast 
cancer 
Considering that so far a protective role for TPOAb among patients with BC 
has been described only in small-scale studies with not all authors agreeing, the 
second aim of this thesis was to investigate the impact of TPOAb on BC prognosis 
in a large-scale cohort of individuals. This will be accurately described in Chapter 
4. 
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2 NEUTRAL SERUM AUTOANTIBODIES TO 
THE SODIUM IODIDE SYMPORTER (NIS) 
2.1 INTRODUCTION 
2.1.1 Human NIS gene and protein: molecular characterization, 
function, regulation 
The Human NIS (hNIS) gene is localized on chromosome 19p12-13⋅2 and 
consists of 15 exons interrupted by 14 introns, with an open reading frame of 1929 
nucleotides (201). In 1995 Carrasco’s group cloned the rat NIS (rNIS) from a Fisher 
rat thyroid line (FRTL-5)-derived complementary-deoxyribonucleic acid (cDNA) 
library (202) and in 1996 Smanik et al. cloned hNIS, having 87% identity with rNIS 
(203). hNIS gene encodes for a 643 amino acid membrane-bound glycoprotein 
located at the baso-lateral portion of the thyroid follicular cell (202, 204). The 
protein has a molecular mass of approximately 70-90 kilodaltons (kDa) due to 
variable levels of glycosylation and presents 13 putative transmembrane domains, 
14 extracellular domains, an extracellular amino-terminus and an intracellular 
carboxyl-terminus (Figure 2-1).  
Figure 2-1: Schematic representation of NIS transmembrane glycoprotein 
 
Adapted from (205). 1-643 = amino acid sequence number. I-XIII = transmembrane 
domains. 1-14 = extra membrane domains. Δ = N-linked glycosylation sites.  
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 NIS carrier co-transports two sodium ions (Na+) along with one iodide (I-), 
with the transmembrane sodium gradient serving as the driving force for iodide 
uptake (Figure 2-2). The sodium gradient is generated by the ouabain-sensitive 
Na+/potassium (K+)-adenosine triphosphatase (Na+/K+-ATPase). NIS-mediated 
iodide transport is therefore inhibited by the Na+/K+-ATPase inhibitor ouabain as 
well as by the competitive inhibitors thiocyanate and perchlorate (204). 
 NIS expression in thyroid tissue is extensively regulated, as illustrated in 
Figure 2-2. Several inhibitors of NIS expression have been identified: 
triiodothyronine (T3), thyroglobulin (Tg), elevated concentrations of iodide (acute 
Wolff-Chaikoff effect), estradiol, transforming growth factor-β (TGFβ), various 
cytokines, ceramide, sphingomyelinase and dexamethasone. The most powerful 
positive regulator is TSH, stimulating both NIS gene and protein expression and 
also its iodide transport activity, acting through the cyclic adenosine 
monophosphate (cAMP) signal transduction pathway. Other positive regulators are 
forskolin and adenosine. Retinoic acid receptor agonists have shown opposing 
effects depending on the differentiation state of thyroid cells: they suppress NIS 
expression and iodide uptake in normal thyroid cells, but in thyroid tumours exert 
the opposite effect, i.e. enhancement of NIS expression and iodide uptake (206).  
Figure 2-2: NIS protein function and regulation 
 
Schematic representation of a thyroid follicular cell and sodium iodide symporter (NIS) 
function and regulation, adapted from (205). ADP = adenosine diphosphate; ATPase = 
adenosine triphosphatase; cAMP = cyclic adenosine monophosphate; I- = iodide ion; K+ = 
potassium ion; Na+ = sodium ion; Pi = inorganic phosphate group, Tg = thyroglobulin, TGFβ 
= transforming growth factor β, TPO = thyroid peroxidase, TSH = thyroid-stimulating 
hormone, TSHR = TSH receptor, T3 = triiodothyronine, T4 = thyroxine. 
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2.1.2 NIS expression in breast tissue and other tissues 
Iodide accumulation in breast tissue was first reported in 1957 and it is 
crucial to supply iodide to the infant for the biosynthesis of thyroid hormones 
(207). Carrasco’s group demonstrated by immunohistochemistry (IHC) that 80% of 
human BC tissues express NIS, compared with 23% of peri-tumoural breast tissue 
(PT) and no expression at all in any of the normal non-lactating breast samples 
obtained from reductive mammoplasties. In the same study, they also analyzed 
rat NIS (rNIS) expression by Western Blot (WB) and found the presence of 
immunoreactivity only in mammary glands from lactating rats, while it was absent 
in non-lactating mammary glands. Authors therefore concluded that NIS protein is 
expressed in lactating breast tissue and BC tissue but not in normal breast tissue 
(200). 
The earlier promise of a potential application of NIS as a specific indicator 
of breast malignancy was uncertain, considering that NIS protein expression has 
been found, even if at a lower extent, also in apparently normal PT (200, 208). 
This promise has also been further undermined by studies showing hNIS protein or 
messenger ribonucleic acid (mRNA) expression and iodide accumulation in benign 
breast tissues (fibroadenoma) (187, 209), with hNIS cDNA expression found to be 
even higher in fibroadenoma compared with BC (210).  
Following Tazebay et al. (200), other authors confirmed the presence of 
NIS protein expression by IHC in 66-90% of BC tissues tested, reviewed in Beyer et 
al. However this interesting study underlined how all the previous authors mainly 
assessed NIS protein by IHC using only one antibody to NIS, often polyclonal 
(therefore more likely to be aspecific compared with monoclonal antibodies) and 
predominantly giving intracellular staining, instead of membranous as expected 
with a transmembrane glycoprotein like NIS. Beyer et al. tested further BC tissues 
by IHC using different antibodies to NIS (monoclonal, polyclonal and affinity 
purified polyclonal), all giving discrepant results. They therefore concluded that 
the previous finding of NIS protein expression by IHC in high percentages of BC 
tissues are likely to be the result of aspecific staining and stated that NIS protein 
could be expressed by a much lower number of BC than previously thought (211). 
Similar conclusions were reached by Peyrottes et al., analyzing by IHC 30 breast 
cancer tissues using 3 different monoclonal NISAb. They found no significant 
membrane staining in any of the samples, with only few samples showing a weak 
and diffuse intracellular anti-NIS staining. By western blot (WB), they did not find 
the fully glycosylated NIS protein expression but only the partially glycosylated 
form; moreover, WB results did not correspond with the few cases found positive 
(intracellular staining) by IHC. They therefore concluded that it could not be 
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excluded that the BC intracellular staining obtained by IHC with antibodies to NIS 
(even if monoclonal) was non-specific (212). The hypothesis that NIS is expressed 
by a minority of BC and usually at a low level (211, 212) is in agreement with the 
evidence that only 17-25% of apparently NIS protein positive BC demonstrate 
functional radionuclide uptake by scintigraphic studies (213, 214), even if an 
impairment of cell surface trafficking in BC cells leading to reduced NIS surface 
expression cannot be excluded (211).       
The nucleotide sequence of hNIS cDNA expressed in thyroid (tNIS) and 
mammary gland (mgNIS) have been found to be identical (215). Regarding the NIS 
protein, studies in rats showed a higher level of glycosylation in tNIS compared 
with mgNIS, having a molecular weight of respectively 100 kDa and 75 kDa (200).  
In addition to thyroid and breast, other tissues have long been known to 
have an active TSH independent process of iodide accumulation (204). 
Accordingly, NIS mRNA and/or protein expression have been found also in other 
tissues, either neoplastic or non-neoplastic, including colon, kidney, ovary, 
endometrium, prostate, lung, gastric mucosa, salivary (parotid) and lacrimal 
glands (207, 208).  
2.1.3 NIS protein as possible autoantigen and autoantibodies to NIS 
(NISAb) 
2.1.3.1 NISAb in autoimmune patients and healthy controls 
Thyroid peroxidase (TPO), Tg and thyroid-stimulating hormone (TSH) 
receptor (TSHR) are well known thyroid autoantigens and Raspè et al. in 1995 
suggested NIS as a possible additional thyroid autoantigen, even if rarely. In fact 
these authors found that 1/147 (0.7%) human sera from patients with several 
types of autoimmunity was able to reduce the I- uptake of dog thyrocytes in 
culture by selective inhibition of NIS carrier. Additional experiments with mouse 
monoclonal antibodies indicated that autoantibodies to NIS (NISAb) are most likely 
responsible for this inhibition, therefore NIS can be considered as a potential 
autoantigen (216). 
Subsequent studies further investigated the presence of inhibiting NISAb 
and reached very contrasting conclusions. Weetman’s group found the presence of 
iodide uptake inhibition in about 30% of sera from patients with Graves’ disease 
and obtained the same results when using purified immunoglobulins (Igs), 
therefore they concluded that inhibiting NISAb exist and are common (217, 218). 
On the other hand, two independent research groups (Costagliola’s and 
Pinchera’s) found respectively very few and moderate iodide uptake inhibition in 
sera from patients affected by thyroid autoimmunity (TA) compared to healthy 
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controls, but in both studies the inhibition disappeared after serum dialysis and 
was not present when testing purified Igs instead of sera, therefore they 
concluded that inhibiting NISAb are very rare or barely exist (219, 220). A possible 
explanation for these discordant results is that many non-specific I- uptake 
inhibitors could have created artifacts, such as inorganic salts including I- itself, 
perchlorate, azide, disyedenin and growth factors, e.g. epidermal growth factor 
(EGF) (216).  
Additional studies investigated the presence of “neutral” NISAb (bind NIS 
but do not affect its symporter function), using recombinant hNIS protein 
produced by an in vitro transcription/translation system. Using 
immunoprecipitation, sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
(SDS-PAGE) and autoradiography, they reported the presence of neutral NISAb in 
24% (218), 20.8% (221) and 14% (222) of autoimmune hypothyroid patients, 
significantly higher than healthy control subjects in all cases. In particular, 
Seissler et al. detected neutral NISAb in 4.8% of healthy controls (221), while both 
authors of Weetman’s group found no NISAb in healthy controls (218, 222). In one 
of these studies NISAb activity was also explored with iodide uptake assays using 
CHO cells transfected with full-length hNIS; the presence of NIS inhibiting activity 
was found in both sera and isolated Igs. Interestingly, a poor correlation was 
observed between neutral and blocking NISAb; in particular, antibodies binding 
NIS (detected by immunoprecipitation) were absent in 50% sera resulted positive 
for inhibiting NISAb (investigated by iodide uptake assays) (218).      
2.1.3.2 NISAb in patients with breast cancer 
Smyth’s group reported a more than 3 fold lower iodine (I2) content in both 
BC tissue specimens and their correspondent PT tissue, compared with benign 
breast tumours (fibroadenoma). They therefore suggested a disorder in I- uptake 
in patients with BC and postulated the presence of inhibiting NISAb in sera from 
patients with BC, able to block NIS function in breast cells and consequently 
reduce I2 content. Therefore in the same study authors investigated sera from 
different individuals for the presence of I- uptake inhibition activity and such 
activity was found to be significantly more prevalent in BC patients (19%) 
compared with healthy controls (3%), even if a similar inhibiting activity was 
present also in sera from patients affected with fibroadenoma (16.3%) and Graves’ 
disease (31.4%). The inhibiting activity was preserved also after Igs purification, 
therefore authors concluded that the reduced I2 content observed in BC tissue 
could arise from the presence in patients’ sera of inhibiting NISAb (187).  
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In order to verify this hypothesis in a different cohort, Pinchera’s group used 
purified Igs from sera of patients with both BC and TA, TA alone and age-matched 
healthy controls. They investigated Igs interference on I- uptake by a Chinese 
hamster ovary (CHO) cell line stably transfected with hNIS and found no inhibiting 
activity in any of the patients’ Igs tested, concluding that the I- uptake inhibition 
cannot be the mechanism to explain the lower content of iodine in BC tissue 
(223). Similarly, these contrasting results may be partially explained by the 
presence of artifacts due to non-specific I- uptake inhibitors, as commented in the 
previous paragraph.  
2.1.4 Hypothesis and aims 
The main hypothesis of the present thesis is the presence of an immune 
response to a shared thyroid/breast auto-antigen, which would explain the 
relationship between TA and both BC prevalence and improved outcome. 
Considering that NIS glycoprotein is expressed in both thyroid and BC cells, in this 
chapter we hypothesized NIS as the likely common antigen and we searched for 
neutral NISAb (binding NIS but not necessarily affecting its function) among sera of 
patients with BC and/or TA. In fact the presence of these antibodies, especially in 
BC patients, would support our hypothesis that NIS is a thyroid/breast-tissue 
shared auto-antigen. 
2.2 MATERIALS AND METHODS 
2.2.1 Establishment of CHO cell lines expressing hNIS  
2.2.1.1 CHO cells transfection with hNIS complementary deoxyribonucleic 
acid (cDNA) 
CHO cells were maintained (+37°C; 5% CO2) in Ham’s F-12 with L-glutamine 
culture medium (BioWhittaker®, Lonza, Belgium) supplemented with 10% foetal 
calf serum (FCS), 2% penicillin/streptomycin (PS), 1 millimolar (mM) sodium 
pyruvate and 0.1% sodium bicarbonate.   
We used hNIS cDNA cloned into the eukaryotic expression vector pcDNA3 
(pcDNA3-hNIS) encoding amino acid 1 to 612 of hNIS and containing the 
aminoglycoside antibiotic G418 resistance gene, gift from Dr. S.M. Jhiang (The 
Ohio State University, Columbus, Ohio) (203, 217).  
CHO cells were transfected with pcDNA3-hNIS (CHO-NIS) and empty pcDNA3 
vector (CHO-Empty) as control using the transfection reagent TransFast® 
(Promega) according to the manufacturer’s instructions. Briefly, a 90% confluent 
25 cm2 flask was split into 3 60 mm dishes. The day after the culture medium was 
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removed, dishes were washed with serum-free culture medium and the following 
were added to each dish: i) 2 mL of serum-free culture medium ii) 5μg of DNA 
(one dish pcDNA3, one dish pcDNA3-hNIS, one dish left without DNA) iii) 
TransFastTM Reagent 15 μl (1:1 ratio with DNA: 3 μl TransFastTM Reagent per μg of 
DNA). After 1 hour of incubation at 37°C, 4 mL of normal culture medium were 
added. The following day, the selection of transfected cells using 400 
micrograms/milliliter (μg/mL) G418 enriched culture medium was started and 
continued for 4 weeks. A total of 3 different consecutive transfections have been 
performed. 
2.2.1.2 Cloning by serial dilutions 
Four weeks after the transfection, CHO-NIS transfected cells were seeded 
by serial dilution into 96-well plates and nourished with G418 enriched culture 
medium, in order to isolate positive CHO-NIS expressing clones. After 7-10 days, 
wells showing only one colony were transferred into 12-well plates, nourished with 
G418 enriched culture medium and, when confluent, transferred into 25 cm2 and 
75 cm2 flasks for freezing or NIS expression testing. A total of 26 different CHO-NIS 
clones were isolated.   
2.2.1.3 Testing for hNIS mRNA expression 
v Ribonucleic acid (RNA) was extracted from CHO-NIS clones, CHO-Empty 
controls and fresh human thyroid tissue (TT) as positive control (obtained with 
ethical approval and informed consent from a patient undergoing 
thyroidectomy for Graves’ disease), using TRI Reagent® solution (monophasic 
solution of phenol and guanidine isothiocyanate from Ambion, Life 
Technologies, Paisley, UK). Preparation of cells (CHO-NIS and CHO-Empty): 80-
90% semi-confluent cells in a 25 squared centimeter (cm2) flask were washed 
twice with 5 mL phosphate-buffered saline solution (PBS), aspirated and then 
2mL TRI Reagent® solution was added, pipetted several times in order to 
obtain a homogeneous lysate and transferred to two 1.5 mL Eppendorf tubes. 
Preparation of fresh tissue (TT): 100 mg fresh frozen TT [fresh tissue snap-
frozen in liquid nitrogen and immediately stored at -80 degrees Celsius (°C) 
until further use] was manually homogenized using a porcelain mortar and 
pestle containing liquid nitrogen to keep the sample frozen during the whole 
procedure and homogenized material finally transferred in a 1.5 mL Eppendorf 
tube containing 500 microliters (µl) of TRI Reagent® solution. Eppendorf tubes 
containing cells/tissue lysates and TRI Reagent® solution had 100 µl 
chloroform added for every 500 µl of TRI Reagent® solution used, shaken 
vigorously for 60 times, left for 5 minutes at room temperature and 
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centrifuged (Mikro 200R, Hettich Zentrifugen, Tuttlingen, Germany) at 4°C at 
13’000 revolutions per minute (rpm) for 15 minutes. The upper aqueous phase 
was transferred to a new 1.5 mL Eppendorf tube containing isopropanol 250 µl, 
gently mixed 6 times, left for 10 minutes at room temperature and centrifuged 
at 4°C at 13’000 rpm for 10 minutes. The supernatant was discarded, the RNA 
pellet was washed with 500 µl of 75% ethanol (brief vortex) and centrifuged at 
4°C at 8600 rpm for 5 minutes. Finally, the supernatant was discarded, the 
RNA pellet air-dried and re-suspended in 20 µl distilled water (dH2O) RNase – 
DNase free (RDf-dH2O). Total RNA concentration in nanograms(ng)/µl was 
determined from spectrophotometric absorption at 260 nanometers (nm) with 
GeneQuant pro ultraviolet–visible (UV/Vis) spectrophotometer (Biochrom Ltd, 
Cambridge, UK); the RNA sample purity was also tested, verifying a ratio of 
the absorbance at 260 and 280 nm (A260/280) between 1.7 and 2.0 with all the 
preparations. The total RNA integrity was tested by separating 1 µl total RNA 
on 2% agarose gel and verifying the presence of ribosomal RNA 28S and 18S 
bands at approximately 5 kilobases (kb) and 2 kb levels. The RNAs were stored 
in water at -80°C until further use. 
v Reverse transcription (RT) procedure was applied to synthesize first-strand 
cDNA from total RNA. 1 µg total RNA previously denatured in RDf-dH2O at 65°C 
for 10 min was added to a RT reaction mixture (Promega, Madison, WI, USA) in 
a final volume of 20 µl containing 8 mM deoxy-nucleoside triphosphate (dNTP) 
mix, 200 units (u) Moloney Murine Leukemia Virus (M-MLV) reverse 
transcriptase, 40 u rRNasin RNase inhibitor, 0.4 µg odT (oligo-deoxy-thymine 
nucleotides short sequence), 4 µl of 5x buffer and RDf-dH2O for final volume 
adjustment. The reaction mixture was incubated at 37°C for 1 hour, heat 
inactivated at 95°C for 5 minutes, finally cooled at 4°C and immediately 
stored at -20°C.   
v Standard polymerase chain reaction (PCR) and agarose gel analysis.  
NIS primers were designed from the published sequences of hNIS gene 
(referred as the member 5 of solute carrier family 5, SLC5A5; GenBank 
NM_000453) using Primer 3 Plus software (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi). Primers were then tested for specificity 
with NCBI Basic Local Alignment Search Tool (BLAST: 
http://blast.ncbi.nlm.nih.gov/Blast.cgi) and produced by Invitrogen (Carlsbad, 
USA): forward primer CTCCCTGCTAACGACTCCAG (1842-1861 exon 12) and 
reverse primer GAGGTCCCACCACAACAATC (2029-2048 exon 14), delimiting a 
hNIS nucleotide sequence of 207 base pairs (bp).  
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The RT-resulting cDNA was amplified by PCR using the AmpliTaq GoldTM 
DNA Polymerase kit (Applied Biosystems, Life Technologies, Paisley, UK) in a 
25 µl PCR reaction mix containing 1 µl (approximately 2 ng) cDNA, 2.5 mM 
magnesium chloride (MgCl2), 2mM dNTP mix, 0.1 µM NIS forward primer, 0.1 
µM NIS reverse primer, 2.5 u AmpliTaq GoldTM DNA Polymerase, 2.5 µl 10x 
buffer II and RDf-dH2O for final volume adjustment. Reactions always included 
a negative control with dH2O in place of cDNA and were performed using the 
TC-512 gradient thermal cycler (Techne, Minneapolis, USA): 1 cycle, 95°C for 5 
minutes; 35 cycles, 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 
minute; 72°C for 6 minutes.  
Resulting PCR products were electrophoresed on 2% agarose gel in TAE 
buffer [Tris-acetate-ethylenediaminetetraacetic acid (EDTA); containing 
ethidium bromide 1 ng/µl] using PowerPacTM 3000 machine (Bio-Rad, Hercules, 
USA). cDNA samples were loaded on the gel using blue/orange loading dye 6x 
(Promega, Madison, WI, USA; 1 µl dye for 9 µl cDNA sample) and 100 bp DNA 
Ladder, ranging from 100 bp to 1000 bp (Promega, Madison, WI, USA), was 
used to estimate the amplicons’ molecular weight. The gel was read with 
MultiImage II AlphaImager HP (Alpha Innotech, San Leandro, USA).    
v Sequencing of PCR amplicon to confirm identity. 
PCR single products were first precipitated and purified by adding an equal 
amount of polyethylene glycol (PEG) solution (26% PEG, 6.6 lM magnesium 
chloride (MgCl2) and 0.6 M Na acetate). The mix was vortexed briefly 
(WhirlimixerTM, Fisons Scientific Equipment, now Fisher Scientific, 
Loughborough, UK), left at room temperature for 10 min, centrifuged at room 
temperature at 13’000 rpm for 30 minutes, supernatant discarded, 500 µl of 
70% Ethanol was added, vortexed for 30 seconds, spun at room temperature at 
13’000 rpm for 10 minutes, supernatant discarded, samples air-dried, pellet 
re-suspended in 15-40 µl distilled water RNAase – DNAase free, vortexed twice 
for 10 seconds each. 5 µL of sample with 1.5 µl of loading dye were analysed 
on a 2% agarose gel in Tris-acetate-EDTA (TAE) buffer in order to verify the 
presence of PCR products after the PEG-purification steps. 
Purified PCR products were sequenced in a 10 µl reaction containing 2 µl 
BigDye Terminator Sequencing Kit (Applied Biosystems [ABI], Life 
Technologies, Waltham, USA), 1 µl NIS forward primer (10 pmol/l), 
approximately 25 ng PEG-precipitated PCR products (5-7 µl) and distilled water 
to reach the final reaction volume (0-2 µL). Sequencing reactions were 
developed on TC-512 gradient thermal cycler (Techne, Minneapolis, USA) using 
the same annealing temperature as for the primer combination.  
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The products where then sodium acetate (NaOAc)-precipitated applying 
the following procedure: to the 10 µL sample was added 3 µl of NaOAc pH4.6, 
62.5 µl of non-denatured 95% ethanol, 24.5 µl deionized water (final volume 
reaction = 100 µl), vortexed briefly, left at room temperature for 15 minutes 
to precipitate the extension products, centrifuged at room temperature at 
13’000 rpm for 20 minutes. Then the following steps have been repeated 
twice: supernatant discarded, 250 µl of 70% ethanol added, mixed briefly, 
centrifuged at room temperature at 13’000 rpm for 5 minutes, supernatant 
discarded. Finally, samples were air-dried and analyzed on an ABI Prism 377 
DNA automatic sequencer (Applied Biosystem [ABI], Life Technologies, 
Waltham, USA).  
2.2.1.4 Testing for hNIS protein expression  
NIS protein expression on the surface of CHO-NIS cells was tested by flow 
cytometry using a mouse monoclonal antibody to hNIS, as described in the next 
paragraph 2.2.2. 
2.2.2 Flow cytometry 
2.2.2.1 Standard protocol  
v CHO cells preparation. CHO cells 70-90% confluent were detached from 75-cm2 
flasks (one for CHO-NIS and one for CHO-Empty) with 5 ml PBS containing 5 mM 
ethylenediaminetetraacetic acid (EDTA)/ethylene glycol tetraacetic acid 
(EGTA), transferred to universal tubes, and washed in a PBS solution 
containing 0.5% bovine serum albumin (BSA), 2mM EDTA and 20 mM Hepes 
(flow buffer). Cells were pelleted at 1200 rpm for 6.5 minutes at 4°C and the 
supernatant removed by inversion. Cells were counted and transferred to BD 
Falcon round bottom polystyrene tubes (Scientific laboratories supplies, 
Nottingham, UK) and adjusted to 50,000 cells/tube.  
v Incubation with first antibody (1st Ab). Incubations with flow buffer (100µl) 
containing the mouse monoclonal antibody VJ2 directed against an 
extracellular domain of hNIS (AA 272 – 515, 1:50 dilution, kindly donated by Dr 
S. Costagliola, Free University of Brussels) (224) or heat inactivated human 
serum (normal or pre-adsorbed, 1:50 dilution) or extracted immunoglobulins 
(Igs) from various patients (1:50 dilution) were performed for 1 hour at room 
temperature (Figure 2-3). 
v Incubation with second antibody (2nd Ab) and viability dye. Cells were then 
washed three times (X3) with flow buffer (1ml) and centrifuged as above, 
followed by a 30 minutes incubation at 4°C in the dark with flow buffer 
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(100µl) containing goat polyclonal heavy and light chains directed against 
mouse Igs class G (IgGs) conjugated with Alexa Fluor 488 at 1:2000 dilution 
(ab150113 goat polyclonal anti-mouse IgG H&L Alexa Fluor 488, abcam, 
Cambridge, UK) or goat polyclonal heavy (H) and light (L) chains directed 
against human IgGs, conjugated with green-fluorescent dye Alexa Fluor 488 at 
1:50 dilution [goat polyclonal anti-human IgG (H+L) Alexa Fluor 488, Life 
Technologies, Carlsbad, USA], like shown in Figure 2-3. 
50µl of 1:1000 diluted viability dye, LIVE/DEAD® Fixable Near-IR Dead Cell 
Stain Kit (Invitrogen, Carlsbad, USA) were finally added to each tube and 
incubated at 4°C in the dark for a further 30 minutes, to facilitate detection 
of damaged cells. Experimental controls omitting 1st Ab (either VJ2 or 
patients’ serum) were also analyzed in the same experiment to investigate 
nonspecific binding of either mouse or human Alexa Fluor conjugated 2nd Ab. 
v Final wash and cells’ fluorescence analysis. Following the final incubation cells 
were washed X3 with flow buffer as before and re-suspended in 250µl Flow 
Buffer. The fluorescence of 10’000 cells/tube was assayed by BD FACSCanto II 
flow cytofluorometer, FACSDiva Software (BD Biosciences, San Jose, USA). 
Channels able to detect fluorescent dyes fluorescein isothiocyanate (FITC) and 
Allophycocyanin - cyanine Cy-7 tandem conjugate (Apc-Cy7) were used to 
detect respectively Alexa Fluor 488 and Near-IR dead cell stain signals. No 
compensation was needed since their excitation-emission peaks had different 
wavelengths (500-520 nm and 633-750 nm respectively) and as expected their 
compensation matrix provided values less than 0.0017. Additional two 
channels were also used to sort cells according to forward scatter (FSC) and 
side scatter (SSC), respectively detecting the size and the granularity of cells. 
Figure 2-3: Schematic representation of a flow cytometry experiment  
 
AF 488 = fluorescent dye Alexa Fluor 488, conjugated to each second antibody (2nd Ab); 
Anti-mouse-IgGs = goat heavy and light chains directed against mouse immunoglobulins 
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class G (IgGs); Anti-human-IgGs = goat heavy and light chains directed against human 
immunoglobulins class G (IgGs); CHO = CHO cells transfected with empty PCDNA3 vector 
(CHO-Empty); CHO-NIS = CHO cells transfected with human NIS (hNIS) gene; VJ2 = mouse 
monoclonal antibody directed against hNIS. Panel A represent the positive control. Panels 
B and D represent the negative controls, respectively for anti-mouse and anti-human 2nd 
Abs. Panel C represents how the presence of NISAb has been investigated: if the human 
serum tested contained anti-NIS IgGs, they would bind to CHO-NIS cells (but not CHO), 
therefore the 2nd anti-human Ab would bind as well (not in CHO). Each human serum has 
been tested separately.   
2.2.2.2 Computer data analysis  
Flow cytometric data were analyzed using FlowJo 8.8.6 Software (TreeStar 
Inc., Ashland, USA).  
Cells were first gated according to FSC and SSC in order to exclude 
damaged cells, usually characterized by low signal intensity in both FSC and SSC, 
as represented in Figure 2-4 (panel A). Then, only cells showing low staining in 
Apc-Cy7 channel were gated and analyzed, in order to exclude damaged and dead 
cells, usually positive for Near-IR dead cell stain and therefore characterized by 
high signal in Apc-Cy7 channel (Figure 2-4 panel B). FITC channel fluorescence 
intensity values, relative to Alexa Fluor 488 dye, were measured in CHO-NIS cells 
and compared with control CHO-Empty cells.  
Figure 2-4: Gating cells with FlowJo in order to exclude damaged and dead cells 
 
FlowJo 8.8.6 software graphs representing the analyzed cell population. Cells are 
represented by dots and their colours indicate cells density in decreasing order: red, 
yellow, green and blue. Panel A shows a side scatter (SSC: ordinate axis) versus forward 
scatter (FSC: abscissas axis) graph. Panel B shows a FSC (ordinate axis) versus APC-Cy7-A 
(abscissas axis) graph. In both panels, the gated cells are those included within the pink 
form and the number indicates the percentage of selected cells compared with the total.  
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2.2.2.3 Statistical analysis 
The geometric mean of FITC-channel fluorescence intensity values detected 
in CHO-NIS and CHO-Empty cells were compared for all sera and the Kolmogorov 
Smirnov univariate two-sample test was used to obtain the greatest difference 
between the two histograms (CHO-NIS and CHO Empty), quoted as D value (D) 
(225). 
Positivity cut-off values were defined based on the mean D + 2 standard 
deviation (SD) of a population reference (6 young males’ sera) defined as group M 
(further described in next paragraph 2.2.3), with all values higher than this 
considered positive (Figure 2-5). 
Figure 2-5: Kolmogorov Smirnov statistics 
 
Representative flow cytometry histograms of FITC fluorescence intensity obtained using 
permeabilized CHO-Empty (empty black line) and CHO-NIS (grey tinted figure). D = D value 
= greatest difference in FITC signal intensity between the two histograms (CHO-NIS and 
CHO Empty). DM = mean D value among group M (6 young males’ sera). 
2.2.2.4 Pre-adsorption of individual human sera using CHO-Empty cells 
Seven representative selected human sera were pre-incubated with CHO-
Empty cells in a pre-adsorption step before incubation with CHO-NIS and CHO-
Empty cells for flow cytometry analysis, in order to pre-adsorb aspecific Igs 
directed towards antigens different from hNIS protein expressed by CHO cells.  
Procedure: CHO-Empty cells (one 75-cm2 flask 80% confluent) were 
detached with 5 ml PBS containing 5 mM ethylenediaminetetraacetic acid (EDTA) 
and 5 mM ethylene glycol tetraacetic acid (EGTA) and re-suspended in 1 mL flow 
buffer. Sera to be tested were diluted 1:10 with CHO-Empty cells in flow buffer 
(90 µl total volume) and mixed gently for 1 hour at room temperature (each 2µl of 
serum were adsorbed approximately with 9x104 cells, very similar to the 
proportion used in flow cytometry assay, assessing the signal obtained with 2µl of 
serum incubated with 5x104 cells). Cells were removed by centrifugation at 1200 
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rpm for 6.5 minutes at 4°C, the pre-adsorbed sera were recovered and used for 
flow cytometry as described in the next paragraph.   
2.2.2.5 Permeabilization protocol  
Seven representative selected human sera were tested by flow cytometry 
following a modified protocol in order to expose hypothetical internal NIS antigens 
through cell membrane permeabilization, which may hypothetically arise during 
the autoimmune destruction of thyroid tissue.  
Modified protocol for flow cytometry (permeabilization): just before the 
incubation with the 1st Ab, CHO cells were fixed in 2% paraformaldehyde in PBS on 
ice for 30 minutes, washed once in PBS/0.1% BSA and then incubated with 0.1% 
BSA, 0.2% saponin PBS for 30 minutes at room temperature. The subsequent steps 
were similar to the original protocol, except they were all performed in 0.1% BSA, 
0.2% saponin PBS instead of flow buffer.  
2.2.3 Human sera tested with flow cytometry 
Human sera from 42 women and 6 young males (Group M) were heat inactivated at 
56°C for 30 minutes before being tested by flow cytometry. Women were divided 
into 4 groups, according to the disease they were affected with: breast cancer 
(BC), thyroid autoimmunity (TA), both TA and BC (BC/TA) and non-autoimmune 
thyroid disorders (e.g. non toxic goitre)  (CO), as shown in Table 2-1. CO group 
was considered as “control group” since patients were not affected neither with 
TA nor BC.  
Anti-TPO autoantibodies (TPOAb) and anti-Tg autoantibodies (TgAb) were 
measured by standard automated immunoenzymometric assay (Tosoh Bioscience, 
Tessenderlo, Belgium) and considered positive if respectively ≥ 10 U/mL and ≥ 30 
U/mL.  
Group M, characterized by young human males, was included in order to 
identify a control population for statistical analysis with very low probability of 
having NISAb. In fact NISAb positivity has also been described among healthy 
adults therefore, considering that TA prevalence is predominant among women 
and increases with age, young males are the part of general population with less 
probability to have NISAb positivity.  
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Table 2-1: Characteristics of individuals providing sera 
 Age: Mean and Range TPOAb positive TgAb positive 
BC 
(n=12) 
66 y ± 12 y SD   
(range 42-81 y)  
0/12 1/12 
TA 
(n=11) 
48 y ± 13 y SD 
(range 31-76 y) 
10/11 9/11 
BC/TA 
(n=10) 
54 y ± 7 y SD  
(range 43–63 y) 
9/10 8/10 
CO 
(n=9) 
51 y ± 21 y SD  
(range 13-68 y) 
0/9 1/9 
M 
(n=6) 
10 y, 3.3 m ± 5 m SD  
(range 9y, 6m – 10y, 6m) 
0/6 0/6 
BC = women affected with breast cancer. TA = women affected with thyroid 
autoimmunity, defined as positivity of TPOAb and/or TgAb. BC/TA = women affected with 
both BC and TA. CO = women affected with non-autoimmune thyroid disorders (e.g. non 
toxic goitre). M = young human males. y = years. m = months. SD = standard deviation. 
2.2.3.1 Flow cytometry with extracted immunoglobulins (Igs) 
Total Igs were extracted from four sera, one for each patient group: BC, 
TA, BC/TA, CO. This has been performed incubating the sera at 4°C for 4 hours 
with ammonium sulphate 3.75M (1.49 ml for each 2 ml serum), centrifuging at 
2000 RPM for 20 minutes, resuspending the pellet in 1 ml dH2O and finally 
dialyzing at 4°C against 100 volumes of PBS X3 (respectively 2 hours, 4 hours and 
overnight) (226).   
The same flow cytometry experiment was then performed, as previously 
described in paragraph 2.2.2, using the same dilution applied for serum (1:50). 
The normal reference range for serum IgGs concentration among women is 7-18 
µg/µl (medium concentration = 12.5 µg/µl) (227). Having used a 1:50 serum 
dilution in flow experiments, consequently 0.25 µg/µl IgGs (12.5 µg/µl divided by 
50) had to be used in the 100 µl sample volume, in order to maintain the same 
concentration used with serum. IgGs concentration of each sample was 
determined from spectrophotometric absorption at 280 nanometers (nm) with 
GeneQuant pro ultraviolet–visible (UV/Vis) spectrophotometer (Biochrom Ltd, 
Cambridge, UK). 
2.3 RESULTS 
2.3.1 Characterization of CHO-NIS cell lines  
2.3.1.1 NIS mRNA expression 
Successful CHO-NIS transfections were confirmed by the presence of a 207 
bp amplicon in different mixed pool of CHO-NIS transfected cells, while no 
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amplicons were obtained in CHO-Empty. The 207 bp amplicon was expressed in 
the positive control (TT) and absent in the negative control with dH2O (Figure 2-
6). 
Figure 2-6: 207bp expected PCR amplicon in CHO-NIS cells 
 
bp = base pairs; CHO-Empty = CHO cells transfected with empty vector pcDNA3; CHO-NIS = 
CHO cells transfected with pcDNA3 containing hNIS gene; L 100 = ladder 100 bp; Neg dH2O 
= negative control with distilled water in place of cDNA; TT = thyroid tissue (positive 
control); 1°, 2°, 3° = numbers of transfection experiment. 
 
Of the 26 CHO-NIS clones isolated, 6 were tested for NIS mRNA expression 
and only clones 1 (CHO-NIS-1) and 6 (CHO-NIS-6) expressed NIS mRNA (images not 
shown).    
2.3.1.2 NIS protein expression 
Flow cytometric analysis indicated a high specific binding of the mouse 
monoclonal NISAb VJ2 to the NIS protein expressed on the CHO-NIS cells surface; 
CHO-NIS-6 expressed the NIS protein at a higher level than CHO-NIS-1, with a 
mean fluorescent signal intensity of 104 and 103 respectively. As expected, a 
negative (102) signal was obtained in CHO-Empty cells (Figure 2-7 panel A). The 
negative control experiment performed using only the 2nd Ab without the 1st Ab 
step excluded the presence of an aspecific binding of the 2nd Ab on the surface of 
CHO cells, since the signal intensity was negative (102) in all three cell lines tested 
(Figure 2-7 panel B).   
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Figure 2-7: Flow cytometry with mouse monoclonal NISAb VJ2 and anti-mouse 2nd Ab 
  
Flow cytometry histograms showing the FITC fluorescence intensity obtained in CHO-NIS-6 
(dark grey tinted figure), CHO-NIS 1 (light grey tinted figure) and CHO-Empty (empty black 
line) cells. Panel A: results obtained using VJ2 as first antibody (1st Ab) and goat polyclonal 
anti-mouse IgG H&L Alexa Fluor 488 as second antibody (2nd Ab). Panel B: results obtained 
using only the goat polyclonal anti-mouse IgG H&L Alexa Fluor 488 as 2nd Ab, without the 
1st Ab step.   
2.3.2 Flow cytometry with human sera  
2.3.2.1 Standard flow cytometry protocol with human sera 
All 42 heat-inactivated human sera were tested for NISAb in 3 separate 
experiments: twice using CHO-NIS-6 (experiments 1 and 2) and once with CHO-NIS-
1 (experiment 3), always including CHO-Empty as negative control and testing 
Group M as reference control. For each experiment, the human sera were split in 
two different sets, each of them analyzing half of them (21 + 21) and the group M 
with both CHO-Empty and CHO-NIS cells.    
In the first experiment using CHO-NIS-6, 8/42 sera (19%) showed a 
fluorescence intensity signal slightly higher in CHO-NIS compared with CHO-Empty 
cells and were classified as borderline positive (Figure 2-8 panel A). The other 
sera were negative, with no difference in signal intensity between CHO-NIS and 
CHO-Empty (Figure 2-8 panel B). When incubating the cells with the 2nd Ab only, 
the signal intensity was negative in both CHO-NIS and CHO-Empty, indicating 
absence of nonspecific binding of the 2nd Ab goat polyclonal anti-human IgG (H+L) 
Alexa Fluor 488 (Figure 2-8 panel C). When using human sera as 1st Ab, an  
aspecific background signal (103-104) was present in both CHO-Empty cells and 
CHO-NIS (CHO-NIS-6 as well as CHO-NIS-1), while absent when using VJ2 (Figure 2-
7 panel A) or when incubating cells with the 2nd Ab only, both the anti-mouse 
(Figure 2-7 panel B) or the anti-human (Figure 2-8 panel C). These findings 
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suggested that the nonspecific signal was due to the human sera itself and this 
will be further evaluated in the next paragraphs 2.3.2.2 and 2.3.2.3.  
Figure 2-8: Flow cytometry results using human sera 
 
Representative flow cytometry histograms showing the FITC fluorescence intensity signal 
obtained in CHO-Empty (empty black line) and CHO-NIS-6 (dark grey tinted figure) after 
incubation with human sera (1st Ab) and goat polyclonal anti-human IgG (H+L) Alexa Fluor 
488 (2nd Ab). Panels A and B show borderline positive and negative results respectively, in 
presence of a high aspecific background signal (103-104). Panel C shows incubation with 
the 2nd Ab only: the signal is negative (102) in both cell lines, with no aspecific 
background. 
 
Using the Kolmogorov Smirnov statistics, the mean D + 2 SD of the 6 Group M sera 
(positivity cut-off) was 0.290 and 0.650 for set 1 and set 2 respectively. Table 2-2 
reports the range of D values found in the 42 human sera tested. The 8 borderline 
positive sera, similarly distributed in all 4 patient groups, had D values close to 
the positivity cut-off but not higher, therefore none of them resulted significantly 
positive for NISAb.  
Table 2-2: D values of human sera 
 D value 
Set 1 
(range) 
D value 
Set 2 
(range) 
Borderline 
human 
sera 
BC 0.110 – 0.180 0.100 – 0.610 2/12 (16.7%) 
TA 0.026 – 0.190 0.100 – 0.280 1/11 (9.1%) 
BC/TA 0.056 – 0.240 0.210 – 0.350 2/10 (20%) 
CO 0.130 – 0.200 0.130 – 0.440 3/9 (33.3%) 
   8/42 (19%) 
BC = breast cancer; BC/TA = breast cancer and thyroid autoimmunity; Borderline human 
sera = sera that gave a D value near to the cut-off (0.290 and 0.650 respectively for set 1 
and set 2); CO = controls (non-autoimmune thyroid disorders); D = greatest difference 
between the geometric mean fluorescence intensity values of histograms obtained 
incubating each sera with CHO-NIS-6 and CHO-Empty; TA = thyroid autoimmunity.  
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Some borderline positive results of experiment 1 were not reproduced in 
experiments 2 and 3. On the contrary, in experiments 2 and 3 some different 
borderline positive sera were identified; they were discordant between 
experiments 2 and 3 and always resulted negative when analyzed with Kolmogorov 
Smirnov statistics (results not shown).   
2.3.2.2 Standard flow cytometry protocol with extracted Igs 
In order to clarify the origin of the aspecific background signal obtained 
when using human sera, flow cytometry experiments were performed using 
extracted Igs from 4 representative sera (one for each patient group), showing the 
same nonspecific background with both CHO-NIS and CHO-Empty cells (Figure 2-9). 
These results suggested the presence of serum antibodies against unknown 
antigens expressed on the CHO cells surface.  
Figure 2-9: Standard flow cytometry with human sera 
 
Flow cytometry histograms showing the FITC fluorescence intensity signal obtained in 
CHO-Empty (empty black line) and CHO-NIS-6 (dark grey tinted figure) after incubation 
with purified human Igs (1st Ab) and goat polyclonal anti-human IgG (H+L) Alexa Fluor 488 
(2nd Ab). Human Igs were purified from patients affected with BC = breast cancer; BC/TA = 
breast cancer and thyroid autoimmunity; CO = controls (non-autoimmune thyroid 
disorders); TA = thyroid autoimmunity. Human Neg = incubation of cells with 2nd Ab only 
and no 1st Ab.   
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2.3.2.3 Modified flow cytometry protocol: pre-adsorption of human sera (1st 
Ab) 
Once determined that the aspecific background is likely due to human IgGs 
directed towards CHO cells antigens, a flow cytometry experiment was carried out 
using 7 human sera pre-adsorbed with CHO-Empty cells (2 BC, 1 TA, 1 BC/TA, 1 CO 
and 2 M), in order to try and eliminate aspecific anti-CHO human IgGs, hoping to 
reduce the nonspecific binding and potentially enhance a hypothetical specific 
NISAb signal. The pre-adsorption step was effective in slightly reducing the 
nonspecific background in 6/7 (85.7%) human sera for both CHO-Empty and CHO-
NIS-6 cells (Figure 2-10). 
Figure 2-10: Pre-adsorbed flow cytometry: difference in aspecific background 
 
Representative flow cytometry histograms of FITC fluorescence intensity. Panel A: CHO-
Empty cells incubated with normal serum (dashed empty black line) or the same serum 
after pre-adsorption step (continuous empty black line). Panel B: CHO-NIS-6 cells 
incubated with the same serum of panel A, normal (dashed empty grey line) or pre-
adsorbed (dark grey tinted figure).  
 
Contrary to what was expected, the pre-adsorption step was unable to 
significantly enhance any difference between CHO-Empty and CHO-NIS-6 cells 
(signal specificity; Figure 2-11), since it was only minimally increased in 4/7 (57%) 
(panels A and D), minimally decreased in 2/7 (29%) (panels B and E) and 
unchanged in 1/7 (14%) (panels C and F). As a consequence, the presence of NISAb 
was investigated in all 42 human sera by flow cytometry without the pre-
adsorption step.  
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Figure 2-11: Pre-adsorbed flow cytometry: effects on signal specificity 
 
Representative flow cytometry histograms of FITC fluorescence intensity in CHO-Empty 
(empty black line) and CHO-NIS-6 (dark grey tinted figure) cell lines incubated with 3 
human sera before (upper panels A, B, C) and after (lower panels D, E, F) adsorption with 
CHO-Empty cells. The signal difference between CHO-Empty and CHO-NIS-6 cells (signal 
specificity) after the pre-adsorption step in respect to before pre-adsorption was slightly 
increased in serum 1, slightly reduced in serum 2 and unchanged in serum 3. 
2.3.2.4 Modified flow cytometry protocol (Cells permeabilization) 
The experiment testing 7 different human sera (4 BC and 1 for each of remaining 
patient groups: TA, BC/TA, CO) with permeabilized CHO-NIS-6 and CHO-Empty 
cells demonstrated a further increase in nonspecific background signal (up to 105) 
in both CHO-NIS and CHO-Empty cells without any significant difference between 
cells expressing NIS and controls (Figure 2-12). Furthermore, cell permeabilization 
also increased the aspecific binding of the 2nd Ab, that was absent when using 
normal CHO cells (Figure 2-9). 
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Figure 2-12: Flow cytometry with permeabilized cells 
 
Representative flow cytometry histograms showing the FITC fluorescence intensity signal 
obtained in CHO-Empty (empty black line) and CHO-NIS-6 (dark grey tinted figure) 
permeabilized cells. Panel A = cells incubated with human sera (1st Ab) and goat polyclonal 
anti-human IgG (H+L) Alexa Fluor 488 (2nd Ab). Panel B = cells incubated with 2nd Ab only. 
2.4 CONCLUSIONS 
2.4.1 NIS as common antigen between thyroid and breast cancer tissues 
In this study 42 examined human sera were analyzed, grouped into 4 
possible categories: patients affected with breast cancer (BC), thyroid 
autoimmunity (TA), BC and TA (BC/TA) or non-autoimmune thyroid disorders (CO). 
None of them was found positive for neutral NISAb (e.g. binding the symporter 
without affecting its function), as no signals consistently above the positive cut-
off value were found. Eight out of 42 (19%) sera, distributed throughout the 4 
patient groups, were considered borderline positive, since they fell near to the 
positive cut-off. These higher D values, even if not statistically significant, could 
be representative of low titre neutral NISAb and/or demonstrate random 
variability without any significance. The second interpretation is the most likely, 
considering that 1) the 8 borderline positive sera were not confirmed in all three 
experiments performed and 2) a great variability was found between the different 
experiments, as evident in the different mean D values of group M between set 1 
and set 2. There are several possible explanations for this variability, including 
the expression of different types and quantities of surface antigens depending on 
cell cycle phase (228). This could partly explain the variations of both aspecific 
background and signal specificity between CHO-Empty and CHO-NIS cells in the 
different experiments. Therefore only D values clearly above the cut-off 
established by Kolmogorov-Smirnov statistics should be considered positive; no 
sera positive for NISAb were found according to this criterion.  
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To my knowledge this is the first reported use of flow cytometry to detect 
neutral serum NISAb binding the symporter. Previously, other groups using a 
recombinant hNIS protein identified neutral NISAb in sera from patients affected 
by TA, but which were also present in the general population (218, 221, 222). The 
results of the present thesis do not confirm these previous reports. The most likely 
explanation is that expression of hNIS using an in vitro transcription/translation 
system may result in different and/or incomplete folding of the hNIS protein. 
Similarly, in those assays glycosylation may be absent or, if present, different 
glycosylation patterns may be involved, compared with the recombinant hNIS 
produced in the CHO cell system used in the present study. In fact NIS is strongly 
bound to the cell membrane with 13 transmembrane segments, therefore it needs 
a cell membrane in order to correctly fold, which is impossible in an in vitro 
transcription/translation system. CHO expression of this complex symporter 
should allow its complete folding and glycosylation, with expression in its original 
location as a transmembrane protein. This is supported by the fact the hNIS 
expressed by CHO-NIS was recognized by the mouse monoclonal Ab VJ2, directed 
versus a conformational epitope, therefore indicating a correct folding of this 
transmembrane protein. It is therefore probable that the conformational hNIS 
epitopes recognized by antibodies are likely to be different between the two 
recombinant protein expression techniques (in vitro transcription/translation 
system versus protein expression in CHO cell lines). Furthermore, the in vitro 
transcription/translation systems are more likely to detect linear epitopes instead 
of conformational. For completeness, it is important to comment that to express 
hNIS we transfected CHO cells with a plasmid encoding for a product of 612 amino 
acid (AA), while the hNIS encodes for a 643 AA protein. The missing AA encode for 
a cytoplasmic portion of the protein, therefore it is unlikely that they represent 
epitope regions recognized by the immune system, or contribute to the final 
folding and conformation of NIS protein. The presence of functional NIS activity, 
e.g. the ability to trap iodide, has not been investigated in the present study, 
although other authors have previously confirmed the function of the same hNIS 
construct (203, 217). 
The finding that serum neutral NISAbs are rare is in agreement with a 
number of previous studies (216, 219, 220) although not all (217, 218). Similarly, 
NISAb interfering with the symporter function have been described as rare by 
several authors who found no iodide uptake inhibitory activity in patients with or 
without TA and hypothesized that the inhibitory activity observed in some sera 
was not antibody-mediated, since purified IgGs lacked NIS blocking activity (219, 
220, 223). On the contrary, Ajjan et al. found iodide uptake inhibitory activity 
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mediated by IgGs, even if 50% of those IgGs did not bind NIS, therefore they also 
postulated that the inhibitory activity could be in part not antibody-mediated or 
due to antibodies that do not act directly on NIS (217, 218).  
In conclusions, despite being expressed in both thyroid and BC cells (200), 
NIS is unlikely to be a shared antigen responsible for a common immune response 
between thyroid and BC tissue. However, to definitively address this question, 
further studies with larger number of sera are needed. In addition, alternative 
techniques such as the enzyme-linked immunosorbent assay (ELISA) or Western 
Blot (WB) could be used to detect NISAb (229), as such techniques may expose 
epitopes of the hNIS protein not accessible when anchored in the cell membrane, 
that could be exposed as a consequence of tissue damage. Furthermore, 
differences in protein folding are possible with these techniques, which again may 
result in a greater diversity of epitope exposure. The presence of NISAb 
recognizing intracellular epitopes potentially arising only during or after tissue 
damage cannot be excluded in this study, since they would be inaccessible in the 
flow cytometry protocol applied. The preliminary experiments using 
permeabilized cells were hampered by high non-specific background staining 
which precluded drawing any conclusions. Finally, the absence of NISAb does not 
exclude that NIS linear epitopes could trigger a hypothetical lymphocytes T 
reaction and specific studies are needed to explore this possibility.  
However, the absence of NISAb in patients affected with both TA and/or 
BC, together with the consideration that NIS could be expressed by BC more rarely 
(211, 212) than initially detected (200), strongly reduces the possibility of NIS as 
potential shared antigen between thyroid and BC tissues. Therefore considering 
the increased prevalence of anti-thyroid peroxidase (TPO) autoantibodies (TPOAb) 
among patients with breast cancer (BC) (166, 179-181) and the suggested 
correlation of TPOAb positivity with a better BC outcome (158, 182-184), the next 
hypothetical shared thyroid/BC antigen to investigate is TPO and this will be 
addressed in chapter 3.  
2.4.2 Aspecific background: human Abs against CHO cells surface 
antigens  
Flow cytometry results were characterized by the presence of a high 
aspecific background, also reported by other authors using flow cytometry to 
detect antibodies to the thyrotropin receptor (TSHR) (230, 231). Since the 
background remained even when using purified Igs and was only slightly reduced 
by pre-adsorption, it was clearly due to antibodies to surface CHO proteins. CHO 
cells are the most commonly used mammalian cell lines for production of 
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therapeutics (232-234) and some 60-70% of recombinant protein pharmaceuticals 
and almost all currently approved therapeutic antibodies are produced in 
mammalian cells (235). This would account for some CHO-reactivity (236, 237) but 
Xue et al. analyzed 83 normal individuals with no known exposure to therapeutic 
biologics and found antibodies to CHO proteins in 45/83 (54%) cases, mainly 
isotype G Igs (IgGs). Therefore they postulated alternative explanations such as 
blood transfusions, vaccinations or keeping animals as pets (238). Despite this 
problem I have confidence in the flow cytometry protocol used, which has 
previously served to demonstrate neutral antibodies to another thyroid 
autoantigen, the receptor of thyroid-stimulating hormone receptor (TSHR) (230, 
231, 239).  
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3 THYROID PEROXIDASE (TPO) EXPRESSION 
IN BREAST CANCER 
3.1 INTRODUCTION 
3.1.1 TPO  
Human TPO is one of the principal antigens involved in thyroid 
autoimmunity (TA) and has been identified as the only component of the 
“microsomal” antigen. Therefore, the measurement of serum autoantibodies to 
TPO (TPOAbs) is generally considered a marker of TA (240).   
Human TPO is a heme-containing enzyme member of the family of 
mammalian peroxidases, which utilize hydrogen peroxide to oxidize a number of 
inorganic and organic substrates and they are active in a variety of anatomic sites 
(241). The main function of TPO protein in thyroid tissue is the synthesis of 
thyroid hormones (1), as previously described in paragraph 1.1.2.  
The human TPO gene is about 150 kilo-base pairs (kbp) in size, located on 
chromosome 2, locus 2p25 and consists of 17 exons and 16 introns (242). The full-
length 3048-bp transcript (TPO1) encodes a protein consisting of 933 amino acids 
(AA) (243, 244), which has a short intracytoplasmatic tail, a transmembrane 
domain encoded by exon 15 and a large extracellular domain which contains the 
catalytic site (Figure 3-1). TPO protein presents different functional domains (245, 
246):  
v Catalytic site containing the region binding the heme group (derivative of 
protoporphyrin IX), included between the distal and proximal histidines, 
respectively AA 239 and 494 (exons 7-8-9) (247). 
v Antigenic site. Serum human TPOAbs mainly recognize conformational 
epitopes, formed by different parts of the AA chain often far between them in 
protein primary structure, becoming juxtaposed as a consequence of the final 
folding of the protein in its tertiary structure. Therefore, it is unusual for 
TPOAbs to recognize linear antigens, consisting in epitopes formed by 
consecutive AA on the protein primary sequence. However, using some 
recombinant TPO polypeptide fragments some linear epitopes recognized by 
patients with TA have been identified: C2 (AA 590-622: encoded by exon 11 
and C21 (AA 710-722: exon 12) (246, 248). TPO conformational and linear 
epitopes will be further discussed in the conclusions paragraph 3.5 and general 
discussion (Chapter 5), paragraph 5.2.2. 
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v Region similar to a complement control protein [CCP (AA 741-795, exon 13)], 
existing in a wide variety of complement and adhesion proteins (244). This 
region is also known as the “sushi domain” and is formed by 2 disulfide bonds 
connecting 1st – 3rd cysteines and 2nd – 4th cysteines (249, 250). 
v Homologous region to epidermal growth factor (EGF)/low density lipoprotein 
(LDL) receptor gene families (EGF-like region): AA 794-839 (exon 14) (246). 
This region contains 6 conserved cysteine residues forming 3 disulfide bonds 
and also contains 5 AA that constitute a consensus sequence for calcium 
binding. The functional consequences of calcium binding are not yet known; 
however a homologous domain has been found in human fibrillin-1, a 
glycoprotein present in connective tissue and it was suggested that calcium 
may stabilize its structure and may protect the molecule from proteolytic 
degradation (250). 
v Transmembrane region (AA 847 – 871; exon 15) (244).   
Figure 3-1: TPO gene and protein 
 
Schematic representation of the correspondence between TPO gene’s nucleotide sequence 
(Nucl.) and TPO protein’s amino acid sequence (AA). bp = base pairs. CCP = complement 
control protein. C2 and C21 = antigenic sites. EGF = epidermal growth factor. START codon 
ATG = nucleotide triplet corresponding to the beginning of translation process. STOP codon 
TGA = nucleotide triplet corresponding to the end of translation process. Transm. Domain 
= transmembrane domain. 1-17 = exon number. 1-3146 = nucleotide number. 1-933 = 
amino acid number. 3’ COOH = 3-prime-end of the gene, encoding the intracellular 
carboxy-terminus (or C-terminus) of the protein. 5’ NH2 = 5-prime-end of the gene, 
encoding the extracellular amino-terminus (or N-terminus) of the protein. 
3.1.1.1 TPO isoforms 
The TPO gene undergoes alternative splicing to generate different TPO 
messenger ribonucleic acid (mRNA) isoforms lacking one or more exons. To date 8 
isoforms have been described in thyroid cells, TPO 1, TPO 2 (244, 251), TPO 3 or 
TPO Zanelli (252), TPO 4, TPO 5, TPO 6, TPO 2/3 and TPO 2/4 (253), as illustrated 
in Table 3-1. While TPO 3 (254) and TPO 4 (253) are able to reach the cell surface 
and show enzymatic activity, TPO 2 and TPO 5 lack enzymatic activity (252, 253). 
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To my knowledge no functional studies have been performed on other TPO 
isoforms. It is also important to state that TPO isoforms’ mRNA sequences to date 
have been only partially characterized because of the difficulty in obtaining full 
length mRNA/cDNA (253); this will be better discussed in the conclusions of the 
present chapter (paragraph 3.5.3) and in the general discussion (chapter 5, 
paragraph 5.2.2).  
So far only the protein translated from the complete mRNA transcript TPO1 
has been characterized and it will be addressed as TPO protein. The apparent MW 
of TPO protein in denaturing western blot (WB) is a doublet at 105-110 kDa (Table 
3-1), which may be due to variants of TPO (251, 253) or differing degrees of 
glycosylation (255, 256). 
Table 3-1: Summary of known TPO isoforms’ characteristics 
 mRNA analysis Protein analysis 
TPO 
Isoform 
N° 
tot 
exons 
Exon  
lacked 
bp N° 
AA 
MW  
(kDa) 
predicted 
MW  
(kDa) 
on WB 
Function 
TPO 1 17 / 3152 933 103 105-110 Yes 
TPO 2 16 10 2981 876 96 ? No 
TPO 3 16 16 3022 890 98 ? Yes 
TPO 4 16 14 2930 889 98 ? Yes 
TPO 5 16 8 2543 760 84 ? No 
TPO 6 12 10,12,13,14,16 2339 662 73 ? ? 
TPO 2/3 15 10,16 2851 832 91 ? ? 
TPO 2/4 15 10,14 2849 832 91 ? ? 
bp= number of base pairs. kDa= kilodalton. MW= Molecular Weight. N° AA=  number of 
amino acids. WB= Western Blot.   
3.1.1.2 Comparison between TPO and other peroxidases 
TPO is a member of the family of mammalian peroxidases, all having 
similar enzymatic functions (oxidation) and including also lactoperoxidase (LPO), 
myeloperoxidase (MPO) and eosinophil peroxidase (EPO) (257) and the more 
recently discovered vascular peroxidase (VPO) (258). MPO, EPO and LPO are all 
encoded by single genes on human chromosome 17, while TPO gene is located on 
chromosome 2, suggesting that TPO gene evolved independently from the other 
peroxidases gene (247). There are two types of VPO, VPO1 and VPO2, 
approximately 63% identical and encoded by genes located in exons 2 and 8 
respectively (258). The main difference between TPO and the other peroxidases is 
that TPO is the only membrane-bound enzyme, while the other peroxidases are 
intracellular or extracellular (257). For this reason TPO is bigger, in fact contains 
similar sequences to MPO, LPO and EPO from AA 1 to 738 (encoded by exons from 
2 to 12), while the AA sequences encoded from exons from 13 to 17 (AA 739 - 
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933), including the transmembrane region (AA 847 – 871), are peculiar of TPO and 
missing from the other peroxidases (246, 247). Table 3-2 summarizes the main 
characteristics of the principal peroxidases, with also indicated their molecular 
weight (MW) in kilodalton (kDa) (244, 245, 247, 257-259). 
Table 3-2: Peroxidases 
 CELLS POSITION N° AA MW (kDa) 
TPO - Thyrocytes 
 
Membrane-bound 
(main part is 
extracellular) 
933 105-110 (single chain) 
MPO -Neutrophil granulocytes  
-Mononuclear phagocytes 
 
Intracellular 
(lysosomal) 
745 
(precursor*) 
150 (dimeric): 2 x 75  
Each part composed by: 
- 1 heavy chain 57 (467 AA) 
- 1 light chain 15 (113 AA) 
LPO - Mammary ductal 
epithelial cell 
- Secrectory cells of 
exocrine glands 
Extracellular 
(milk, saliva, 
tears) 
712 80-90  
(single chain with different 
glycosylation grades) 
EPO - Eosinophils Intracellular 
(lysosomal) 
715 70  
Monomer composed by: 
- 1 heavy chain 58 
- 1 light chain 12 
VPO - Vessels endothelium and 
smooth muscle 
- Heart 
- Many other tissues (only 
mRNA, no protein) 
Intracellular >1200 
 
165 
AA = amino acid. kDa = kilodalton. MW = molecular weight. 
* MPO precursor (745 AA) is glycosylated and then cleaved by 125 AA to form the mature 
dimeric protein (580 AA x 2) 
3.1.2 Hypothesis  
In the general introduction (Chapter 1, paragraph 1.4) the association 
between TA and breast cancer (BC) has been discussed. Of relevance, serum 
TPOAbs have been described to be more prevalent among patients with BC 
compared with controls (166, 179-181) and several studies suggested that BC 
patients with positivity for serum TPOAb had a better prognosis compared with 
TPOAb negative patients (182-184, 260), as will be better explained in chapter 4.  
The consequent main hypothesis of the present thesis is the presence of a 
shared immune activity between thyroid and BC tissue, leading to TA on one hand 
and to a better control of BC tumour growth on the other hand. In chapter 2 we 
did not find any autoantibodies directed towards the sodium iodide symporter 
(NIS), known to be expressed by both BC/thyroid tissues, therefore NIS is unlikely 
to be the hypothesized shared antigen. Since TPOAbs, considered a marker of TA 
(240), are more prevalent among patients with BC, we hypothesized TPO itself as 
possible candidate common antigen.   
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3.1.3 Aims 
The aim of the present chapter is to explore TPO gene expression (mRNA 
and protein) in BC, using relevant ex vivo and in vitro samples. 
First, we investigated TPO gene expression, both messenger RNA (mRNA) 
and protein, in BC and breast peri-tumoural (PT) ex vivo tissues, using thyroid 
tissue (TT) as positive control. Considering that TPO expression has already been 
described in orbital adipose tissue (261), other tissues were included in order to 
investigate whether an hypothetical TPO expression by BC would be exclusive or 
not: adipose tissue from different depots and other cancers, as detailed below in 
materials section.     
Subsequently, in vitro models using 3 different BC cell lines grown with  
known regulators of breast function were conducted in order to investigate the 
regulation of TPO gene expression in BC cell lines. In fact in chapter 1 (paragraph 
1.3.1.2) it has been explained that breast function is regulated by many different 
hormones and growth factors, including oestrogens and Insulin-like growth factors 
(110). Oestrogens exert a stimulatory activity by increasing the rate of cell 
division and proliferation of breast epithelium (118), while IGF I and II (IGF-I and 
IGF-II) are potent mitogens for a variety of cell types and considered important 
regulators of epithelial tumour growth in BC (262, 263). In particular oestrogen 
receptor (ER) and IGF-I receptor (IGF-IR: able to bind both IGF-I and IGF-II) are co-
expressed in the MCF-7 BC cell line and engage in a crosstalk that results in 
synergistic growth (264).  
A possible TPOAb cross-reactivity with LPO expressed in mammary tissue will 
be also discussed in the conclusions session of the present chapter (paragraph 
3.5.2) and in the general discussion (chapter 5, paragraph 5.2.1). 
3.2 MATERIALS  
3.2.1 Tissues 
Fresh human surgical tissues (from scheduled operations and obtained with 
informed consent) were collected in liquid nitrogen and immediately frozen (-
80°C). Eight BC (7 infiltrating ductal adenocarcinoma and 1 mucinous carcinoma) 
and their 8 corresponding peri-tumoural breast tissues (PT) were collected. Since 
breast tissue contains fat, 17 adipose tissues (AD) from various depots including 
abdominal (AD-A; n=4), subcutaneous (AD-S; n=8), knee (AD-K; n=1) and orbital fat 
(AD-O; n=4) were studied and also malignant tissues, including pancreatic 
adenocarcinoma (PC; n=3), primary kidney carcinoma (PKC; n=1) and hepatic 
metastasis of kidney carcinoma (MKC; n=1) were obtained for controls. Human 
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thyroid tissue (TT) from thyroidectomy for multinodular goitre was used as a 
positive control.  
Two additional fresh frozen BC and also 9 paraffin embedded BC sections 
(all infiltrating ductal adenocarcinoma) were also collected, for a total of 19 
different BC samples analyzed with various techniques, later explained in the 
Methods section (paragraph 3.3). Data about thyroid autoimmunity status were 
available only in 8/19 BC patients and 1/8 had serum TPOAb positivity; age was 
known only in 10 BC patients (Table 3-3).  
Table 3-3: Characteristics of BC tissues analyzed 
Sample 
number 
BC 
histological 
type 
TPO gene 
expression: 
analyses performed 
TPOAb 
 (U/ml)  
v.n. <10 
TgAb 
(U/ml)  
v.n. <30 
TSH 
(µU/ml) 
v.n. 0.4-3.4 
Age 
(yrs) 
BC n°1 
(f) 
 
Ductal mRNA: PCR, QPCR 
Protein: WB 
<1 5.89 1.03 85 
BC n°2 
(f) 
Ductal mRNA: PCR, QPCR 
Protein: WB 
<1 90.42  0.453 72 
BC n°3 
(f) 
Ductal mRNA: PCR, QPCR 
Protein: WB 
<1 <1 0.911 58 
BC n°4 
(f) 
Ductal mRNA: PCR, QPCR 
Protein: WB 
<1 <1 1.23 70 
BC n°5 
(f) 
Ductal mRNA: PCR, QPCR, 
        LongRange PCR 
Protein: WB 
443.87 64.07  2.02 68 
BC n°6 
(f) 
Mucinous mRNA: PCR, QPCR, 
        LongRange PCR 
Protein: WB 
<1 <1 0.653 81 
BC n°7 
(f) 
Ductal mRNA: PCR, QPCR 
Protein: WB 
<1 <1 1.92 72 
BC n°8 
(f) 
Ductal mRNA: PCR, QPCR 
Protein: WB 
<1 <1 0.809 79 
BC n°9 
(f) 
Ductal Protein: IHC / / / 73 
BC n°10 
(f) 
Ductal Protein: IHC / / / 70 
BC n°11 
(p) 
Ductal Protein: IF / / / / 
BC n°12 
(p) 
Ductal Protein: IF / / / / 
BC n°13 
(p) 
Ductal Protein: IF / / / / 
BC n°14 
(p) 
Ductal Protein: IF / / / / 
BC n°15 
(p) 
Ductal Protein: IF / / / / 
BC n°16 
(p) 
Ductal Protein: IF / / / / 
BC n°17 
(p) 
Ductal Protein: IF / / / / 
BC n°18 
(p) 
Ductal Protein: IF / / / / 
BC n°19 
(p) 
Ductal Protein: IF / / / / 
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Summary of all 19 different breast cancer (BC) tissues collected and their relevant 
information, when available. Ductal= infiltrating ductal adenocarcinoma; f = fresh frozen 
tissue; IF= immunofluorescence; IHC= immunohistochemistry; Mucinous = mucinous 
adenocarcinoma; p = paraffin embedded sections; PCR= polymerase chain reaction; QPCR= 
absolute real-time quantitative PCR; TgAb= autoantibodies to thyroglobulin; TPOAb= 
autoantibodies to thyroid peroxidase, v.n.= normal value; WB= western blot; yrs = years; / 
= no data available.   
3.2.2 BC cell lines 
3 different BC cell-lines obtained from pleural effusion of breast 
adenocarcinoma were used: MCF-7 and T-47D, both oestrogen-progesterone 
receptor positive (ER+/PR+) and MDAMB-231, triple-negative: ER-/PR- and human 
epidermal growth factor receptor type 2 negative (HER2-). All BC cell lines were 
obtained from the American Type Culture Collection and stored in liquid nitrogen 
until use.  
3.3 METHODS 
3.3.1 Analysis of TPO mRNA expression 
3.3.1.1 Total RNA extraction and reverse transcription (RT) 
Total RNA was extracted from both fresh tissues and BC cell lines and 
reverse transcribed in complementary DNA (cDNA) by RT following the same 
procedure previously described in chapter 2, paragraph 2.2.1.3. The only 
difference consisted in primers used for RT (0.4 µg in 20 µl reaction); oligo-deoxy-
thymine nucleotides short sequence (odT) or random primers (both from Promega, 
Madison, WI, USA) to obtain cDNA to be analyzed respectively by standard 
polymerase chain reaction (PCR) and Absolute Real-time Quantitative PCR (QPCR). 
In some standard PCR reactions, a TPO reverse primer was used instead of odT or 
random primers, used at the same dilution.  
3.3.1.2 TPO primers design 
TPO forward (F) and reverse (R) primers were designed from the published 
sequences of human TPO gene (Genbank: NM_000547) as previously described in 
chapter 2, paragraph 2.2.1.3; in this case, BLAST alignment was always performed 
in order to exclude homology with peroxidases other than TPO, especially 
lactoperoxidase (LPO). As reported in Table 3-4, 6 different primers (3 F and 3 R), 
were initially designed for standard PCR; two additional primers located in exon 2 
(F2) and in the junction region between exons n° 3 and 4 (R 3-4) were 
subsequently designed to perform QPCR and LongRange RT-PCR as later described.  
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Table 3-4: TPO F and R primers  
PCR 
technique 
Forward (F) 
or 
Reverse (R) 
TPO 
Exon 
TPO mRNA 
Nucleotide 
N° 
Primer’s 
nucleotide sequence 
(5’ – 3’) 
Primer 
acronym 
S-PCR F 7 859-878 GGCTGACTGCCAGATGACTT F7 
S-PCR F 9 1527-1546 CCACTGTGTCCAACGTGTTC F9 
S-PCR F 13 2400-2418 ACGGGTATGAGCTCCAAGG F13 
S-PCR R 9 1546-1527 GAACACGTTGGACACAGTGG R9 
S-PCR R 11 1885-1866 GCAGAACTCCCTCCACTCAT R11 
S-PCR, LR-PCR R 17 2884-2865 TCTCGGCAGCCTGTGAGTAT R17 
QPCR, LR-PCR F 2 109 - 128 GCTGTCTGTCACGCTGGTTA F2 
QPCR R 3-4 278 – 259 TGAGGTTTCTCTGCATCGTG R3-4 
LR-PCR = LongRange PCR; QPCR = Absolute Real-time Quantitative PCR; S-PCR = standard 
polymerase chain reaction. 
 
Primers were combined into different primer pairs in order to distinguish 
between the different TPO mRNA isoforms. The expected size of PCR amplicons 
according to each primer pair used and known TPO isoforms are summarized in 
Table 3-5.  
Table 3-5: PCR expected amplicons according to known TPO mRNA isoforms 
 QPCR Standard  RT-PCR LongRange 
RT-PCR 
 F2/R3-4 
(bp) 
F13/R17 
(bp) 
F7/R9  
(bp) 
F7/R11  
(bp) 
F9/R17 
(bp) 
F2/R17 
(bp) 
TPO 1 170 485 688 1027 1357 2776 
TPO 2 
No exon 10 (171bp) 
170 485 688 856 1186 2605 
TPO 3 
No exon 16 (130bp) 
170 355 688 1027 1227 2646 
TPO 4 
No exon 14 (132bp) 
170 353 688 1027 1225 2644 
TPO 5 
No exon 8 (519bp) 
170 485 169 508 1357 2257 
TPO 2/3 
No exon 10 (171bp) 
No exon 16 (130bp) 
170 355 688 856 1056 2475 
TPO 2/4 
No exon 10 (171bp) 
No exon 14 (132bp) 
170 353 688 856 1054 2473 
TPO 6 
No exons 10 (171bp),  
12 (209bp), 13 (171bp),  
14 (132bp), 16 (130bp) 
170 No  
product 
688 856 544 1963 
 
LR-PCR = LongRange PCR; QPCR = Absolute Real-time Quantitative PCR; S-PCR = standard 
polymerase chain reaction. 
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3.3.1.3 Standard PCR 
Standard PCR was performed on cDNA using the AmpliTaq GoldTM DNA 
Polymerase kit (Applied Biosystems, Life Technologies, Paisley, UK) in a 25 µl PCR 
reaction mix, as previously described in chapter 2, paragraph 2.2.1.3. The thermal 
cycle program used was the following: 1 cycle, 95°C for 5 minutes; 40 cycles, 
95°C for 30 seconds, 52°C for 30 seconds, 72°C for 1 minute; 72°C for 6 minutes. 
A small quantity of obtained PCR products were electrophoresed on 2% agarose gel 
in Tris-acetate-EDTA (TAE) buffer (containing ethidium bromide 1 ng/µl) as 
previously described in chapter 2, paragraph 2.2.1.3. The rest of the PCR product 
was further amplified with 10 additional PCR cycles and then sequenced.  
In order to verify the quality of amplified cDNA, control PCR was also 
performed for all samples to test the expression of housekeeping gene adenine 
phosphoribosyltransferase (APRT). The 25 µl reaction solution was the same as 
previously described for TPO PCR, but using the following APRT primer pair, 
GCTGCGTGCTCATCCGAAAG (F) and CCTTAAGCGAGGTCAGCTCC (R), selecting an 
amplicon of 247 bp. The PCR machine program used was the following: 1 cycle, 
95°C for 5 minutes; 35 cycles, 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 
1 minute; 72°C for 6 minutes. 
3.3.1.4 LongRange RT-PCR 
In order to characterize TPO mRNA variants in their full-length, the 
LongRange 2Step RT-PCR kit (Qiagen, Manchester, UK) was used to generate cDNA 
and amplify it using TPO primers F2 and R17. Representative tissues were 
analyzed, TT (n=1), BC (n=2) and AD-S (n=1), according to the following 
procedure: 
v Total RNA extracted from tissues was initially denatured at 65°C for 5 
minutes, in order to reduce RNA secondary structures. 
v The percentage of guanosine (G) and cytosine (C) present in total RNA was 
calculated using “Oligo Calc: Oligonucleotide Properties Calculator” software 
(http://www.basic.northwestern.edu/biotools/oligocalc.html). If RNA/cDNA 
sequence is rich in GC regions, then the use of Q solution in the reaction mix is 
recommended. 
v LongRange RT step. The 20 µl reaction solution, containing 4 µl of LongRange 
RT Buffer 5x, dNTP mix (1 mM each dNTP), 1 µM odT, 0.04 U/µl LongRange 
RNase inhibitor, 1x (1µl) LongRange Reverse Transcriptase and 1 µg RNA, was 
incubated at 42°C for 90 minutes and finally heated at 85°C for 5 minutes to 
inactivate the enzyme, using an unstirred water bath (Clifton, UK). 
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v LongRange PCR Step. The 50 µl reaction solution contained 5 µl of LongRange 
PCR Buffer with magnesium ion (Mg2+) 10x (2.5 mM final Mg2+ concentration), 
dNTP mix (500 µM each dNTP), 0.4 µM F2, 0.4 µM R17, 2 total U LongRange 
PCR Enzyme Mix and 200 ng cDNA. Reactions, always including a negative 
control with dH2O in place of cDNA and performed both with or without the Q-
solution addiction, were performed using the TC-512 gradient thermal cycler 
(Techne, Minneapolis, USA): 1 cycle, 93°C for 3 minutes; 45 cycles, 93°C for 
15 seconds, 57°C for 30 seconds, 68°C for 3 minutes. Resulting products were 
electrophoresed on 1.5% agarose gels in TAE buffer (containing ethidium 
bromide 1 ng/µl) and sized using 2 different ladders, 100 bp (described in 
chapter 2, paragraph 2.2.1.3) and Quick-Load® 1 kb DNA Ladder (BioLabs), 
ranging from 0.5 to 10 kilobases (kb).  
Before proceeding to the sequencing of PCR products, PCR was repeated using 
the first PCR reaction product in place of cDNA, in order to increase the 
quantity of amplicons and improve the chances to successfully sequence long 
sequences of nucleotides. 
3.3.1.5 Sequencing of PCR products 
The PCR amplicons obtained with standard PCR (F9/R11; F13/R17) and 
LongRange RT-PCR (F2/R17) were sequenced. Single PCR products were purified 
using Polyethylene Glycol (PEG) solution as previously described (chapter 2, 
paragraph 2.2.1.3). PCR multiple products were extracted from cut gel fragments 
using the Qiaquick gel extraction kit (Qiagen, Manchester, UK) according to the 
manufacturer’s instructions. Briefly, DNA fragments were excised from the 
agarose gel with a scalpel, weighed and 3 volumes of Buffer QG were added to 
each 1 volume gel. After 10 minutes of incubation at 55°C and quick vortex, 1 gel 
volume of isopropanol was added and mixed. The sample was then applied to a 
QIAquick column and centrifuged for 1 minute at 13’000 RPM; the flow-through 
was discarded and the QIAquick column placed back on the same tube. 
Subsequently, 0.75 ml of Buffer PE were added to the QIAquick column, left to 
stand for 5 minutes and then centrifuged x2 for 1 minute at 13’000 RPM, 
discarding the flow-through. Finally, the QIAquick column was placed into a clean 
1.5 ml microcentrifuge tube and 30 µl of Buffer EB were added, left to stand for 4 
minutes and then centrifuged for 1 minute at 13’000 RPM: the flow-through 
containing the extracted PCR product was collected and stored at -20°C. 
Purified PCR products were then sequenced using the BigDye Terminator 
Sequencing Kit [Applied Biosystems (ABI), Life Technologies Ltd, Paisley, UK] and 
an ABI Prism 377 DNA automatic sequencer, as previously described in chapter 2, 
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paragraph 2.2.1.3, using the appropriate TPO F or R primer of the relative PCR 
reactions (F9, F11, R11, R17 for standard PCR and F2, R17 for LongRange RT-PCR). 
The program used was the same applied in the relative PCR reaction.  
3.3.1.6 QPCR 
QPCR experiments were conducted using Platinum® SYBR® Green qPCR 
supermix-UDG (Invitrogen by Life technologies, ThermoFisher scientific, USA) 
incorporation measured on a Stratagene (La Jolla, CA, USA) MX 3000. TPO primers 
F2 and R3-4 were used, in order to quantify an amplicon of 170 bp ideally common 
between the different TPO mRNA isoforms (mainly differing from exon 8 onwards) 
and hence providing a measure of total TPO transcripts (Table 3-1).  
The TPO standard template consisted of a 170 bp amplicon amplified from 
TT in a PCR reaction conducted as described before (paragraph 3.3.1.3) using F2 
and R3-4 as TPO primers and subsequently purified using the Wizard® SV Gel and 
PCR Clean-Up System (Promega, Madison, USA), according to the manufacturer’s 
instructions. The DNA concentration of the amplicon was measured using a 
spectrophotometer as described before (paragraph 2.2.1.3) and the correspondent 
number of DNA copies was assessed using the “URI Genomics & Sequencing Center 
Calculator for determining the number of copies of a template” created by 
Andrew Staroscik, 29 January 2004 (http://cels.uri.edu/gsc/cndna.html). 
Subsequently, different dilutions (100nM, 300nM, 500nM) of TPO primers F2 
and R-4 were tested in a 25 µl reaction solution containing 1µl F, 1µl R, 12.5 µl 
SYBR and 1µl F2/R3-4 purified amplicon template; 2 separate reaction solutions 
with different F2/R3-4 template dilutions were performed (102 and 105 cDNA 
copies). 
A TPO standard curve was generated using 25 µl reaction solutions 
containing 12.5 µl SYBR, 1 µl F2 300 nM, 1 µl R3-4 300 nM and 1 µl of F2/R3-4 
purified amplicon template in different amounts obtained by serial dilutions: 101, 
102, 103, 104, 105, 106 cDNA copies number.   
The TPO cDNA copies number present in every BC cell line and human 
tissue sample was assessed using cDNA obtained with RT from 1 µg total RNA as 
described before (paragraph 2.2.1.3), using random primers instead of odT in 
order to optimize the transcripts quality. In particular, the 25 µl reaction solution 
contained 12.5 µl SYBR, 1 µl F2 300 nM, 1 µl R3-4 300 nM and 1 µl (approximately 
50 ng) of cDNA template. A complete TPO standard curve was included in each 
experiment to calculate the absolute values for each sample (transcripts/µg input 
RNA), as well as a negative control containing dH20. In a single QPCR experiment 
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all measurements were made in triplicate and the standard curve was run at least 
in duplicate. 
In addition, transcripts for the housekeeping gene APRT were measured: 
the applied QPCR methods were the same as TPO, except for using F and R APRT 
primers previously described for standard PCR (see paragraph 3.3.1.3) at the final 
concentration of 0.4 µM each. The APRT plasmid used to produce the APRT 
standard curve was a gift from Alenka Janezic (Cardiff University) and consisted of 
a 247 bp APRT fragment obtained by the previously described APRT PCR reaction 
(paragraph 3.3.1.3), subcloned into a pGEM®-T Easy plasmid (Promega, Madison, 
USA) and purified before use, as described above for TPO standard.   
3.3.2 Analysis of TPO protein expression 
3.3.2.1 Indirect immunofluorescence (IF) 
Indirect IF was initially performed on 4 paraffin embedded human BC tissue 
samples and human TT as positive control. Tissue sections were dewaxed and 
rehydrated through 10 consecutive passages of 5 minutes each through graded 
alcohols, distilled water (dH20) and phosphate-buffered saline solution (PBS), as 
summarized in Table 3-6. 
Table 3-6: Deparaffination and rehydration procedure 
1 2 3 4 5 6 7 8 9 10 
Xylene 
100% 
Xylene 
100% 
Xylene 50% 
Ethanol 50% 
Ethanol 
100% 
Ethanol 
100% 
Ethanol 
90% 
Ethanol 
70% 
Ethanol 
50% 
dH2O PBS 
dH2O = distilled water; numbers indicate the order of passages 
 
Tissues sections were then incubated with the first antibodies (1:10 dilution) at 
room temperature for 1 hour. The primary antibodies comprised pooled sera from 
4 women with high titres of TPOAb (range 446 - >1000 U/ml) or free of TPOAb 
(n=3); TPOAb determination was performed by immune enzymometric assay 
(Tosoh Bioscience, Tessenderlo, Belgium; positive if >10 U/ml). Tissue sections 
were then washed 5 minutes x3 in PBS and then incubated with a polyclonal rabbit 
anti-human-IgG fluorescein isothiocyanate (FITC)-coniugated (Dako, DK-2600 
Glostrup, Denmark) 1:70 dilution for 1 hour at room temperature. Tissue sections 
were then washed again 5 minutes x3 in PBS, rinsed, mounted and left overnight 
at 4°C to dry and fix.  
The same 4 BC and TT paraffin embedded tissue sections were also 
analyzed in a similar protocol using mouse monoclonal to TPO ab76935 (abcam, 
Cambridge, UK) as first antibody (1:100 dilution) and Alexa Fluor 488 goat anti-
mouse IgG (Life Technologies Ltd, Paisley, UK) as second antibody (1:50 dilution).  
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A further 5 paraffin embedded BC samples were analyzed with a modified 
protocol in which slides, after the deparaffination and rehydration procedure, 
were initially blocked for two hours at room temperature with goat serum 10%; 
primary and secondary antibodies were also diluted in goat serum 10%, 
maintaining the same incubation conditions of the first protocol (one hour at room 
temperature). Primary antibodies were pooled human sera from women with high 
titres of TPOAb or free of TPOAb as above (1:10 dilution) and mouse TPO 
monoclonal ab12500 (abcam, Cambridge, UK; 1:25 dilution). Secondary antibodies 
were respectively goat polyclonal to human IgG-H&L (FITC) ab97164 (abcam, 
Cambridge, UK; 1:500 dilution) and Alexa Fluor 488 goat polyclonal anti-mouse IgG 
H + L (Life Technologies Ltd, Paisley, UK; 1:1000 dilution).  
In all IF experiments images were analysed using Olympus BX51 
microscope, trinocular brightfield / fluorescence (Olympus America Inc., Center 
Valley, PA, USA).    
3.3.2.2 Indirect Immunohistochemistry (IHC) 
Indirect IHC was performed on 2 frozen human BC tissue samples and 
frozen human TT as positive control, using Vectastain® ABC-AP Kit (mouse IgG; 
Vector Laboratories Inc, Burlingame, CA, USA) with Vector Red Alkaline 
Phosphatase Substrate Kit I (Vector Laboratories Inc, Burlingame, CA, USA), as 
described in the manufacturer’s protocol.  
v Briefly, frozen tissue sections were air dried, fixed with acetone 100% for 10 
minutes and then transferred into PBS.  
v Tissue sections were incubated for 20 minutes with Vectastain® blocking horse 
serum (1:67 dilution) and then with mouse monoclonal to TPO ab12500 
(abcam, Cambridge, UK) diluted 1:25 in PBS for one hour at room 
temperature.  
v Tissue sections were subsequently washed for 5 minutes in PBS and then 
incubated for 30 minutes with Vectastain® biotinylated secondary antibody 
solution (horse anti-mouse IgG).  
v After, they were washed for 5 minutes in PBS, incubated for 30 minutes with 
Vectastain® ABC-AP reagent, washed for 5 minutes in PBS and incubated in 20-
30 minutes in alkaline phosphatase substrate solution (Vector Red).  
v Tissue sections were then rinsed in tap water and counterstained with 
hematoxylin: 3 minutes incubation with 20% hematoxylin (diluted in water), 3 
minutes wash in tap water, 3 minutes incubation in tap water containing 
ammonium 2%, 3 minutes in 95% alcohol, 3 minutes in 99% alcohol and 1 
minute in 100% xylene. Tissue sections were finally cleared and mounted.   
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v Images were analysed using Olympus BX51 microscope, trinocular brightfield / 
fluorescence (Olympus America Inc., Center Valley, PA, USA). 
3.3.2.3 Western Blot (WB) 
Fresh human tissues samples and BC cell lines were investigated for TPO 
protein expression with WB, applying the following procedure:  
v Protein extraction. From fresh frozen tissues: frozen tissue (200 mg) was diced 
using a razor blade and thawed in 600 µL of RIPA buffer [1% tergitol-type NP40 
detergent, 0.5% sodium deoxycholate and 0.1% Sodium Dodecyl Sulphate (SDS) 
in phosphate buffered saline (PBS)] containing 10 µL/ml proteases inhibitor 
[phenylmethanesulfonylfluoride (PMSF) in isopropanol] and homogenized with 
a Dounce homogenizer at 4°C. Samples were then centrifuged at 15000xg for 
20 minutes at 4°C and the protein extract (supernatant) was stored at -20°C in 
loading buffer (LB) containing 40% of 10% SDS, 20% glycerol, 0.5M Tris pH 6.8 
and 16% pure water.  
From cells: 6-well plates were washed X2 with 2 ml PBS and cells were scraped 
with LB and transferred into 1.5 ml Eppendorf tubes, then boiled for 5 minutes 
in order to break DNA, inactivate proteases and break tertiary and quaternary 
protein structure. Finally, samples were centrifuged at 13000 rpm for 5 
minutes and the protein extract (supernatant) was stored at -20°C.    
v Measure of protein concentration. 60% trichloroacetic acid was added (1:1 
ratio) to 50 µl of protein sample in LB  and the optical density at 630 nm was 
measured with a microprocessor-controlled photometer (Opsys MRTM 
Microplate Reader (Dynex Technologies, Chantilly, USA), using different 
dilutions of bovine serum albumin (BSA) 1mg/ml (in LB) as standard.  
v SDS - PolyAcrylamide Gel Electrophoresis (SDS-PAGE). Extracted proteins (5-15 
ug of TT and 50 ug for all other tissues and BC cell lines) were added with 2% 
pyronin Y 0.2% and 2% β-mercaptoethanol; cells protein only were added also 
with 10 µl/ml PMSF 100 mM, already present in tissue proteins (contained in 
previously used RIPA buffer). Protein samples were boiled for 5 minutes and 30 
seconds respectively for tissue and cells protein (since cells protein extracts 
had already been previously boiled for 5 minutes). Samples where then loaded 
on 8% tris-glycine SDS-acrylamide gels [2.64 ml 30% acrylamide, 3.75 ml 1M tris 
pH 8.8, 100 µl 10% SDS, 100 µl ammonium persulfate (APS), 5 µl 
tetramethylethylenediamine (TEMED) and 2.92 ml distilled water (dH2O)] and 
separated for half a hour by electrophoresis in running buffer (tris 15g, glycine 
72g and SDS 5g in 1L dH2O). In order to mark the protein size, the Prestained 
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Protein Marker, Broad Range 7-175 kDa (New England BioLabs®, Ipswich, USA) 
was diluted 1:1 in LB and loaded on the gel. 
v Membrane blotting. After electrophoresis proteins were transferred onto a 
Polyvinylidine Fluoride (PVDF) membrane Amersham Hybond-P (GE Healthcare, 
Chalfont St Giles, Buckinghamshire, UK) by electrophoresis for 1 hour. 
v Membranes blocking and incubation with first and second antibody. Membranes 
were blocked for 2 hours at room temperature with 5% non-fat dry milk 
powder (Marvel, Long Sutton, Spalding, UK), followed by overnight incubation 
at 4°C with mouse monoclonal TPO ab76935 (Abcam, Cambridge, UK) raised to 
TPO amino acids 672-780, diluted (1:1000) with 5% bovine serum albumin [BSA 
(Sigma-Aldrich, Gillingham, Dorset, UK)] or 5% not-fat dry milk powder, 
respectively for tissues and cells protein analysis. Membranes were then 
washed three times for 5 minutes with TBS-T (Tris-buffered saline, 0.1% Tween 
20). After washing, membranes were incubated for 1 hour at room 
temperature with ECL anti-mouse IgG horseradish peroxidase (HRP)-linked 
whole antibody (from sheep; GE Healthcare UK limited, Little Chalfont 
Buckinghamshire) diluted (1:5000) with 5% non-fat dry milk powder. 
Membranes were then washed with TBS-T two times for 30 seconds, 1 time for 
15 minutes and three times for 5 minutes.   
v Blot developing. The blot was developed in a dark room with Amersham ECL 
Plus western blotting detection system (GE Healthcare, Chalfont St Giles, 
Buckinghamshire, UK) according to manufacturer’s instructions. Films were 
analysed using the Alpha Imager 1200 digital imaging system (Alpha Innotech 
Corp., San Leandro, CA, USA). 
v Stripping and re-probing for human-actin. Membranes were then stripped for 
30 min at 60°C in stripping buffer (6.25 ml tris 0.5M pH 6.8, 10 ml 10%SDS, 
0.35 ml mercaptoethanol and 33.5 ml dH2O), washed 10 minutes X3 with large 
volumes of TBS-T (50 ml/blot), blocked for 2 hours at room temperature with 
5% non-fat dry milk powder and re-probed with rabbit polyclonal anti-human 
actin IgG (I-19, sc-1616-R, Santa Cruz Biotechnology, Dallas, USA) at 1:000 
dilution and ECL anti-rabbit IgG HRP-linked whole antibody (from donkey; GE 
Healthcare UK limited, Little Chalfont Buckinghamshire) at 1:5000 dilution, 
following the same procedure described above.   
A primary antibody absorption test by antigen peptide (TPO and LPO) was 
performed in order to verify the specificity of identified bands on WB.  
Primary TPO antibody ab76935 (8 µg) was pre-incubated overnight at 4° C 
with TPO recombinant fragments (8 µg) produced in bacteria, either TPO 3 (Glu 
471 - Ser 720) or TPO 4 (Phe 709 - Leu 933) (265) in 5% BSA. These TPO fragments 
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were generated by others in Prof. Marian Ludgate’s laboratory in Cardiff 
University and stored frozen until further use.  
The same primary antibody absorption test was also performed using 10 µg 
bovine LPO (Sigma-Aldrich, Gillingham, Dorset, UK).   
3.3.3 Cell culture conditions 
BC cell lines were cultured (+37°C; 5% CO2) in 6-well plates until 90% 
confluent in the following medium: 
v MCF-7: Dulbecco's modified Eagle's medium (DMEM; BioWhittaker®, Lonza, 
Belgium) supplemented with 10% foetal calf serum (FCS), 2% 
penicillin/streptomycin (PS), 1 millimolar (mM) sodium pyruvate and 10 µg/ml 
bovine insulin.  
v T-47D: Roswell Park Memorial Institute (RPMI) medium supplemented with 2 ml 
of L-Glutamine 200 mM in 0.85% NaCl, 10% FCS and 2% PS.  
v MDAMB-231: DMEM (BioWhittaker®, Lonza, Belgium) supplemented with 10% 
FCS and 2% PS. 
4 different culture conditions were used for all the 3 different BC cell lines: 
normal culture medium (N) or supplemented with 1nm β-estradiol (Sigma-Aldrich; 
E), 100ng/µl IGF-II (Sigma; I) or the two agents combined (EI). Cells were 
harvested at 6 hours (6), 24 hours (24), 72 hours (72) and 8 days (8) for RNA or 
protein extraction, for a total of 16 different combinations, as summarized in 
Table 3-7.  
Table 3-7: 16 different combinations for each BC cell line 
 Cell collection time 
6 hours 
(6) 
24 hours 
(24) 
72 hours 
(72) 
8 days 
(8) 
C
el
l 
cu
lt
ur
e 
co
nd
it
io
ns
 
Normal culture medium (N) 6N 24N 72N 8N 
+ 1nm β-estradiol (E) 6E 24E 72E 8E 
+ 100ng/uL IGF-II (I) 6I 24I 72I 8I 
+ 1nm β-estradiol  
and 100ng/uL IGF-II (EI) 
6EI 24EI 72EI 8EI 
3.4 RESULTS 
3.4.1 TPOAb display auto-reactivity to a breast cancer antigen 
The hypothesis of TPO expression in BC tissue was first explored by IF 
performed on 4 deparaffinized and rehydrated BC tissue samples with human TT 
as positive control using pooled human sera positive for TPOAb at high titre 
(TPOAb+) or negative for TPOAb (TPOAb-). 5 additional paraffin embedded BC 
tissues were later tested with a slightly modified indirect IF protocol, as 
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previously described in paragraph 3.3.2.1. When using TPOAb+ pooled human sera, 
the immunoreactivity was apparent in 9/9 BC tested (Figure 3-2 panel A) and the 
IF signal was strong on TT, much more evident on the apical surface of the thyroid 
cells, most likely reflecting binding to TPO (Figure 3-2 panel B). The 
immunoreactivity was absent in both BC and TT tissues when using TPOAb- pooled 
human sera (Figure 3-2 panels C and D respectively).   
Figure 3-2: Indirect IF results using pooled human sera 
 
Representative results of indirect Immunofluorescence using pooled human sera as primary 
antibody. Panel A (10x magnification): breast cancer (BC) tissue incubated with pooled 
human sera strongly positive for TPOAb (TPOAb+). Panel B (10x magnification): thyroid 
tissue (TT) incubated with TPOAb+ pooled human sera (positive control). Panel C (20x 
magnification): BC incubated with TPOAb free (TPOAb-) pooled human sera. Panel D (20x 
magnification): TT incubated with TPOAb- pooled human sera (negative control). In panels 
A and B is present a positive signal (green stain), which is absent in panels C and D, where 
is visible only a weak aspecific staining (negative).  
 
Figure 3-3 shows the indirect IF results obtained with the initial 4 paraffin 
embedded BC tissues and TT as positive control using a monoclonal TPOAb; they 
confirmed the results obtained with pooled human sera in Figure 3-2.  
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Figure 3-3: Indirect IF results using monoclonal TPOAb 
 
Representative results of indirect immunofluorescence (IF) staining for thyroid peroxidase 
(TPO), 20x magnification. In the small box for each picture there is the correspondent 10x 
magnification. Panels A,B: thyroid tissue (TT) tested with goat serum 10% lacking primary 
antibody [A] and mouse monoclonal antibody to TPO [B]. Panels C,D: breast cancer tissue 
(BC) tested with goat serum 10% lacking primary antibody [C] and mouse monoclonal 
antibody to TPO [D]. Panels B and D show a positive signal (green stain), which is absent in 
panels A and C. 
 
The above reported IF results clearly indicated the presence of 
immunoreactivity to BC in TPOAb+ women, thus further experiments were 
conducted to accurately investigate TPO expression, both mRNA and protein, in 
BC and other tissues.  
3.4.2 TPO gene expression (mRNA) 
3.4.2.1 Quality controls for RNA extraction and cDNA synthesis by RT 
Figure 3-4 shows the results of 2% agarose gel electrophoresis of RNA (1 µl) 
extracted from representative tissue samples: the presence of 2 bands 
corresponding to ribosomal RNA 28S and 18S indicated the integrity of extracted 
RNA. In cases of degraded RNA, e.g. BC2, the RNA was extracted again and used 
for cDNA synthesis and analyses only if passing the quality control. BC 
characteristics had been previously summarized in Table 3-3.  
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Figure 3-4: RNA quality control (representative samples) 
 
L 1 kb = ladder 1 kilobases. L 100 bp = ladder 100 base pairs. BC = breast cancer. PT = 
breast peri-tumoural tissue. TT = thyroid tissue. 100-10’000 = number of bp.    
 
Figure 3-5 reports some APRT PCR results in representative tissue samples. 
All samples analyzed contained the expected 247 bp amplicon and the bands 
obtained in BC tissues tended to be sharper compared with the correspondent PT, 
possibly reflecting higher efficiency of RT reaction in some samples. When a 
sample showed a faint APRT band (e.g. TT1^), the RT reaction was repeated in 
order to try and increase the quality of obtained cDNA (TT1). 
Figure 3-5: Standard PCR for APRT gene (representative samples) 
 
BC = breast cancer. L 100 bp = ladder 100 base pairs. Neg = negative control with distilled 
water (dH2O). PT = breast peri-tumoural tissue. TT= thyroid tissue. TT^= cDNA obtained 
from TT via a poor quality reverse transcription reaction. 100-1500 = number of bp. 
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3.4.2.2 Standard PCR and TPO isoforms  
Table 3-5 (paragraph 3.3.1.2) reports the expected amplicons using 
different TPO primer pairs. The best results were obtained with F13/R17 and 
nearly all samples were tested and produced one or more amplicons. F7/R9 and 
F9/R11 PCR gave less quality PCR experiments, therefore only few representative 
samples were investigated. 
 
F13/R17 
Figure 3-6 shows results obtained in standard RT-PCR reactions in 
representative TT, BC and PT samples after 40 (panel A) and 50 (panel B) PCR 
cycles. As previously summarized in Table 3-5, the expected 485 bp band 
corresponded to TPO 1, TPO 2 or TPO 5 and 353-355 bp band corresponded to TPO 
3, TPO 4, TPO 2/3 or TPO 2/4; this was verified by sequencing. The sequence 
analysis of 400/450 bp and 320 bp unexpected bands revealed that they were just 
nicked PCR products corresponding respectively to the 485 bp or 353-355 bp 
bands.  
Figure 3-6: F13/R17 PCR results in representative tissue samples 
 
BC = breast cancer; L 100 bp = ladder 100 base pairs; Neg (dH2O) = negative control with 
distilled water; PT = breast peri-tumoural tissue; TT= thyroid tissue; 100-600 = number of 
bp. Panel A = after 40 PCR cycles. Panel B = after 50 PCR cycles. 
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The sequence analysis of the unexpected 130 bp band was inconclusive, 
since the sequence analysis performed on BLAST did not show similarities with any 
existing human gene. The sequence analysis of the 220 bp band revealed a newly 
described TPO mRNA isoform lacking both exons 14 and 16, therefore still 
expressing exon 15 corresponding to the transmembrane region, as shown in 
Figure 3-7.  
Figure 3-7: New TPO mRNA isoform lacking exons 14 and 16 
 
Panel A: Electropherogram showing the sequencing result of the 220 bp unexpected 
amplicon with PCR using forward primer in exon 13 and reverse primer in exon 17 
(F13/R17 PCR). A = adenosine; C = cytosine; G = guanosine; T = thymidine. Exons 14 and 
16 are missing, therefore exons 13, 15 and 17 are consecutive in the nucleotide sequence. 
Panel B: schematic representation of the newly identified TPO mRNA isoform. 1-17 = TPO 
exons; white squares = exons present; white squares containing a grey cross = exons 
absent; grey squares = exons not investigated with F13/R17 PCR.  
 
All 3 BC cell lines and all tissue samples except for AD were tested with F13/R17 
PCR. Only 9/17 (52.9%) AD were tested: 3 AD-A, 4 AD-SC, 1 AD-K and 1 AD-O. 
Table 3-8 and Table 3-9 summarize the detected amplicons in tissue samples (40 
cycles) and BC cell lines (40 and 50 cycles) respectively.  
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Table 3-8: Summary of F13/R17 PCR (40 cycles) in tissue samples  
 485 bp 353/355 bp 220 bp 130 bp 
BC 8/8 
(100%) 
8/8 
(100%) 
6/8 
(75%) 
1/8 
(12.5%) 
PT 5/8 
(62.5%) 
5/8 
(62.5%) 
6/8 
(75%) 
3/8 
(37.5%) 
AD 9/9 
(100%) 
9/9 
(100%) 
8/9* 
(88.9%) 
1/9* 
(11.1%) 
PC 0/3 0/3 0/3 0/3 
PKC 0/1 0/1 0/1 0/1 
MKC 0/1 0/1 0/1 0/1 
Summary of PCR products after 40 cycles obtained in all samples. AD = adipose tissue; BC = 
breast cancer; MKC = hepatic metastasis of kidney carcinoma; PC = pancreatic 
adenocarcinoma; PKC = primary kidney carcinoma; PT = peri-tumoural breast tissues. 
* The only AD not expressing the 220 bp amplicon was abdominal (AD-A): the same sample 
was the only AD expressing the 130 bp amplicon. 
Table 3-9: Summary of F13/R17 PCR in BC cell lines 
  40 PCR cycles  50 PCR cycles  
Cell 
line 
Ampl. 
(bp) 
6 
hours 
24 
hours 
72 
hours 
8 
days 
 6 
hours 
24 
hours 
72 
hours 
8 
days  
MCF-7 
485     
 6EI     
0/16  
(0%) 
353-
355 6I    
 
6I   8EI 
2/16 
(12.50%) 
220 6EI 24N, 
24EI 
72I 8E, 8I 
 
6EI 24N, 24E, 
24EI 
72I 8E, 
8I 
7/16 
(43.75%) 
150 6N, 6E, 6I 24EI 72EI  
 6N, 
6E, 6I 24I, 24EI 
72I, 
72EI  
7/16 
(43.75%) 
            
T-47D 
485    8EI     8EI 1/16 (6.25%) 
353-
355   72I  
 6E  72I  2/16 
(12.50%) 
220 6I 24I 72 EI 8 EI  6I 24I 72EI 8EI 4/16 (25%) 
130       24E, 24EI  8EI 3/16 (18.75%) 
            
MDAM
B-231 
485      6 E 24I   2/16 
(12.50%) 
353-
355   72 EI 8 I 
   72EI  8I 2/16 (12.50%) 
220 6 I 24 N 72 N   6 I 24 N 72 N  3/16 (18.75%) 
150 6 N     6 N    1/16 (6.25%) 
Summary of F13/R17 PCR products after 40 and 50 cycles obtained in BC cell lines MCF-7, 
T-47D and MDAMB-231 cultured in normal medium (N), or supplemented with 1nm β-
estradiol (E), 100ng/uL IGF-II (I) or both (EI), collected after 6 hours (6), 24 hours (24), 72 
hours (72) or 8 days (8) from the beginning of treatment. The amplicons (Ampl.) size is 
expressed in base pairs (bp) in the second column on the left. The last column on the right 
summarize the number and percentage of cell combinations expressing (calculated after 
50 cycles) a particular amplicon.  
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Known TPO isoforms (amplicons 485 and 353-355 bp) were expressed after 
40 PCR cycles by TT (positive control), all BC and AD tested and the great majority 
of PT, but in none of the other tumours tested (PC, PKC, MKC). Results after 50 
PCR cycles were identical, except that the 485 bp amplicon was expressed also in 
1/3 PC and MKC. In the 3 BC cell lines, known TPO isoforms were detected only in 
some culture conditions, notably in the presence of oestrogen and/or IGF1, but 
this was unrelated to the incubation time (Figure 3-8). 
The 220bp amplicon corresponding to the newly identified TPO mRNA 
variant missing exon 14 and 16 was expressed by the great majority of BC, PT and 
AD, while it was absent in the other tumours tested and only faintly expressed in 
TT, as previously shown in Figure 3-6. Importantly, the 220bp amplicon was the 
most abundant in all the 3 cell lines, especially MCF-7, compared with the 
amplicons corresponding to the other TPO isoforms (Figure 3-8). TPO expression 
was present in all the different culture medium combinations, however it seemed 
to be slightly more prevalent in stimulated cells, especially with IGF-I, alone or in 
combination with estradiol.  
Figure 3-8: F13/R17 PCR results (50 cycles) in all BC cell line combinations 
 
Panel A, B and C: MCF-7, T-47D and MDAMB-231 cell lines respectively. Numbers indicating 
the collection time of cells: 6 = 6 hours, 24 = 24 hous, 72 = 72 hours, 8 = 8 days. Letters 
indicating the cells culture medium: N = normal, E = supplemented with 1nm β-estradiol, I 
= supplemented with 100ng/uL IGF-II, EI = supplemented with both 1nm β-estradiol and 
100ng/uL IGF-II. The arrows indicate the expected (485 and 353/355 bp) and newly 
described (220 and 130 bp) amplicons. L 100 bp = ladder 100 base pairs; Neg = negative 
control (distilled water); TT = thyroid tissue; 100-600 = number of bp. 
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Other TPO primer combinations in standard PCR 
PCR with TPO primer pairs different from F13/R17 gave poor results and were 
performed mainly on TT and only a few samples of BC and PT; contrary to other 
standard PCR reactions, they were often performed using cDNA obtained from RT 
using TPO reverse primers instead of odT (e.g. R11 for F7/R9 PCR), since giving 
better results. As representative example, Figure 3-9 shows the results obtained 
with F7/R9 PCR after 50 cycles performed on TT, two BC and one PT: after 40 
cycles only very faint bands were obtained (not shown).  
Figure 3-9: F7/R9 PCR (50 cycles)  
 
L 100 bp = ladder 100 base pairs; BC = breast cancer; Neg (dH2O) = negative control 
(distilled water); PT = peritumoural breast tissues; TT = thyroid tissue. The arrows indicate 
the expected (169 and 688 bp, corresponding respectively to TPO 5 and all the other TPO 
isoforms) and newly described (220, 340 and 500 bp) amplicons. 100-700 = number of bp. 
 
According to Table 3-5, 2 amplicons were expected: 169 bp corresponding to 
TPO 5 isoform missing exon 8 and a 688 bp corresponding to all the other TPO 
isoforms. The expected 169 bp amplicon was present, but not the 688 bp, while 
several intermediate bands were present: 500, 340 and 220 bp.  
Similarly to F7/R9 PCR, the other primer pair combinations gave additional 
unexpected bands, then identified as new TPO mRNA isoforms by gene sequencing 
(agarose gel results not shown). 
 
TPO mRNA isoforms identified by standard RT-PCR 
Figure 3-10 summarizes the newly identified TPO mRNA isoforms identified 
by standard PCR and gene sequencing.  
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Figure 3-10: Summary of newly identified TPO mRNA isoforms with standard PCR 
 
Numbered squares from 7 to 17 represent TPO gene exons. White and grey squares 
represent respectively expressed and missed exons. bp = base pairs (size of the sequenced 
amplicon). 
 
The TPO mRNA isoform corresponding to the 220bp F13/R17 amplicon was 
demonstrated to be present also in BC (both tissues and cell lines), PT and AD, as 
described above. The other TPO variants/amplicons were sequenced only in TT 
due to time restrictions. It is very likely that the 220bp F13/R17 and the 900 bp 
F9/R17 amplicons identified the same TPO variant. 
The discovery of so many TPO mRNA isoforms never identified before lead me 
to further explore this topic with different techniques, considering that standard 
RT-PCR gives poor quality results when investigating long amplicons. 
3.4.2.3 LongRange RT-PCR and TPO mRNA isoforms 
In an attempt to characterize the various TPO isoforms detected by 
standard RT-PCR, TPO primers in exons 2 (location of start codon) and 17 (location 
of stop codon) were used in LongRange RT-PCR. Due to time restrictions, only few 
samples were tested: TT, BC 5, BC 6, PT 3, one AD-S and MCF-7 EI. All samples 
were tested both with (Q) and without (N) Q solution; amplicons were obtained in 
all samples except PT 3, MCF-7 EI and AD-S when tested with Q solution (Figure 3-
11). Different amplicons were obtained with or without Q solution and this will be 
further discussed in the conclusions section (paragraph 3.5.3).  
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Figure 3-11: LongRange RT-PCR (F2/R17) results 
 
Panel A: agarose gel 1.5% bands obtained with LongRange RT-PCR using TPO primers in 
exon 2 and 17 (F2/R17). AD-S = subcutaneous adipose tissue; BC = breast cancer; TT = 
thyroid tissue; * = Q solution added to the PCR reaction mix. Panel B: schematic 
representation of novel TPO mRNA isoforms found sequencing PCR products obtained with 
LongRange RT-PCR F2/R17. Numbered squares from 2 to 17 represent TPO gene exons. 
White and grey squares represent respectively expressed and missed exons. 
 
Table 3-5 shows the expected amplicons with PCR F2/R17 according to 
known TPO isoforms. In particular, TT showed the presence of a faint amplicon at 
2700 bp, corresponding to the full length TPO1, only in the presence of Q solution 
(Figure 3-11 panel A); sequencing confirmed that it was the full length TPO 1 
isoform (Figure 3-11 panel B). The most abundant thyroid transcript was the 
previously described TPO 5 which lacks exon 8, and hence enzymatic activity. 
Additional smaller transcripts were also present in TT but these did not 
correspond to other known TPO isoforms, either previously reported or already 
described in this study.  
In non-thyroid samples many different bands were detected; a 2000 bp 
variant was present in BC n°5 (with Q solution) lacking exons 8-9 or in BC n°6 
lacking exon 8 (TPO 5); a 1500-1700 bp variant lacking exons 8-10 was present in 
BC n°5 (with Q solution) and AD-S; whilst a 1000 bp transcript in which exon 7 
then skipped to exon 15 was abundant in the two BC (without Q solution); a short 
transcript comprising exons 2 linked to 15-17 was present in AD-S, BC n°6 and TT. 
As in the case of TT, we did not find other known TPO isoforms or the new TPO 
mRNA variant lacking exons 14 and 16 identified with standard RT-PCR F13/R17.  
Figure 3-11 panel B summarizes all TPO mRNA isoforms found with LongRange RT-
PCR using primer pair F2/R17. Many other transcripts were isolated but they were 
not successfully identified by gene sequencing due to the presence of overlapping 
sequences. 
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3.4.2.4 QPCR 
Table 3-10 reports the cycle threshold (Ct) and copy number (N° copy 
referred to estimated 50 ng of input cDNA) of TPO gene obtained in human 
tissues. BC and PT expressed TPO mRNA at the same level, around 104 fold less 
than in TT. The AD tissues expressed TPO mRNA 102 fold less than in TT and 
therefore 100-fold higher than in BC/PT, with no depot-specific differences. In the 
other tumours (PC, PKC and MKC), TPO transcripts were at the limit of detection. 
Table 3-10: Absolute QPCR values for TPO copy number obtained in human tissues 
Sample Ct 
N° 
copy 
 
Sample Ct N° copy 
 
Sample Ct N° copy 
BC 1 31,74 4,43E+02  AD-A 1 31.65 1.04E+04  PKC NO 0 
BC 2 30,59 9,58E+02  AD-A 2 29.79 3.40E+04  MKC NO 0 
BC 3 32,56 2,57E+02  AD-A 3 28.72 6.73E+04     
BC 4 29,33 2,21E+03  AD-A 4 30.48 2.19E+04  PC 1 35 5,02E+01 
BC 5 31,72 4,50E+02  AD-S 1 29.28 4.72E+04  PC 2 36,94 1,38E+01 
BC 6 31,82 1,50E+03  AD-S 2 29.64 3.74E+04  PC 3 33,12 1,77E+02 
BC 7 31,7 4,56E+02  AD-S 3 28.45 8.03E+04  Mean 
 
8.02E+01 
BC 8 30,75 8,58E+02  AD-S 4 30.64 1.98E+04     
Mean  8.92E+02  AD-S 5 31.42 1.21E+04  TT 18,53 3,01E+06 
    AD-S 6 30.71 1.89E+04     
PT 1 32,01 3,71E+02  AD-S 7 32.49 6.07E+03     
PT 2 29,19 2,43E+03  AD-S 8 37.76 2.10E+02     
PT 3 28,97 2,82E+03  AD-K 28.33 8.64E+04     
PT 4 35,55 3,50E+01  AD-O 1 33.72 2.77E+03     
PT 5 31,23 6,25E+02  AD-O 2 28.82 6.32E+04     
PT 6 29,91 4,20E+02  AD-O 3 28.99 5.68E+04     
PT 7 32,53 2,62E+02  AD-O 4 30.04 2.89E+04     
PT 8 36,13 2,36E+01  Mean   3.49E+04     
Mean  8.73E+02         
AD-A = abdominal adipose tissue; AD-K = adipose tissue from knee; AD-O = orbital adipose 
tissue; AD-S= subcutaneous adipose tissue; BC = breast cancer; Ct = cycle threshold; MKC = 
hepatic metastasis of kidney carcinoma; N° copy = TPO cDNA copy number (referred to 
approximately 50 ng of cDNA); PC = pancreatic adenocarcinoma; PKC = primary kidney 
carcinoma; PT = breast peri-tumoural; TT = thyroid tissue. 
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Table 3-11 reports the cycle threshold (Ct) referred to input cDNA 
(estimated 50 ng) obtained in all different combinations of MCF-7 BC cell line with 
TPO primers and APRT primers. Ct TPO values showed that TPO mRNA was 
expressed at the limit of detection in all the combinations of MCF-7 BC cell lines. 
Even if not shown in the present thesis due to space restrictions, both TPO and 
APRT quantifications, with the relative TPO and APRT standard curves and always 
including positive control with TT and negative control with dH2O, have been 
performed for all tissues and BC cell lines.  
Table 3-11: Absolute TPO and APRT QPCR values obtained in MCF-7 BC cell lines 
MCF-7 Ct TPO Ct APRT  Sample Ct TPO Ct APRT 
6 N 37,41 22,23  TT 27,88 29,16 
6 E 36,54 21,71     
6 I 37,70 21,50  TPO/APRT 106 25,76 20,52 
6 EI 38,14 21,74  TPO/APRT 105 31,55 24,21 
24 N 36,76 20,80  TPO/APRT 104 33,10 27,76 
24 E 36,62 21,43  TPO/APRT 103 37,38 30,34 
24 I 37,60 21,83  TPO/APRT 102 35,90 30,79 
24 EI No 22,66  TPO/APRT 101 36,84 31,07 
72 N 37,95 22,28     
72 E 38,70 22,91     
72 I 36,35 21,70     
72 EI 38,40 23,59     
8 N 36,68 22,53     
8 E 37,39 22,02     
8 I 38,49 21,58     
8 EI 37,33 23,23     
Cells cultured in normal medium (N), or supplemented 1nm β-estradiol (E), 100ng/uL IGF-II 
(I) or both (EI), collected after 6 hours (6), 24 hours (24), 72 hours (72) or 8 days (8) from 
the beginning of treatment. Ct TPO and Ct APRT = cycle threshold to obtain respectively 
TPO and APRT cDNA detection (referred to approximately 50 ng cDNA); TT = thyroid 
tissue.  
 
TPO mRNA was expressed at the limit of detection also in all the 
combinations of T-47D and MDAMB-231 cell lines, as shown in Table 3-12. 
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Table 3-12: Absolute TPO QPCR results for T-47D and MDAMB-231 BC cell lines 
T-47D Ct TPO  MDAMB-231 Ct TPO  TT Ct TPO 
6N No	Ct  6N 35.1	 	 16.82	
6E 33.99  6E 33.02	 	 	
6I No	Ct  6I 34.66	 	 	
6EI No	Ct  6EI No	Ct	 	 	
24N 36.31  24N No	Ct	 	 	
24E 32.94  24E 37.03	 	 	
24I No	Ct  24I 34.15	 	 	
24EI 35.14  24EI No	Ct	 	 	
72N No	Ct  72N No	Ct	 	 	
72E No	Ct  72E 34.4	 	 	
72I No	Ct  72I No	Ct	 	 	
72EI No	Ct  72EI 34.46	 	 	
8N No	Ct  8N No	Ct	 	 	
8E No	Ct  8E No	Ct	 	 	
8I 37.81  8I 34.31	 	 	
8EI No	Ct  8EI 35.23	 	 	
Cells cultured in normal medium (N), or supplemented 1nm β-estradiol (E), 100ng/uL IGF-II 
(I) or both (EI), collected after 6 hours (6), 24 hours (24), 72 hours (72) or 8 days (8) from 
the beginning of treatment. Ct TPO = cycle threshold to obtain TPO cDNA detection 
(referred to approximately 50 ng cDNA); TT = thyroid tissue. 
3.4.3 TPO gene expression (protein) 
3.4.3.1 Western Blot (WB) 
105-110 kDa band 
As previously explained in paragraph 3.1.1.1. and summarized in Table 3-1, 
TPO protein is usually detected by WB as a double band of 105-110 kDa molecular 
mass. When the blot was exposed for a short time (from 15 seconds to 3 minutes: 
depending from the strength of antibodies and reagents used), the 105-110 kDa 
band was present only in TT. However, exposing the blots for extended times (up 
to 40 minutes), combined with loading 10 times more protein extract than for TT, 
lead to the detection of similar bands in 7/8 BC, 4/8 PT, 2/4 AD, 1/1 PKC, 1/1 
MKC and 1/2 PC (only 2 of the 3 PC were examined because PC3 sample was 
insufficient for protein analysis), as shown in Figure 3-12 (panel A and B). Similar 
results were obtained with all the 3 different BC cell lines, where a 105-110 kDa 
band was present independently from the cell collection time and the addition of 
growth factors to the cell medium (Figure 3-12 panel C). 
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Figure 3-12: 105-110 kDa band observed with WB 
 
Western Blot representative results of 105-110 kDa band expression observed in human 
tissues (panels A and B: 40 minutes exposition time) and MCF-7 cell line (panel C: 20 
minutes exposition time), using mouse monoclonal to TPO ab76935. Tissues: AD-A = 
abdominal adipose tissue; AD-K = adipose tissue from knee; AD-O = orbital adipose tissue; 
AD-S = subcutaneous adipose tissue; BC = breast cancer; MKC = metastatic kidney cancer; 
PC = pancreatic adenocarcinoma; PT = breast peri-tumoural tissue; TT = thyroid tissue. 
Cells: 6 = cell collection after 6 hours from treatment; 24 = cell collection after 24 hours 
from treatment; E = culture medium supplemented with 1nm β-estradiol; EI = culture 
medium supplemented with 1nm β-estradiol and 100ng/uL IGF-II; I = culture medium 
supplemented with 100ng/uL IGF-II; N = normal culture medium. / = no proteins loaded. 
 
In order to test the specificity of obtained signals, the primary antibody 
was absorbed using recombinant fragments of TPO spanning the region of the 
epitope recognized by the antibody. As shown in Figure 3-13 (panels A and B), the 
105-110 kDa signal in TT was greatly reduced and that in the other tissues 
completely eliminated by the treatment. Conversely, when the primary antibody 
was absorbed with bovine LPO, the intensity signal was not reduced and 
paradoxically enhanced in some cases (Figure 3-13 panel C).  
Figure 3-13: Absorption of first antibody with TPO fragments and bovine LPO 
 
Representative results of 105-110 kDa band expression at Western Blot (5 minutes 
exposure) in BC = breast cancer, MKC = hepatic metastasis of kidney cancer, PT = breast 
peri-tumoural tissue, TT = thyroid tissue, / = no protein loaded. Panel A: normal ab76935. 
Panel B: TPO absorbed ab76935: the signal is strongly reduced or eliminated. Panel C: 
bovine LPO absorbed ab76935: the signal is unchanged or paradoxically enhanced.  
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Additional bands 
When exposing the blot for longer times (3-40 minutes), additional bands 
corresponding to proteins of apparent molecular weight (MW) 70, 60 and 30-35 
kDa were identified in TT, in addition to the doublet at 105-110 kDa (Figure 3-14 
panel A). Absorption with recombinant TPO strongly reduced not only the 105-110 
kDa band corresponding to complete TPO protein (TPO 1) but also the signals at 70 
and 60 kDa, indicating that they could be smaller isoforms of TPO or degraded 
fragments of TPO 1; the 30-35 kDa band was not affected by absorption (Figure 3-
14 panel B). Absorption with LPO did not reduce the signal (Images not shown).  
Figure 3-14: Entire WB obtained in thyroid tissue 
 
Panel A: complete WB results in thyroid tissue (TT) using normal ab76935; it shows the 
doublet at 105-110 kDa and 3 additional bands at 70, 60 and 30-35 kDa.  Panel B: complete 
WB results in the same TT of panel A using TPO absorbed ab76935: the 105-110, 70 and 60 
kDa bands are strongly reduced, whilst the 30-35 kDa band is not significantly modified. 
 
The 70 and 60 kDa bands were also present in breast tissues BC/PT and PKC 
in addition to proteins of 50 and 150 kDa, all of which were reduced by absorption 
of TPO monoclonal antibody ab76935 with recombinant TPO (Figure 3-15). 
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Figure 3-15: Entire WB on human tissues 
 
Entire Western blot representative images (40 minutes exposition time) of various tissues 
probed with TPO monoclonal antibody ab76935 normal (panel A) or pre-absorbed with TPO 
fragments (panel B). The numbers on the left indicate the molecular weight (kDa). In each 
small box there is the correspondent magnification of the 105-110 kDa band expression 
(full-length TPO), previously shown in Figure 3-13. BC = breast cancer; MKC = hepatic 
metastasis of kidney carcinoma; PT = peri-tumoural breast tissue; TT = thyroid tissue; / = 
no sample loaded. In panel B the signal related to 105-110 kDa band and to other 
additional bands (50, 60, 70, 150 kDa) is strongly reduced or eliminated, while the 
aspecific signal of 30-35 kDa band is not significantly modified.      
 
After being probed for TPO, the membranes were stripped and re-probed for 
human actin to reveal the presence of a 42 kDa band as expected, corresponding 
to β-actin in these tissues (Figure 3-16).  
Figure 3-16: Western Blot for β-actin 
 
Representative Western Blot images (20 minutes exposition time) of the 42 kDa obtained 
in various tissues probed with primary antibody to human actin. BC = breast cancer; PT = 
breast peri-tumoural tissue.  
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3.4.3.2 Indirect Immunohistochemistry (IHC) 
The PCR and WB results indicated that both breast (tumoural and peri-
tumoural) and adipose tissues contain low levels of TPO protein. Considering that 
breast is rich in fat, indirect IHC experiments were performed in order to identify 
the cellular location of TPO protein in BC tissues. A weak TPO immunoreactivity 
was found in a small proportion of breast epithelium, and obtained in 2/2 fresh 
frozen BC tissues analyzed (Figure 3-17). 
Figure 3-17: Indirect IHC results in 2 fresh frozen BC 
 
Panels A and B show two different breast cancer tissues (BC) analyzed by indirect IHC 
using TPO mouse monoclonal ab12500 as primary antibody (20x magnification); in the 
small square is represented thyroid tissue (TT) as positive control (10x magnification). In 
TT the TPO signal (red) is strongly positive and located in thyrocytes that express TPO, 
disposed around the colloid follicles; in BC the TPO signal (red) is weaker but present and 
located in breast epithelium cells. 
 
3.4.4 TPO gene expression: correspondence between mRNA and protein 
Table 3-13 summarizes the results of TPO mRNA and protein expression in 
BC, PT and other tumours. A similar comparison has not been performed for AD, 
since only 9 and 4 tissue samples were analyzed respectively for TPO mRNA and 
protein expression, not paired because of scarcity of available material. 
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Table 3-13: Correspondence between TPO mRNA and protein expression 
Tissue TPO mRNA TPO1 
Protein 
WB  
105-110 kDa 
Tissue TPO mRNA TPO1 
Protein 
WB  
105-110 kDa 
TPO1 New 
isoform 
(no  14/16) 
TPO1 New 
isoform 
(no 14/16) 
1 BC 1 2 0 PT 0 0 0 
2 BC 3 3 1 PT 3 2 1 
3 BC 3 0 3 PT 3 3 1 
4 BC 3 3 1 PT 0 1 2 
5 BC 2 2 3 PT 2 2 0 
6 BC 3 3+ 1 PT 3 3 0 
7 BC 1 0 1 PT 0 0 0 
8 BC 3 1 3 PT 3 2 2 
PKC 2 0 2     
MKC 3 0 1     
1 PC 0 0 2     
2 PC 0 0 0     
3 PC 2 0 NA     
TPO mRNA expression is referred to PCR F13/R17 (50 cycles). kDa = kilodaltons; NA = not 
available (not performed because of scarcity of tissutal material); No 14/16 = absence of 
exons 14 and 16 (variant corresponding to 220 base pairs band); TPO1 = TPO isoform 1 
(complete, corresponding to 485 base pairs); WB = western blot. Numbers indicate the 
intensity of expressed bands in PCR (mRNA) or WB (protein): 0 = absent, 1 = very low, 2 = 
low, 3 = moderate, 3+ = high (values from 1 to 3+ were considered positive). 
3.5 CONCLUSIONS 
3.5.1 TPO gene is expressed in breast cancer and other tissues 
These experiments demonstrate that thyroid peroxidase (TPO) mRNA and 
protein are not confined to thyroid cells but are also present in other tissues, 
albeit it at low levels. Our results confirm those of Lai et al. (261) who 
demonstrated TPO expression, both mRNA and protein, in orbital tissue (fat and 
fibroblasts). In my study, the highest level of TPO mRNA expression, around 100 
times less than in thyroid tissue (TT), was found in adipose tissue (AD), 
independently from its source (abdominal, subcutaneous, orbital or knee-derived). 
Breast cancer (BC) and its relative peri-tumoural breast tissue (PT) expressed TPO 
mRNA 50-100 times less than AD and therefore 104 fold less than TT. TPO 
expression in BC tissue could explain both the known association between BC and 
thyroid autoimmunity (TA) and the protective role of serum thyroid peroxidase 
(TPOAb) in patients with aggressive BC; this will be further discussed in chapters 4 
and 5.  
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The other cancers investigated as controls did not express substantial 
levels of TPO mRNA when investigated with QPCR, the same was true for the 3 BC 
cell lines. However, the tumoural tissues were found to be negative for TPO mRNA 
expression also with standard PCR, differently from all the 3 BC cell lines that 
showed TPO relative amplicons after 40 cycles of PCR, even if faint. Considering 
that a high number of PCR cycles were needed in order to detect such amplicons 
(up to 50 PCR cycles), initially the hypothesis of “illegitimate transcripts”, 
corresponding to the low level presence of specific transcripts in non-specific 
cells, was considered (266). However, TPO protein was present in the majority of 
analysed tissues with western blot (WB), including the other tumoural tissues 
examined, even in some negative for TPO mRNA expression; therefore TPO gene 
expression seemed to be real. Specificity tests using pre-absorption of the first 
antibody with TPO fragments and bovine lactoperoxidase (LPO) confirmed that the 
obtained signal at WB was TPO. The specificity test is really important, since 
TPOAb could cross-react with non-TPO components in the examined tissues, 
especially in immunofluorescence experiments using pooled human sera positive 
for TPOAb, and therefore led to aspecific signal and false positive conclusions. 
The discrepancy between mRNA and protein expression may be first of all a 
consequence of the fact that WB is not a quantitative technique and long exposure 
times have often been used, therefore a signal present in the other tumours may 
have been overestimated. To this purpose, it is important to highlight that the 
monoclonal TPOAb used for WB experiments was obtained new, delivered on ice 
and immediately stored at -20°C. Despite this, even thawing it just once 
determined a reduction of the intensity signal and longer exposure times were 
needed in order to develop a good signal (from 5 to 40 minutes). Moreover, gene 
expression is a complex process involving several fundamental steps: 
transcription, mRNA degradation, translation and protein degradation (267). 
Several authors agreed that there is a poor correlation between mRNA and 
correspondent protein levels mainly due to uncoupled processes of synthesis and 
degradation. Levels of mRNA (transcription) explain only around 40% of the 
variability in protein levels; post-transcriptional, translational and degradation 
regulation processes contribute at least at the same extent (268). In the study of 
Schwanhäusser et al. proteins were found to be on average 5 times more stable 
than mRNA (267) and this could explain the presence of TPO protein expression in 
samples negative for TPO mRNA expression. Furthermore, tumoural tissue is 
characterized by a general dis-regulation of many normal cellular functions, 
leading to a different phenotype compared with normal tissue and to an aberrant 
gene expression (269). Unfortunately in the present study no normal tissues were 
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available as controls, while it would have been interesting to test whether normal 
kidney or pancreatic tissue expressed tiny amount of TPO as found in the 
correspondent tumours. Similarly to BC, an increased prevalence of serum TPOAb 
and other thyroid autoantibodies has been found in several other cancers including 
kidney (270), pancreas (271), lung (272) and stomach (273); TPO expression in 
these cancers could explain a raise in TPOAb levels and further experiments are 
needed to verify this hypothesis.  
The presence of TPO in BC is even more convincing, since found at a higher 
level and not confined to the tumoural tissue, but also in the peri-tumoural breast 
tissue (PT). PT tissue could express neoplastic or pre-neoplastic features, 
therefore further experiments with normal breast tissue obtained from reductive 
mammoplasty would be the ideal control in order to assess whether TPO is 
expressed in breast tumoural cells or also in normal breast cells. Importantly, 
considering that fat is abundant within the breast and that RNA and protein were 
extracted from the whole homogenized tissue, the positive TPO expression found 
in PT could represent the TPO expressed by AD within the breast. This could also 
explain the discrepancy between BC tissue and cell lines results, with TPO mRNA 
found to be expressed at a higher level in tissue and at the limit of detection in 
BC cell lines. However, TPO expression by BC cells has been demonstrated by 
immunohistochemistry (IHC) experiments that clearly showed the presence of 
signal in the ductal breast epithelium. Furthermore, a recent review reported that 
adipocytes within mammary gland carcinomas are dynamic cells that may 
contribute to human BC progression (274). Therefore I can hypothesize that the 
tissue micro-environment present within BC may induce or enhance TPO 
expression in in vivo tissues, while in in vitro experiments, where the BC cells are 
grown alone, TPO expression is reduced.  
In BC cell lines no significant differences in terms of TPO expression were 
found between the different stimulation conditions and collection times. However 
stimulated cells, especially with Insulin-like growth factor type II (IGF-II), alone or 
in combination with ϐ-estradiol, tended to express more TPO compared to the 
other ones. This is plausible since, as previously introduced in paragraphs 1.3.1.2 
and 3.1.3, both IGF-II and oestrogens are considered mitogens for BC cells growth 
(118, 262, 263) and are engaged in a crosstalk resulting in synergistic growth in 
MCF-7 BC cell line (264). As an afterthought, a possible link between oestrogens 
activity and TPO expression it is likely to have been underestimated considering 
that phenol red, a usual component of culture media (e.g. DMEM and RPMI) in 
quality of pH indicator, has been demonstrated to partially have an oestrogenic 
stimulatory activity on MCF-7 cells at concentrations used in tissue culture media 
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(275). Similarly, foetal calf serum (FCS) could also represent an additional 
uncontrolled source of oestrogens in the cell culture conditions. It is also 
important to highlight that MCF-7 cells, the most differentiated BC cell line, 
expressed more TPO compared with MDAMB-231, the less differentiated one. 
These data taken together may suggest the possibility that TPO expression in BC 
could be regulated by hormones and growth factors, in a similar way to the 
sodium iodide symporter (NIS), whose expression has been found to positively 
correlate with the oestrogen receptor expression (210). However, experiments 
with BC cell lines provided equivocal results and did not allow to draw substantial 
conclusions about the regulation of TPO gene expression. Further studies are 
needed to investigate the regulatory mechanisms of TPO expression in breast 
tissues; in particular, using culture medium phenol red free and containing 
charcoal stripped foetal bovine serum instead of FCS, where hormones are 
selectively removed.  
TPO is not the only thyroidal antigen present in orbital adipose tissue, 
since thyroid-stimulating hormone (TSH) receptor (TSHR) has been demonstrated 
to be also expressed and represents one of the major antigen involved in Graves’ 
orbitopathy (1). Interestingly, TSHR transcripts have also been found in different 
depots of adipose tissue, even if at a lower level compared with orbital fat (276) 
and adipose tissue is also a key target for thyroid hormones (1, 277). Therefore 
the discovery of TPO transcripts and protein expression in adipose tissue from 
different depots further increases the similarities and connections between 
thyroid and adipose tissue; however, this topic is not related to the present thesis 
and will be developed in collateral research projects.   
Finally, it is important to state that this study verified the quality of RNA 
and protein analyzed, therefore the results of gene expression experiments 
presented in this thesis are reliable. In particular, the good quality of RNA was 
verified by the presence of ribosomal RNA 28S and 18S and an absorbance ratio at 
260 and 280 nm (A260/280) between 1.7 and 2.0 obtained with UV 
spectrophotometry. The good quality of cDNA obtained from RNA by reverse 
transcription and of extracted proteins was guaranteed by the verified expression 
of housekeeping genes, such as adenine phosphoribosyltransferase (APRT) and β-
actin. APRT protein is a ubiquitous enzyme that catalyzes the formation of AMP 
and inorganic pyrophosphate from adenine and 5-phosphoribosyl-1-pyrophosphate 
(278). β-actin is a non-muscle cytoskeletal actin involved in cell structure and 
motility, therefore highly conserved and used as housekeeping control protein in 
WB (279).  
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Therefore we can conclude that variable levels of TPO seem to be 
expressed in a wide variety of different tissues, adipose tissue and breast cells in 
particular; further and larger experiments are needed in order to better 
investigate in which other human tissues TPO is expressed (and why). 
3.5.2 TPOAb cross-reactivity with other peroxidases 
Considering that LPO is highly expressed in breast tissue and that the 
peroxidase family members have many similarities (257), when discussing TPO 
protein expression results it is important to exclude the presence of TPOAb cross-
reactivity with other peroxidases, LPO in particular. In terms of TPO mRNA 
expression there is no need for such proof, considering that 1) PCR products have 
been sequenced and they 100% correspond to TPO; 2) PCR experiments have been 
mainly performed with primers designed in exons 13 and 17, that are specific to 
TPO and missing in the other peroxidases, as previously explained in paragraph 
3.1.1.2. 
3.5.2.1 Structural similarities between TPO and other peroxidases 
AS previously introduced in paragraph 3.1.1.2, TPO has considerable 
structural similarity with the other members of the peroxidase family, previously 
summarized in Table 3-2; in particular, the highest homology is with 
myeloperoxidase (MPO), as summarized in Table 3-14. The TPO sequence of amino 
acids (AA) 122-737, encoded from exon 5 and 12 (referred as “MPO like” region), 
has 71% similarity and 46% identity with MPO (280).    
Table 3-14: Summary of TPO regions in relation to MPO 
EXONS AA REGION NAME COMPARISON WITH MPO 
2-5 1-121 Pro-sequence MPO Cleaved away in final MPO sequence 
5-12 122-737 MPO-like 46% identical, 71% similar  
13 741-795 CCP-like Absent  
14 794-842 EGF-like Absent  
15 842-871 Transmembrane Absent  
16-17 872-933 Intracellular  Absent  
 AA = amino acids. CCP = complement control glycoprotein. EGF = epidermal growth 
factor. MPO = myeloperoxidase. TPO = thyroid peroxidase. 
However, considering that lactoperoxidase (LPO) is highly expressed in 
breast tissue, as previously reported in paragraph 3.1.1.2, in the present study it 
is important to compare TPO and LPO structures, in order to investigate for 
possible cross-reactivity of TPOAb with LPO. Human LPO is a single chain 
monomeric protein of 712 residues, 46% identical to human TPO and 57% and 58% 
respectively to human MPO and human eosinophil peroxidase (EPO) (281).  
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Figure 3-18: Amino acidic sequence of human peroxidases alignment and comparison  
 
Adapted from (281). HEPO = human eosinophil peroxidase; HLPO = human lactoperoxidase; 
HMPO = human myeloperoxidase; HTPO = human thyroid peroxidase. The identical 
sequences are highlighted in green. Cysteine (Cys) residues are highlighted in yellow.  
 
Although LPO was first isolated in 1943 (282) and its primary structure has 
been known since 1991 (283), the crystal structure of caprine LPO was achieved 
only in 2008 (284). On the contrary, even if human TPO protein sequence was first 
reported in 1987 (244), despite much effort, TPO crystals suitable for X-ray 
diffraction have not been obtained yet (246, 285); as a consequence, insights into 
the structure of TPO come from related proteins. Even if the primary AA sequence 
is known for both LPO and TPO, the comparison of the relative tertiary and 
quaternary structures is essential since, as further explained in paragraph 5.2.2, 
TPOAb usually recognize conformational and not linear epitopes. To this purpose, 
interesting attempts at TPO structure modeling have been realized (286), based 
on the known crystal structure of MPO (287), factor H (a typical CCP module) 
(288) and EGF-like domain of fibrillin-1 (289), for respectively the MPO-like, EGF-
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like and CCP-like domains of TPO. In particular, CCP-like TPO region (encoded by 
exon 13) has 21% identity and 48% similarity with factor H, while EGF-like TPO 
region (encoded by exon 14) has 36% identity and 62% similarity with EGF-like 
domain of fibrillin-1 (286). TPO modeling with particular focus on surface epitopes 
will be further discussed in the general discussion chapter (paragraph 5.2.2).  
3.5.2.2 TPOAb cross-reactivity with other peroxidases, in particular LPO 
In this study 2 different mouse monoclonal antibodies to TPO were used for 
TPO protein detection (Figure 3-19):   
v ab76935 (abcam, Cambridge, UK), originated using a TPO recombinant 
fragment corresponding to AA 672-780 (encoded by exons 12 and 13) as 
immunogen. The ab76935 has been used for western blot (WB) and indirect 
immunofluorescence (IF). 
v ab12500 (abcam, Cambridge, UK), originated using human TPO purified from 
thyroid microsomes by immunoaffinity chromatography as immunogen. 
Ab12500 is a mouse monoclonal antibody 47 (MoAb47) clone (290), found to 
recognize a linear sequence (AA 710-722, encoded by exon 12) identified as 
one of the major antigenic site in human TA (defined C21), as previously 
introduced in paragraph 3.1.1 (246). The ab12500 has been used for indirect 
immunohistochemistry (IHC). 
Figure 3-19: ab76935 and ab12500 binding site on human TPO 
 
Schematic representation of the correspondence between TPO nucleotide sequence 
(Nucl.) and TPO amino acid sequence (AA). bp = base pairs; CCP = complement control 
glycoprotein; C2, C21 = antigenic sites; EGF = epidermal growth factor; MoAb47/ab12500 
and ab76935 = mouse monoclonal antibodies to TPO; START codon ATG = nucleotide triplet 
corresponding to the beginning of translation process; STOP codon TGA = nucleotide triplet 
corresponding to the end of translation process; 1-17 = exon number; 1-3146 = nucleotide 
number; 1-933 = amino acid number; 3’ COOH = 3-prime-end of the gene, encoding the 
intracellular carboxy-terminus (or C-terminus) of the protein; 5’ NH2 = 5-prime-end of the 
gene, encoding the extracellular amino-terminus (or N-terminus) of the protein.  
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Figure 3-20 summarizes the sequence alignment of TPO and LPO residues 
corresponding to the two mouse monoclonal antibodies. The ab76935, used for WB 
and IF experiments, has been produced against the TPO peptide AA 672-780 and 
the first half of this region is similar to LPO (encoded by TPO gene exon 12), but 
the second part (encoded by TPO gene exon 13) is exclusive to TPO, since a 
correspondent sequence in LPO protein does not exist. The ab12500, used for IHC, 
recognizes a small portion of the TPO peptide sequence used to generate 
ab76935, containing only 4/13 (30.77%) identical AA and not in sequence. 
Figure 3-20: TPO and LPO amino acidic sequence alignment (TPO AA 672-780) 
 
LPO = lactoperoxidase; TPO = thyroid peroxidase. Numbers indicate the amino acids 
(indicated by letters). Amino acids identical between TPO and LPO are reported in red. AA 
672-780 represent the primary sequence of TPO peptide used to generate ab76935. The 
square identifies the epitope recognized by ab12500 (TPO = 710-722; LPO = 685-697). 
 
Despite the large similarity of the first epitope part, WB pre-adsorption 
experiments of ab76935 with LPO clearly demonstrated that this antibody does 
not bind LPO, since the signal was not reduced after its pre-adsorption with 
bovine LPO. Bovine LPO has been used instead of purified human LPO; this is 
possible since mammalian LPOs have a very high rate of identity, in particular 
bovine and human LPO have 85 % homology (281). For this reason bovine LPO is 
routinely used for similar cross-reaction studies in place of human LPO (290, 291). 
In particular Ruf et al. tested MoAb47, recognizing the same epitope as ab12500 
used for IHC in my study, for cross-reactivity with bovine LPO, human MPO and 
horseradish peroxidase (HRP) in an enzyme-linked immunosorbent assay (ELISA), 
with negative results. On the contrary, 3/13 (23.1%) of tested mouse monoclonal 
TPOAb (raised against the whole TPO protein) cross-reacted with bovine LPO, 
more strongly compared with human MPO, therefore the authors concluded that 
some TPO epitopes are phylogenetically conserved through evolution and shared 
by different peroxidases (290).  
I therefore conclude that, despite TPO and LPO proteins possibly share similar 
epitopes, TPO protein expression results obtained with monoclonal antibodies in 
my study are specific for TPO and any cross-reactivity with LPO can be excluded, 
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considering that: 1) Western Blot (WB) showed the expected 105-110 kDa band, 
relative to TPO, while the expected molecular weight of LPO is 80-90 kDa, 2) WB 
signal reduction was obtained after pre-adsorption of ab76935 with TPO but not 
with LPO, 3) The epitope recognized by ab12500 used for IHC has already been 
demonstrated to be absent in LPO (290). 
In this study not only were monoclonal antibodies to TPO used, since IF 
experiments were performed using human sera positive for TPOAb and a possible 
cross-reactivity with LPO has not been tested. However, this has already been 
investigated by different authors (291) and will be further discussed in chapter 5, 
paragraph 5.2.1.  
3.5.3 TPO isoforms 
Standard PCR gave the best results with primer pair F13/R17 amplifying 
TPO mRNA from exon 13 to 17, probably because the PCR product is shorter 
compared with the other primer pairs (Table 3-5). In addition it excludes exon 8, 
which is large (519 bp) and rich in G and C nucleotides, therefore difficult to 
amplify. In particular PCR F13/R17 revealed a new TPO mRNA variant without 
exons 14 and 16, mainly expressed in breast and adipose tissues (Figure 3-7). 
Standard PCR performed with different primer pairs identified new TPO mRNA 
variants too, as summarized in Figure 3-10. 
In order to identify these new isoforms in their entirety, in particular that 
identified with F13/R17 PCR, LongRange RT-PCR was used to amplify the full-
length TPO mRNA sequence; to my knowledge this is the first study of such kind. A 
special technique had to be used, considering the extreme fragility and instability 
of long RNA sequences and consequent difficulty to obtain good quality long cDNA 
sequences. In fact, due to these existing limitations, the TPO mRNA isoforms 
known so far and reported in Table 3-1 have been identified amplifying TPO mRNA 
with standard PCR only from exon 9 to exon 17; therefore, nothing is known about 
their sequence from exon 2 to 8 (253). LongRange RT-PCR has improved efficiency 
in amplifying long and difficult tracts of RNA/cDNA by using enzymes and buffer 
solutions designed to work at elevated temperatures, resulting in improved 
denaturation of difficult templates. In particular the PCR enzyme mix is a blend of 
thermostable DNA polymerases with proofreading-assisted fidelity and a high 
extension rate and the RT buffer contains the RNase H quencher, much more 
effective in preventing RNA degradation compared with different RNAse inhibitors. 
Different amplicons were obtained with or without Q solution, usually bigger in 
the first case: this because Q solution modifies the melting behavior of DNA, 
therefore facilitates the amplification of cDNA regions rich in C and G nucleotides, 
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or in general difficult to amplify in normal conditions because of the presence of 
secondary structures.  
LongRange RT-PCR revealed a great variety of newly described isoforms in 
all examined tissues, mainly preserving exons from 2 to 7, while exons from 8 to 
16 were strongly subjected to deletion. Surprisingly, neither the previously 
described TPO mRNA isoforms (TPO2, TPO3, etc…), nor the newly TPO mRNA 
variant missing exons 14 and 16 were identified; only TPO5 (missing only exon 8) 
and one new variant identified with F9/R17 PCR (missing exons from 10 to 14), 
were identified (Figure 3-11). I hypothesized two possible explanations: 1) many 
other LongRange RT-PCR amplicons were present but not successfully identified 
because of intense overlapping of TPO sequences of similar size, 2) alternative 
START codons not located in exon 2 may exist in TPO mRNA sequence, therefore 
the above mentioned TPO isoforms would not be detected in a PCR reaction with a 
forward primer designed in exon 2, as the case of LongRange RT-PCR F2/R17. The 
last hypothesis is plausible since other in-frame methionine AA (encoded by START 
codon AUG) are present in TPO mRNA sequence, with one of them (located in 
exon 3) followed by AA sequences essential for protein insertion into the 
endoplasmic reticulum (251). 
The results of this study suggest that the real number of different TPO 
mRNA isoforms, resulting from different combinations between exons, is large. If 
TPO mRNA isoforms corresponding to virtually all the possible combinations 
between exons from 2 to 17 really exist, their identification would be quite 
challenging, since they would correspond to transcripts of every length, many 
having the same size but different nucleotide sequence, therefore impossible to 
separate on an agarose gel and sequence. However, the highest variety of TPO 
mRNA isoforms was found in thyroid tissue (TT), while breast cancer (BC) and 
adipose tissue (AD) showed a much smaller number of transcripts and, more 
importantly, different between them. In particular, it is important to state that 
the two different BC analyzed by LongRange RT-PCR, BC 5 and 6, represented 
respectively ductal and mucinous invasive carcinomas (Table 3-3), therefore it is 
plausible that they have a different pattern of gene expression. Furthermore, the 
TPO mRNA variant identified by PCR F13/R17 was expressed only by breast and 
adipose tissue and expressed in thyroid tissue only as a faint band, while in 
adipose/breast tissues it was sharper and BC cell lines expressed it much more 
than TPO1 and the other known isoforms. We could hypothesize that TPO isoforms 
are not only tissue specific, but in case of BC also may be related to different 
histological and molecular classification. In order to clarify this aspect, further 
studies on a larger number of samples are needed.  
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Another key point is to establish whether these isoforms are translated in 
the correspondent protein. WB results identified the presence of several 
additional bands of lower molecular weight compared with entire 105-110 kDa 
TPO protein (Figure 3-15), disappearing after pre-adsorption of primary antibody 
with TPO fragments but no LPO, suggesting a specific binding to TPO (Figure 3-
14). If these proteins really exist, further studies are needed to investigate their 
function and immunogenic properties. The region included from exon 5 and exon 
12 encodes for the myeloperoxidase (MPO) like sequence which contains important 
catalytic residues, so we can hypothesize that TPO isoforms that lack exons in this 
region are not functional, as in fact has been already demonstrated for TPO 2 that 
lacks exon 10 (252) and TPO 5 that lacks exon 8 (253). However, the absence of 
functional activity does not influence the antigenic role: to this purpose TPO 
protein sequence must just contain those short linear peptides processed and 
presented to T-lymphocytes by antigen presenting cells via Major 
Histocompatibility Complex (MHC) molecules. Furthermore, smaller TPO isoforms 
are likely to fold differently compared with full-length protein, therefore exposing 
different conformational epitopes; TPO epitopes will be discussed in chapter 5, 
paragraph 5.2.2. In an alternative hypothesis, smaller MW bands present on WB 
could represent degraded parts of full length TPO protein. WB also showed the 
presence of bigger bands of 150-170 kDa and above, already described in previous 
studies and found to be TPO homodimers (292). In order to solve the question of 
additional bands, further experiments including protein sequencing need to be 
performed.  
Finally, in presence of a so intense TPO mRNA alternative splicing 
phenomenon, the possibility of template switching was taken into consideration. 
Template switching is a phenomenon that may happen during RT-PCR processes, 
leading to the amplification of an artificially deleted cDNA, which can be wrongly 
interpreted as an alternative transcript (293). Several mechanisms may be 
involved: 1) template switching (ability to switch from a template to another 
presenting a homologous region) of the reverse transcriptase enzyme during cDNA 
synthesis, 2) mRNA hydrolysis, 3) cDNA synthesis interruption caused by strong 
secondary RNA structures, 4) template switching of the DNA polymerase enzyme 
during cDNA copying (294). In this study specific experiments in order to exclude 
the above mentioned possibilities were not performed. However, the phenomenon 
of template switching is unlikely to explain the presence of TPO mRNA alternative 
and shorter transcripts since: 1) the cDNA sequencing revealed that TPO isoforms 
transcripts corresponded only to exonic sequences, with the intronic sequences as 
the only exclusively missing, 2) LongRange RT-PCR, working at higher 
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temperature, is less subject to RNA/cDNA secondary structures potentially leading 
to template switching phenomenon. Future experiments searching for the 
correspondent protein of TPO isoforms transcripts would also help to solve this 
doubt.     
 113 
4 TPOAb IMPACT ON BREAST CANCER 
PROGNOSIS 
4.1 INTRODUCTION 
As previously discussed in chapter 1, paragraph 1.4.3, thyroid autoimmunity 
(TA) and in particular anti-thyroid peroxidase (TPO) autoantibodies (TPOAb), have 
been found to be more prevalent among patients with breast cancer (BC) 
compared with the general population: 36% versus 19% (P<.001)(179), 23.5% versus 
8% (P=.002)(180) and 15% versus 9.8% [Odds Ratio= 3.0; 95% Confidence Interval 
(95%CI), 1.4-6.5](166). However, these findings have not been confirmed in 
another study that observed no differences in the incidence of thyroid 
autoimmune diseases between BC patients and controls (163).       
In the literature the prevalence of TPOAb and TgAb among the general 
population has been estimated to be 13% (8.7% males, 17% females) and 11.5% 
(7.6% males, 15.2% females) respectively (63), with other authors describing an 
even higher prevalence of general autoantibodies to the thyroid (TAb: TPOAb & 
TgAb combined) of 26.4%, (64). All authors agree that TPOAb and TgAb prevalence 
in general population increases with age (63-67). 
Regarding thyroid function, hypothyroidism has been associated with both 
an increased (166, 295, 296) or reduced (167, 168) risk of developing BC, whilst 
other authors did not report any correlation (159, 191, 297-299).  
Of relevance, TA but more specifically TPOAb, have been found to be 
significantly associated with an improved prognosis for BC. These results were 
obtained in small-scale studies, with the majority agreeing but with also some not 
confirming, as discussed in the next paragraph 4.1.1. Considering that, as shown 
in chapter 3, TPO is expressed in BC tissue, albeit at a lower level compared with 
thyroid tissue, this could provide a possible mechanistic link: a thyroid/breast 
shared cytotoxic autoimmune response against a common antigen (likely TPO) 
might target tumour cells and improve BC outcome. The increased prevalence of 
circulating TPOAb could represent the epiphenomenon of such protective immune 
activity and blood TPOAb could therefore represent an indicator of good BC 
prognosis. 
The aim of the present study was to clarify the impact of circulating TPOAb 
on BC prognosis in a large, well powered cohort of patients, following the 
“REporting recommendations for tumour MARKer prognostic studies (REMARK) 
guidelines” (300). The Taxotere as Adjuvant Chemotherapy Trial (TACT) recruited 
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4162 women diagnosed with early BC and an indication for adjuvant chemotherapy 
to evaluate whether sequential docetaxel (Taxotere) after traditional 
anthracycline therapy would improve patient outcome compared with standard 
anthracycline chemotherapy (301). Of relevance, stored plasma was available in a 
significant number of these patients, permitting retrospective analysis of the 
impact of TPOAb and thyroid hormone status on BC prognosis with 97.5 months 
medium follow-up available (302). 
Currently there are no major validated blood prognostic markers in BC: as 
previously discussed in chapter 1, paragraph 1.3.5, cancer antigen 15.3 (Ca 15.3) 
and carcinoembryonic antigen (CEA) are characterized by low specificity and 
sensitivity, while circulating tumour DNA (ctDNA) and circulating tumour cells 
(CTCs) represent very promising blood tumoural markers, but are not yet 
validated in routine clinical practice.  
Therefore, assessing TPOAb as a prognostic marker, measurable in blood, for 
BC in a large and mature cohort would provide an important clinical observation 
with possibilities to develop TPO-targeted therapies in the future. In this study 
the thyroid function parameter has also been taken into consideration, since 
thyroid hormones have been also described as potential factors influencing BC 
prognosis, even if with contrasting conclusions, as described in the next paragraph 
4.1.1.2.   
4.1.1 Impact of thyroid autoimmune diseases on breast cancer 
prognosis 
4.1.1.1 Thyroid autoimmunity  
A better BC outcome has been reported in TPOAb positive (TPOAb+) versus 
TPOAb negative (TPOAb-) patients in most (182-184, 260), but not all (185) 
studies. 
In particular, Smyth et al. evaluated the 5 years disease-free survival (DFS) 
and overall survival (OS) of 142 women affected with BC. TPOAb absence resulted 
in a poor prognostic factor for both DFS [Relative Risk (RR) 1.84, p=0.047)] and OS 
(RR 3.46, p=0.016) and this effect was confirmed in the multivariate analysis with 
other BC risk factors (182). Fiore et al. analyzed the 5 years OS of a small but 
homogeneous group of 47 women affected with high malignancy ductal infiltrating 
BC and found a 5 years mortality of 6.7% in patients positive for TAb, mainly 
TPOAb, compared with 46.9% in negative patients and this protective effect was 
confirmed in the multivariate analysis with other BC risk factors (183). In contrast, 
Jiskra et al. prospectively followed 84 patients with BC for a median of 136 
months and found no impact of TPOAb on BC prognosis in terms of both DFS and 
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OS, registering a BC recurrence in 26.7% and 25.9% of patients affected 
respectively with and without TA (185).   
A protective role for TPOAb was also suggested by Farahati et al. in a study 
conducted among 314 patients newly diagnosed with BC. Authors found an 
absence of distant metastasis among BC patients with TPOAb positivity (0/56) 
compared with metastasis prevalence of 6.6% (17/258) among TPOAb negative 
patients (184). Kim et al. prospectively followed 564 patients affected with BC for 
a median time of 36 months and incidentally found that an increased thyroid 
uptake of 18F-FDG on PET/CT images due to the presence of thyroid autoimmunity 
was related to a significantly improved DFS, especially for locally advanced and 
secondary cancer stage (260). 
4.1.1.2 Thyroid function 
The role of thyroid function on BC prognosis has been debated during the 
last century and conflicting results are present in the literature. As previously 
introduced in paragraphs 1.4.1 and 1.4.2, since 1896 thyroid extract was proposed 
as a treatment for BC, based on the suspicion that hypothyroidism could represent 
a poor prognostic factor for BC (153, 303). In contrast, subsequent studies 
proposed thyroid supplementation as a possible risk factor for BC (304), not 
confirmed by other studies (305, 306).  
However, subsequent findings supported the possibility that increased 
levels of thyroid hormones could be a poor prognostic factor for BC. In particular, 
in 2005 an American retrospective study based on 2226 women, reported that 
hypothyroid BC patients are more likely to be diagnosed with a BC at an earlier 
stage, of smaller size and without pathologic lymph node involvement (167). In 
agreement with these findings, a recent Swedish population-based prospective 
cohort study based on 2185 women (followed for more than 20 years) showed that 
baseline triiodothyronine (T3) serum levels were associated with an increased risk 
of BC specific death and with the presence of more aggressive BC, in particular 
larger, ER and PR negative and with a higher prevalence of positive lymph node 
metastases (307, 308).  
Well powered prospective studies evaluating the effects of thyroid function 
on BC prognosis in terms of recurrence and survival are lacking.  
4.1.2 Impact of thyroid autoimmunity on other cancer prognosis 
TAb impact on cancer prognosis has also been analyzed in other tumours. 
Franke et al. analyzed 329 patients with metastatic renal cell cancer and found 
that patients positive for circulating TAb, present both before or triggered by the 
treatment with IL-2 and IFN-α2, had a statistically significant better 5 years OS 
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compared with patients negative for TAb (270). In contrast, Fyssas et al. showed 
that 33 patients with pancreatic adenocarcinoma had an increased prevalence of 
TAb (25%), mainly TPOAb, compared with healthy controls, but their presence was 
associated with a survival reduction of 2.4 months: 9.4 and 11.8 months 
respectively in TAb positive and negative patients (271). 
4.1.3 Major breast cancer known prognostic factors 
In order to correctly analyze the effects of two potential prognostic factors 
for BC such as TPOAb and thyroid function and exclude possible biases, it is 
essential to evaluate in the same study the impact of already known prognostic 
factors for BC that will be described in the present paragraph. Furthermore, a 
brief overview of the currently available treatments for BC will be provided, in 
order to better comprehend this observational study where patients were exposed 
to BC treatments. The key-elements of BC molecular classification already 
described in chapter 1, paragraph 1.3.3.2, such as the expression of oestrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor type 2 (HER2), represent known BC prognostic factors and are also 
crucial for BC treatment decision making. 
4.1.3.1 Tumour size, lymph node metastasis and TNM staging 
When distant metastases are present, irrespective of their size, number 
and location, the survival of patients affected with BC suddenly drops. After 
distant metastases, tumour size and lymph node metastatic involvement are the 
two most important prognostic factors for BC (309). These 3 elements represent 
the basis of the TNM staging classification for cancer, that has been adopted 
worldwide for many years and initially developed by Denoix of France, based on 
the description of the primary tumour (T), the regional lymph nodes involvement 
(N) and the presence or absence of distant metastases (M) (310). 
There are many different subcategories of T, N and M listed in ascending 
order of numbers and letters, directly proportional to the increasing tumoural size 
and extension. For example, T category is described with a number from 0 
(absence of evidence) to 4 (any tumour size with extension to chest wall or skin), 
with letters (a, b, c, d) providing additional information. The acronym Tis 
indicates the presence of a carcinoma in situ, characterized by malignant 
epithelial cells without evidence by light microscopy of invasion through the 
basement membrane. The acronym T1mi indicates a tumour with dimensions of 
0.1 cm across or less. A similar system is used for N, but the maximum number 
and letter used are respectively 3 and c. Distant metastases are assessed by only 2 
numbers, 0 and 1, indicating respectively absence or presence of distant 
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metastases, without distinction in their number and location. The letter X 
indicates that the parameter cannot be assessed and it can be applied to all 3 
categories T, N and M. The subcategories of T, N and M are then grouped in 
various combinations to describe four different tumoural staging, as summarized 
in Table 4-1. TNM staging is a good prognostic indicator, with worsening of BC 
prognosis according with increasing TNM stage (311).   
Table 4-1: BC TNM staging of breast cancer 
BC Stage T N M 
0 Tis N0 M0 
I T1* N0 M0 
II IIA T0 or T1* N1 M0 
T2 N0 M0 
IIB T2 N1 M0 
T3 N0 M0 
III IIIA T0 or T1* or T2 N2 M0 
T3 N1 M0 
T3 N2 M0 
IIIB T4 N0 or N1 or N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
Adapted from (311). BC= breast cancer. N= regional lymph nodes involvement. M= distant 
metastases. T = primary tumour. Tis: carcinoma in situ. *T1 includes T1mi.  
 
Based on this classification, generally BC is commonly subdivided into 3 different 
categories: 1) “Early BC”, when potentially curable by surgery since it is not 
locally advanced and with absence of distant metastasis (stage 0, I, II and T3N1M0 
case of stage IIIA) 2) “Locally advanced BC” (stage III except T3N1M0) 3) 
“Metastatic BC” (stage IV).  
4.1.3.2 Breast cancer histological grading 
Invasive BC are routinely graded based on the assessment of 3 biological 
parameters: 1) tubule and gland formation, 2) nuclear pleomorphism, 3) mitotic 
count. Each parameter is classified with an individual score from 1 to 3 and the 
final grading reflects the total score deriving from the 3 parameters taken 
together: 1 or low (score: 3-5), 2 or medium (score: 6-7), 3 or high (score: 8-9) 
(136).  
The initial grading score system based on methods from Patey & Scarff 
(312) and Bloom & Richardson (313) was characterized by a high variability across 
different centres and became more objective after its modification by Elston & 
Ellis, known as the “Nottingham grading system” (314). Since then, histological 
 118 
grading has been routinely adopted to assess BC prognosis and many studies 
demonstrated a significant association between histological grade and survival of 
BC patients (inverse correlation: high grades are associated with shorter 
survivals), assessing histological grade as the fourth main prognostic factor for BC 
after the presence of distant metastases, tumour size and metastatic lymph node 
involvement (315, 316).   
4.1.4 Prognostic tools and decision-making for breast cancer treatment 
BC treatment is highly dependent on BC classification and phenotype, as 
shown in this paragraph. The main types of treatment for BC are surgery, 
radiation therapy (RT), chemotherapy (CT), hormonal therapy and targeted 
therapy: 
v Surgery.  Breast conservation surgery, consisting in the removal of just the 
lump or area of cancer and also called wide local excision (WLE), is the 
trending approach in the treatment of localized BC. The alternative is 
mastectomy, where the whole breast is removed; usually it is required when 
the tumour is large or multifocal (i.e. multiple areas of cancer in different 
parts of the breast). Sometimes surgery can be preceded by neo-adjuvant 
therapy (either RT or CT) in order to shrink the tumour bulk (317). In the case 
of lymph node metastasis, the surgery of the axilla is recommended, however 
axillary dissection may be omitted in patients with one or two positive sentinel 
nodes following breast-conserving surgery when whole breast RT is planned 
(318).  
v RT is a process where cancer cells are exposed to high level of radiation 
directly. This is extremely recommended as adjuvant treatment (i.e. following 
the surgery) especially after performing WLE, since it may kill cancerous cells 
not seen during surgery and therefore not removed (317). 
v Systemic CT is usually recommended as adjuvant treatment in particular 
cases, especially those not-responding to endocrine treatments because of 
histological type (e.g. apocrine, medullary, adenoid cystic and metaplastic) or 
molecular phenotype (ER negative, high Ki-67 levels) (318). The main drugs 
used in CT for BC, usually in combinations, are: anthracyclines (epirubicin, 
doxorubicin, mitoxantrone), cyclophosphamide, fluorouracil, methotrexate, 
mitomycin, docetaxel (Taxotere) and gemcitabine (319). A discussion of 
different chemotherapy protocols for BC is beyond the aims of the present 
thesis.   
v Endocrine treatment aims to block the oestrogen stimulation pathway in BC 
and it is indicated in all patients with detectable ER expression, defined as 
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≥1% of ER+ cells. The choice of medication is primarily determined by the 
patient’s menopausal status (317). The first treatment choice for 
premenopausal patients is a selective oestrogen receptor modulator called 
“Tamoxifen”, usually taken for 5 years, exerting anti-oestrogen effects on BC 
cells (therefore acting as an ER antagonist), but paradoxically having ER 
agonist effects on different cells and tissues, e.g. bone and blood lipids (320). 
In case of contraindications to the use of Tamoxifen, an alternative treatment 
is the use of a gonadotropin-releasing hormone (GnRH)-agonist (e.g. 
goserelin), determining a reduction in oestrogen release. GnRh-agonists may 
be prescribed alone or in association with aromatase inhibitors, that block the 
peripheral conversion of androgens into oestrogens (317). In postmenopausal 
women, both Tamoxifen and aromatase inhibitors are valid options, usually 
prescribed for 5-10 years (317).  
v Targeted therapy. As described below, HER2 protein expression allows the use 
of highly effective targeted treatments. The most renowned is trastuzumab 
(Herceptin®), a monoclonal antibody interfering with HER2 receptor. It can be 
used also in combination with endocrine treatments, RT and CT however, due 
to its cardiotoxicity, it should not be routinely administered concomitantly 
with anthracyclines. However new alternative target therapy drugs have been 
developed, such as lapatinib, a dual tyrosine kinase inhibitor which interrupts 
both HER2 and epidermal growth factor (EGF) receptor pathways. Their 
clinical use is likely to increase and substitute trastuzumab in the future (317).  
 
In conclusion BC molecular biomarkers, previously described in paragraph 
1.3.3.2, have become more and more important in BC prognostic assessment and 
treatment decision-making. In particular: 
v The positivity of oestrogen receptor (ER) and/or progesterone receptor (PR) 
(range: ≥1% - 100%) represents the indication to hormonal therapy and the 
likelihood of response to this treatment is directly correlated to the level of 
their expression; only entirely negative tumours (0%) are essentially 
unresponsive (321). Four possible phenotypes of ER/PR combined expression 
are possible and each of them is associated with significantly different rates of 
response to hormonal therapy, which would not be apparent measuring ER or 
PR only (322). The phenotype ER-positive/PR-positive is the most frequent 
(70%) and associated with the best rate of response (60%). ER-negative/PR-
negative is the next common combination (25%) and these tumours are 
essentially unresponsive (0%). The remaining two discordant phenotypes are 
associated with intermediate response rates (136).  
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v Recent studies demonstrate that HER2-positive invasive BC respond favorably 
to therapies that specifically target the HER2 protein, e.g. trastuzumab 
(Herceptin®) or lapatinib. The best response to HER2-targeted therapy in any 
clinical setting is shown by positive HER2 tumours showing strong (3+) or 
moderately strong (2+) HER2 protein expression by IHC (136, 323).  
Complex multivariate outcome prediction models combining different clinical, 
histological, biological and molecular prognostic factors for BC have been 
developed as prognostic tools to choose the best regimen of treatment and to 
predict the probability of response (324). The two most often used are The 
Nottingham Prognostic Index and Adjuvant! Online (http://www. 
adjuvantonline.com) (325, 326).  
For example, in ER-positive/HER2-negative BC, the option of adding chemotherapy 
to hormonal therapy is evaluated according to the tumour size, nodal status, 
occurrence of peri-tumoural vascular invasion, grade and proliferative fraction 
(Ki67) (141). 
4.1.5 Aims of the study 
The aim of the present study was to clarify the impact of circulating TPOAb 
and thyroid function on BC prognosis in a large and well-powered cohort of 
patients affected with BC having blood samples available, previously enrolled in 
the TACT study (301). The median long-term follow-up was 97.5 months, resulted 
from a subsequent more mature analysis of the same trial population (302).   
4.2 MATERIALS AND METHODS 
4.2.1 Patients 
The Taxotere as Adjuvant Chemotherapy Trial (TACT) was a multicentre, 
open-label, phase III, randomized controlled trial of women aged more than 18 
years diagnosed with operable early BC (pT1-3a,pN0-1,M0), with an indication for 
adjuvant chemotherapy, including patients both lymph-node positive (node+) and 
high risk (eg, tumour grade 3, hormonal-receptor expression negative, or lympho-
vascular invasion) lymph-node negative (node-). A total of 4162 women were 
enrolled between February 2001 and June 2003 across 103 UK centres and one 
Belgian centre (including specialist cancer hospitals, university teaching hospitals, 
and smaller community general hospitals). Additional inclusion criteria were 
normal hematological, hepatic and renal function. Exclusion criteria included 
locally advanced or distant disease, bilateral breast cancer, pregnancy, and 
previous invasive malignancy within 10 years (301).  
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All subjects underwent surgery (mastectomy or wide local excision) and 
were randomized in a 1:1 ratio to the experimental regimen FEC-D [n=2073; 
fluorouracil 600mg/m², epirubicin 60mg/m², cyclophosphamide 600mg/m² (FEC) 
at 3-weekly intervals for four cycles followed by docetaxel 100mg/m² at 3-weekly 
intervals for four cycles] or centre’s choice of control chemotherapy, either FEC 
for eight cycles (n=1265) or epirubicin 100mg/m² at 3-weekly intervals for four 
cycles followed by CMF (cyclophosphamide 600mg/m², methotrexate 40mg/m², 
and fluorouracil 600mg/m² at 4-weekly intervals) for four cycles (E-CMF, n=824). 
Adjuvant radiotherapy, starting within 4 weeks of chemotherapy, was 
mandatory after breast conserving surgery or used after mastectomy according to 
local guidelines.  
Endocrine treatments (tamoxifen monotherapy, tamoxifen followed by 
aromatase inhibitor or aromatase inhibitor monotherapy) were administered to 
patients with positive oestrogen receptor (ER) expression (ER+). Patients positive 
for human epidermal growth factor receptor 2 (HER2) expression (HER2+) were 
allowed to enter clinical trials assessing trastuzumab. 
Analyses at 62 months (301) and 97.5 months (302) of follow-up 
respectively showed no evidence of a difference and little clear benefit in terms 
of BC outcome in patients treated with sequential docetaxel after traditional 
anthracycline therapy (FEC-D), compared with the control chemotherapy regimens 
(FEC, E-CMF). 
4.2.2 Laboratory measurements 
In November 2002, following a protocol amendment, patients were asked 
to provide one 10ml EDTA blood sample to extract plasma for future translational 
research.  Consenting patients who had been already recruited provided a blood 
sample at their next follow-up visit; new patients had blood taken at the time of 
randomization. 
Samples were stored at -20°C for a range of 6.5-13 years at the Institute of 
Cancer Research - Clinical Trials & Statistics Unit (ICR-CTSU, London, Surrey). All 
available samples (one aliquot each) were transferred to the Institute of Molecular 
& Experimental Medicine (Cardiff) for TPOAb, thyroid stimulating hormone (TSH) 
and free-thyroxine (FT4) analysis. Stored plasma samples were thawed, aliquoted 
and analyzed in the same assays in October 2014 in the Department of Medical 
Biochemistry, School of Medicine, Cardiff University, using an ADVIA Centaur 
automated immunoassay analyzer (Bayer plc, Newbury, Bucks, UK) and 
Chemiluminescent Microparticle Immunoassay (CMIA) methods by the ARCHITECT® 
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System (ABBOTT Laboratories, Abbott Park, USA). TPOAb positivity cut-off was ≥6 
kU/L; FT4, TSH normal ranges respectively 9.0–19.1 pmol/L and 0.30–4.40 mU/L.  
TPOAb values were dichotomized as ≥6 kU/L (positive: TPOAb+) versus <6 
kU/L (negative: TPOAb-); TPOAb+ were also categorized into tertiles (exploratory 
analysis). FT4 and TSH were combined in a thyroid function status variable: 
euthyroidism (FT4 and TSH within the normal ranges), hypothyroidism (FT4 <9.0 
pmol/L and/or TSH >4.40 mU/L); hyperthyroidism (FT4 >19.1 pmol/L and/or TSH 
<0.3 mU/L).  
4.2.3 Statistical analysis 
When formulating the study hypothesis, it was anticipated that 20% of 
individuals with BC will be TPOAb+ in keeping with its prevalence in females in the 
general population (64, 327). Assuming the average 5-year OS from BC in UK is 82% 
(328, 329), the TACT trial, with more than 1900 available plasma samples and 5-
year DFS and OS rates of 74.9% and 82.7% respectively (301), was a suitable 
candidate trial in which to test the study hypothesis. Power calculations indicated 
that 1158 and 1430 samples would be needed to provide respectively 80% and 90% 
of power to detect a 81% 5-year DFS in TPOAb+ versus 73% in TPOAb- subjects (HR 
0.64; two-sided log rank test with a .05 probability of a type I error), consistent 
with a DFS rate in the whole cohort of 74.9%. 
To assess whether the thyroid antibody project samples were 
representative of the TACT population, baseline characteristics, BC treatments 
and DFS-related characteristics for all patients with blood samples available for 
analysis were compared with TACT patients not included in our study and all 
patients recruited in the TACT trial (n=4162). Baseline characteristics were also 
presented by dichotomized TPOAb (TPOAb+, TPOAb-) and thyroid function status 
(hypothyroid, euthyroid, hyperthyroid). Correlations between biomarkers (TPOAb, 
TSH, FT4) were assessed using the Spearman rank method. 
The primary outcome was to assess the prognostic significance of 
circulating TPOAb in relation to DFS as defined in the main TACT trial (301). 
Secondary outcomes were the prognostic significance of circulating TPOAb in 
relation to OS and time to recurrence (TTR) and blood TSH and FT4 levels in 
relation to DFS, OS and TTR.    
For DFS, OS and TTR, Kaplan-Meier curves were plotted and biomarkers 
compared by use of the log-rank test. Hazard Ratio (HR) with 95% CI were 
obtained from Cox proportional hazards regression models stratified by each 
centre’s choice of control chemotherapy regimen and ER status, with HR<1 
indicating a better BC prognosis. The proportionality assumption of the Cox model 
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was tested with Schoenfeld’s residuals and found to hold. All biomarkers were 
assessed initially in a univariate Cox model and subsequently included in a 
multivariable Cox model along with known prognostic factors for BC: age, HER2 
status and trastuzumab use, nodal involvement, tumour size and tumour grade. 
Additional variables such as trial treatment (experimental versus control), type of 
surgery, radiotherapy use and menopausal status were included if, by stepwise 
selection (p<0.05), was shown to add value. Once the optimal model for the 
primary endpoint was established, TSH and T4 were considered for inclusion to 
investigate whether they added independent prognostic information in addition to 
TPOAb. Interaction tests were also used to explore differential effects within 
subgroups (TPOAb with trial treatment, age, HER2 status, nodal involvement, 
tumour size and tumour grade).  
All patients with a biomarker value available were included in the analysis, 
regardless of whether they were found to be ineligible, a protocol violator, given 
the wrong treatment allocation, never treated, etc. in the main TACT trial (as per 
an intention to treat analysis). Comparisons were made by randomized treatment 
where appropriate. Sensitivity analyses including node+ patients who did not 
receive radiotherapy (similar to Fiore et al. population (183)) and patients with 
blood samples taken after surgery but before any adjuvant cancer therapy were 
conducted. All analyses were conducted using Stata version 13.1 (STATACORP, 
College Station, TX). This analysis was based on a database snapshot taken on 25 
November 2011 when median follow-up was 97.5 months [Interquartile Range 
(IQR): 87.6-107.4, range 0-126.9](301, 302).  
My part in this study was: i) to formulate and design the study, in 
collaboration with my supervisors (e.g. establishment of the principal and 
secondary outcomes); ii) to collect and aliquot the blood samples from ICR-CTSU 
and ensure they were measured in the Department of Medical Biochemistry, 
School of Medicine, Cardiff University, with results correctly reported on an Excel 
database; iii) to interpret the blood results (e.g. subdividing patients in different 
categories of thyroid function); iv) to direct the statistical analysis (e.g. 
suggesting to analyze the correlation between TPOAb, TSH and FT4 or suggesting 
specific sensitivity analyses); v) to analyze and interpret the results according to 
the current available literature. The calculations of the statistical analysis have 
been performed by Lucy Kilburn, statistician at the ICR-CTSU, since this 
Department holds the clinical data and preferred to directly deal with them.  
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4.3 RESULTS 
All available plasma samples taken for the TACT trial (n=2000) were 
analyzed for thyroid biomarkers. After excluding multiple samples from the same 
patients, retaining the sample with the earliest time-point, a final number of 1974 
(47.4%) samples (defined as the “analysis population”), one for each patient, was 
considered for the statistical analysis (Figure 4-1). 
Figure 4-1: Flowchart regarding sample availability and data handling 
 
 
Blood collection date was available in 1914/1974 (97%) patients and its 
median was 15.5 months (IQR= 7.0-24.0 months; range= 0.5–57.2 months] after 
surgery. Median follow-up in the analysis population was 96.7 months (IQR: 87.4-
106.3, range 3.4-126.4). According to our power calculation, this number was 
adequate for this assessment, with a margin for error for the final proportion 
found to be TPOAb+ and differences in DFS in the subpopulation studied. In 
summary, patients included in the analysis population (TPOAb study: n=1974) had 
a mean age of 49.1 years [standard deviation (SD)= 8.4 years], 1567 (79.4%) were 
node+, 1079 (54.7%) had a mastectomy, 1745 (88.4%) had radiotherapy, 1396 
(70.7%) were ER+ of which 1378 (98.7%) received hormonal therapy and 408 
(20.7%) were HER2+, of which 48 (11.8%) were treated with trastuzumab (Table 4-
2 and Table 4-3). Patients included in the analysis population were not 
comparable with not included TACT patients (not having blood available: n=2188) 
in terms of baseline characteristics (Table 4-2), BC treatments received and 
events contributing to DFS analysis (Table 4-3). In particular, patients within the 
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analysis population were more often treated with trastuzumab (11.8% vs 6.4%) and 
had less distant recurrence (20.5% vs 26.1%) and less deaths (20.1% vs 28.3%), both 
BC-related (18.7% vs 26%) or not (1.4% vs 2.4%), compared with not included 
patients. 
Table 4-2: Baseline characteristics of all TACT trial participants, those in the TPOAb 
study and non-studied women  
 TACT trial 
N=4162 
TPOAb study  
N=1974 
Not-studied 
N= 2188 
Age (years), mean (SD);              p<0.001 48.6 (8.5) 49.1 (8.4) 48.2 (8.6) 
Age group (years), n (%);              p=0.02    
     <40 718 (17.3) 306 (15.5) 412 (18.8) 
     40-49 1567 (37.7) 726 (36.8) 841 (38.4) 
     50-59 1487 (35.7) 757 (38.4) 730 (33.4) 
     ≥60 390 (9.4) 185 (9.4) 205 (9.4) 
Nodal status, n (%);                       p=0.09    
     Node negative 835 (20.1) 407 (20.6) 428 (19.6) 
     1-3 positive nodes 1839 (44.2) 890 (45.1) 949 (43.4) 
     ≥4 positive nodes 1488 (35.8) 677 (34.3) 811 (37.1) 
Tumour grade, n (%);                    p=0.56     
     Grade 1 229 (5.5) 100 (5.1) 129 (5.9) 
     Grade 2 1536 (36.9) 758 (38.4) 778 (35.6) 
     Grade 3 2382 (57.2) 1111 (56.3) 1271 (58.1) 
     Unknown 15 (0.4) 5 (0.3) 10 (0.5) 
Tumour size, n (%);                     p=0.003    
     ≤2cm 1436 (34.5) 725 (36.7) 711 (32.5) 
     >2 and ≤5cm 2330 (56.0) 1077 (54.6) 1253 (57.3) 
     >5cm 392 (9.4) 171 (8.7) 221 (10.1) 
     Unknown 4 (0.1) 1 (0.1) 3 (0.1) 
ER & HER2 status, n (%);               p=0.01    
     ER+ 2875 (69.1) 1396 (70.7) 1479 (67.6) 
           & HER2+ 494 (11.9) 247 (12.5) 247 (11.3) 
           & HER2- 1963 (47.2) 973 (49.3) 990 (45.2) 
           & HER2 unknown 418 (10.0) 176 (8.9) 242 (11.1) 
     ER- 1287 (30.9) 578 (29.3) 709 (32.4) 
           & HER2+ 355 (8.5) 161 (8.2) 194 (8.9) 
           & HER2- 761 (18.3) 350 (17.7) 411 (18.8) 
           & HER2 unknown 171 (4.1) 67 (3.4) 104 (4.8) 
Molecular subgroup, n (%);           p=0.01    
     ER+/HER2-* 2001 (48.1) 987 (50.0) 1014 (46.3) 
     HER2+ 849 (20.4) 408 (20.7) 441 (20.2) 
     Triple negative 723 (17.4) 336 (17.0) 387 (17.7) 
* includes ER-, PgR+, HER2- 
ER = oestrogen receptor. HER2 = human epidermal growth factor receptor 2. PgR = 
progesterone receptor. SD = Standard deviation. 
 
 
 
 
 
 126 
Table 4-3: BC treatments and DFS events of all TACT trial participants, those in the 
TPOAb study and non-studied women 
 TACT  
trial 
N=4162 
TPOAb 
study  
N=1974 
Not-studied 
N= 2188 
Type of surgery and radiotherapy, n(%);    p=0.08    
     Mastectomy 2265 (54.4) 1079 (54.7) 1186 (54.2) 
          with radiotherapy 1814 (43.6) 865 (43.8) 949 (43.4) 
breast 413 (9.9) 159 (8.1) 254 (11.6) 
chest wall 1402 (33.7) 709 (35.9) 693 (31.7) 
supraclavicular fossa 980 (23.5) 480 (24.3) 500 (22.9) 
axilla 188 (4.5) 85 (4.3) 103 (4.7) 
     Wide local excision 1897 (45.6) 895 (45.3) 1002 (45.8) 
          with radiotherapy 1841 (44.2) 880 (44.6) 961 (43.9) 
breast 1777 (42.7) 856 (43.4) 921 (42.1) 
chest wall 78 (1.9) 31 (1.6) 47 (2.1) 
supraclavicular fossa 574 (13.8) 291 (14.7) 283 (12.9) 
axilla 173 (4.2) 103 (5.2) 70 (3.2) 
Endocrine treatment in ER+ patients, n (%);        
                                                                  p=0.01 
   
     Tamoxifen monotherapy 1790 (62.3) 863 (61.8) 927 (62.7) 
     Tamoxifen followed by AI 893 (31.1) 454 (32.5) 439 (29.7) 
     AI monotherapy 137 (4.8) 61 (4.4) 76 (5.1) 
     No endocrine treatment/unknown 55 (1.9) 18 (1.3) 37 (2.5) 
Trastuzumab in HER2+ patients, n (%);     p=0.02    
     Yes 76 (9.0) 48 (11.8) 28 (6.4) 
     No/Not known 773 (91.0) 360 (88.2) 413 (93.7) 
Chemotherapy, n (%);                              p<0.001    
     Control (FEC) 1265 (30.4) 626 (31.7) 639 (29.2) 
     Control (E-CMF) 824 (19.8) 332 (16.8) 492 (22.5) 
     FEC-D 2073 (49.5) 1016 (51.5) 1057 (48.3) 
Number of patients with event contributing to 
DFS analysis;                                           p<0.001 
1329 (31.9) 551 (27.9) 778 (35.6) 
     Local recurrence 183 (4.4) 76 (3.8) 107 (4.9) 
     Distant recurrence 977 (23.5) 405 (20.5) 572 (26.1) 
     New breast disease 91 (2.2) 43 (2.2) 44 (2.0) 
     Death from other cause (no recurrence) 78 (1.9) 27 (1.4) 51 (2.3) 
Distant relapse ever reported;                p<0.001 1117 (26.8) 462 (23.4) 655 (29.9) 
New breast disease ever reported;            p=0.78 124 (3.0) 57 (2.9) 67 (3.1) 
All non-breast cancer second primary;      p=0.77 106 (2.5) 52 (2.6) 54 (2.5) 
All deaths;                                               p<0.001 1017 (24.4) 397 (20.1) 620 (28.3) 
     Breast cancer 937 (22.5) 369 (18.7) 568 (26.0) 
     Death from other causes  80 (1.9) 28 (1.4) 52 (2.4) 
          Cancer (non-breast) 36 (0.9) 15 (0.8) 21 (1.0) 
          Treatment toxicity 5 (0.1) 0 5 (0.2) 
          Other 39 (0.9) 13 (0.7) 26 (1.2) 
* includes ER-, PgR+, HER2- 
AI = Aromatase Inhibitors. DFS = disease-free survival. ER = oestrogen receptor. E-CMF = 
epirubicin 100 mg/m2 for 4 cycles followed by CMF (cyclophosphamide 600 mg/m2, 
methotrexate 40 mg/m2 and fluorouracil 600 mg/m2) for 4 cycles. FEC = fluorouracil 600 
mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 for 8 cycles. FEC-D = FEC 
for 4 cycles followed by docetaxel 100 mg/m2 for 4 cycles. HER2 = human epidermal 
growth factor receptor 2.  
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The total number of events available in the analysis population for DFS was 
551 (27.9%), with overall 5-year estimate of 79.5% (95%CI 77.6-81.2). For OS, 397 
(20.1%) events were available, with overall 5-year estimate of 87.4% (95%CI 85.9-
88.8). For TTR, 498 (25.2%) events were available, with overall 5-year estimate of 
81.1% (95%CI 79.3-82.8). TACT patients without blood samples available, therefore 
not included in the analysis population, had overall 5-year estimates of 71.4% 
(95%CI, 69.5-73.3), 79.0% (95%CI, 77.3-80.7) and 73.7% (95%CI, 71.7-75.5) for DFS, 
OS and TTR respectively.  
4.3.1 Distribution of TPOAb and thyroid function 
 TPOAb positivity was detected in 406 (20.6%) patients, distributed in the 
following tertiles: 137 (6.9%) 6-40 kU/L (T1), 134 (6.7%) 41-238 kU/L (T2) and 135 
(6.8%) 240-2000 kU/L (T3).  
Mean FT4 value was 13.5 pmol/L ± 2.1 standard deviation (SD), range 5.2 – 
28.7 pmol/L. TSH mean value was 2.05 mU/L ± 5.49 SD, range: 0.02 – 159.83 
mU/L. FT4 values were normally distributed, while TSH values were right skewed, 
therefore the logarithm of TSH values, ln(TSH), was used in the statistical analyses 
involving TSH as a continuous variable (Figure 4-2). When FT4 and TSH were 
considered combined as thyroid function, 1760 (89.2%), 96 (4.9%) and 118 (6.0%) 
patients were found to be respectively euthyroid, hypothyroid and hyperthyroid. 
Figure 4-2: Histograms of TSH, ln(TSH) and FT4 values 
 
Free T4 = free thyroxine; TSH = thyroid-stimulating hormone; ln(TSH) = logarithm of TSH 
values. 
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Baseline characteristics (Table 4-4) and BC treatments (Table 4-5) by TPOAb 
status were largely comparable, apart from age, where TPOAb+ patients tended to 
be slightly older than TPOAb- patients, as expected  (mean age ± SD = 50.2±7.7 
years versus 48.8±8.5 years; p=0.005). Baseline characteristics (Table 4-4) and BC 
treatments (Table 4-5) were similar between the different thyroid function 
classifications. 
Table 4-4: Baseline characteristics by TPOAb and thyroid function status  
 TPOAb- 
N=1568 
TPOAb+ 
N=406 
Hypothyroid 
N=96 
Euthyroid 
N=1760 
Hyperthyroid 
N=118 
Age (years): mean (SD)  48.8 (8.5) 50.2 (7.7) 50.5 (6.6) 48.9 (8.5) 50.7 (7.6) 
Age group (years): n (%)       
     <40 257 (16.4) 49 (12.1) 8 (8.3) 287 (16.3) 11 (9.3) 
     40-49 575 (36.7) 151 (37.2) 36 (37.5) 647 (36.8) 43 (36.4) 
     50-59 590 (37.6) 167 (41.1) 45 (46.9) 657 (37.3) 55 (46.6) 
     ≥60 146 (9.3) 39 (9.6) 7 (7.3) 169 (9.6) 9 (7.6) 
Nodal status: n (%)       
     Node negative 314 (20.0) 93 (22.9) 18 (18.8) 367 (20.9) 22 (18.6) 
     1-3 positive nodes 719 (45.9) 171 (42.1) 33 (34.4) 808 (45.9) 49 (41.5) 
     ≥4 positive nodes 535 (34.1) 142 (35.0) 45 (46.9) 585 (33.2) 47 (39.8) 
Tumour grade: n (%)       
     Grade 1 77 (4.9) 23 (5.7) 4 (4.2) 88 (5.0) 8 (6.8) 
     Grade 2 603 (38.5) 155 (38.2) 35 (36.5) 681 (38.7) 42 (35.6) 
     Grade 3 883 (56.3) 228 (56.2) 57 (59.4) 986 (56.0) 68 (57.6) 
     Unknown 5 (0.3) 0 (0.0) 0 (0.0) 5 (0.3) 0 (0.0) 
Tumour size: n (%)       
     ≤2cm 578 (36.9) 147 (36.2) 25 (26.0) 659 (37.4) 41 (34.8) 
     >2 and ≤5cm 857 (54.7) 220 (54.2) 61 (63.5) 952 (54.1) 64 (54.2) 
     >5cm 132 (8.4) 39 (9.6) 10 (10.4) 148 (8.4) 13 (11.0) 
     Unknown 2 (0.1) 0 (0.0) 0 (0.0) 2 (0.1) 0 (0.0) 
ER & HER2 status: n (%)      
     ER+ 1107 (70.6) 289 (71.2) 69 (71.9) 1248 (70.9) 79 (67.0) 
           & HER2+ 198 (12.6) 49 (12.1) 13 (13.5) 220 (12.5) 14 (11.9) 
           & HER2- 772 (49.2)  201 (49.5) 46 (47.9) 873 (49.6) 54 (45.8) 
           & HER2 unknown 137 (8.7) 39 (9.6) 10 (10.4) 155 (8.8) 11 (9.3) 
     ER- 461 (29.4) 117 (28.8) 27 (28.1) 512 (29.1) 39 (33.1) 
           & HER2+ 118 (7.5) 43 (10.6) 8 (8.3) 141 (8.0) 12 (10.2) 
           & HER2- 289 (18.4) 61 (15.0) 15 (15.6) 313 (17.8) 22 (18.6) 
           & HER2 unknown 54 (3.4) 13 (3.2) 4 (4.2) 58 (3.3) 5 (4.2) 
Molecular subgroup: n (%)      
     ER+/HER2-* 784 (50.0) 203 (50.0) 47 (49.0) 885 (50.3) 55 (46.6) 
     HER2+ 316 (20.2) 92 (22.7) 21 (21.9) 361 (20.5) 26 (22.0) 
     Triple negative 277 (17.7) 59 (14.5) 14 (14.6) 301 (17.1) 21 (17.8) 
* includes ER-, PgR+, HER2-    
ER = oestrogen receptor. HER2 = human epidermal growth factor receptor 2. PgR = 
progesterone receptor. SD = Standard deviation.   
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Table 4-5: BC treatments by TPOAb and thyroid function status 
 TPOAb- 
N=1568 
TPOAb+ 
N=406 
Hypothyroid 
N=96 
Euthyroid 
N=1760 
Hyperthyroid 
N=118 
Type of surgery and 
radiotherapy use: n (%)  
     
     Mastectomy 854 (54.5) 225 (55.4) 53 (55.2) 962 (54.7) 64 (54.2) 
        with radiotherapy ^ 688 (80.6) 177 (78.7) 47 (88.7) 772 (80.2) 46 (71.9) 
     Wide local excision 714 (45.5) 181 (44.6) 43 (44.8) 798 (45.3) 54 (45.8) 
        with radiotherapy # 704 (98.6) 176 (97.2) 41 (95.3) 787 (98.6) 52 (96.3) 
Endocrine treatment in 
ER+ patients: n (%)* 
     
 Tamoxifen monotherapy 696 (62.9) 167 (57.8) 43 (62.3) 772 (61.9) 48 (60.8) 
 Tamoxifen followed by AI 354 (32.0) 100 (34.6) 20 (29.0) 409 (32.8) 25 (31.7) 
 AI monotherapy 46 (4.2) 15 (5.2) 6 (8.7) 53 (4.3) 2 (2.5) 
 No treatment/unknown 11 (1.0) 7 (2.4) 0 (0.0) 14 (1.1) 4 (5.1) 
Trastuzumab in HER2+ 
patients: n (%)** 
     
     Yes 40 (12.7) 8 (8.7) 1 (4.8) 44 (12.2) 3 (11.5) 
     No/Not known 276 (87.3) 84 (91.3) 20 (95.2) 317 (87.8) 23 (88.5) 
Chemotherapy: n (%)      
     Control (FEC) 498 (31.8) 128 (31.5) 27 (28.1) 568 (32.3) 31 (26.3) 
     Control (E-CMF) 271 (17.3) 61 (15.0) 16 (16.7) 301 (17.1) 15 (12.7) 
     FEC-D 799 (51.0) 217 (53.4) 53 (55.2) 891 (50.6) 52 (44.1) 
^  denominators calculated using patients treated with mastectomy 
#   denominators calculated using patients treated with wide local excision 
*   denominators calculated using ER+ patients 
**  denominators calculated using HER2+ patients 
ER = oestrogen receptor. E-CMF = epirubicin 100 mg/m2 for 4 cycles followed by CMF 
(cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2 and fluorouracil 600 mg/m2) for 4 
cycles. FEC = fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 
mg/m2 for 8 cycles. FEC-D = FEC for 4 cycles followed by docetaxel 100 mg/m2 for 4 
cycles. HER2 = human epidermal growth factor receptor 2.  
 
As expected, FT4 and TSH were inversely correlated (Spearman rank= -
0.23, p<0.001; Figure 4-3 panel A) and TPOAb were positively associated with TSH 
(Spearman rank= 0.24, p<0.001; Figure 4-3 panel B). The inverse correlation 
between TPOAb and FT4 was weak (Spearman rank= -0.04, p=0.09; Figure 4-3 
panel C). When considering FT4 and TSH combined together (thyroid function 
status), TPOAb positivity was more prevalent among hypothyroid and hyperthyroid 
patients compared with the euthyroid group, as expected [TPOAb+: 73 (76.0%) 
hypothyroid, 288 (16.4%) euthyroid, 45 (38.1%) hyperthyroid; p<0.001].  
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Figure 4-3: Correlation between thyroid markers 
 
Panel A: inverse correlation between thyroid-stimulating hormone (TSH) in logarithmic 
scale (ln) and free-thyroxine (FT4). Panel B: positive correlation between autoantibodies 
to thyroid peroxidase (TPOAb) and TSH. Panel C:  inverse correlation between TPOAb and 
FT4. p = p value 
 
4.3.2 TPOAb and breast cancer prognosis  
In both TPOAb+ and TPOAb- groups the majority of events contributing to 
DFS related to distant recurrence; similarly, the major cause of death was BC 
(Table 4-6). 
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Table 4-6: Events contributing to DFS and numbers of deaths by dichotomized TPOAb 
status 
 TPOAb- 
N=1568 n (%) 
TPOAb+ 
N=406 n (%) 
Number of patients with event contributing to DFS 
analysis 
442 (28.2) 109 (26.8) 
     Local recurrence 59 (3.8) 17 (4.2) 
     Distant recurrence 327 (20.9) 78 (19.2) 
     New breast disease 33 (2.1) 10 (2.5) 
     Death from other cause (no recurrence) 23 (1.5) 4 (1.0) 
All deaths 325 (20.7) 72 (17.7) 
     Breast cancer 301 (19.2) 68 (16.7) 
Death from other causes (without distant recurrence) 24 (1.5) 4 (1.0) 
          Cancer (non-breast) 14 (0.9) 1 (0.2) 
          Treatment toxicity 0 (0.0) 0 (0.0) 
          Other 9 (0.6) 3 (0.7) 
               Vascular (cardiac) 1 (0.1) 1 (0.2) 
               Vascular (cerebral) 1 (0.1) 0 (0.0) 
               Vascular (thromboembolic) 0 (0.0) 0 (0.0) 
               Respiratory 0 (0.0) 0 (0.0) 
               Accident, suicide, alcoholism 5 (0.3) 0 (0.0) 
               Infection (not treatment related) 0 (0.0) 1 (0.2) 
               GI bleed 0 (0.0) 0 (0.0) 
               Chronic liver disease 1 (0.1) 0 (0.0) 
               Unknown 2 (0.1) 1 (0.2) 
DFS = disease free survival. TPOAb = autoantibodies to thyroid peroxidase. 
4.3.2.1 Dichotomized TPOAb 
There was no evidence of a difference in DFS between TPOAb+ and TPOAb- 
patients in both univariate (unadjusted-HR = 0.97, 95%CI, 0.78 - 1.19; p=0.75; 
Figure 4-4) and multivariable (adjusted-HR=1.00, 95%CI,0.81-1.23; p=1.00; Table 
4-7) analyses.  
Figure 4-4: Univariate analysis of DFS by dichotomized TPOAb 
 
DFS = disease free survival. HR = Hazard Ratio. TPOAb = autoantibodies to thyroid 
peroxidase. 95%CI = 95% confidence interval. p= p value.  
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Table 4-7: Multivariable analysis of DFS by dichotomized TPOAb 
 HR 95%CI P-value 
TPOAb status negative 1.00 - - 
positive 1.00 0.81, 1.23 1.00 
Nodal status positive 1.00 - - 
negative 0.49 0.38, 0.64 <0.001 
HER2 status and 
trastuzumab use 
negative 1.00 - - 
positive, 
trastuzumab 
0.91 0.52, 1.59 0.74 
positive, no 
trastuzumab 
1.23 1.00, 1.52 0.05 
unknown 0.93 0.71, 1.23 0.63 
Age group <40 1.00 - - 
40-49 0.79 0.62, 1.00 0.05 
50-59 0.75 0.59, 0.95 0.02 
60+ 0.94 0.69, 1.30 0.72 
Tumour grade G1 1.00 - - 
G2 1.15 0.74, 1.78 0.55 
G3 1.39 0.89, 2.16 0.15 
unknown 0.75 0.10, 5.63 0.78 
Tumour size (cm) ≤2 1.00 - - 
>2 and ≤5 1.36 1.12, 1.66 0.002 
>5 1.89 1.41, 2.53 <0.001 
Type of surgery Mastectomy 1.00 - - 
WLE 0.79 0.66, 0.95 .01 
DFS = disease free survival. HER2 = human epidermal growth factor receptor 2. HR = 
Hazard Ratio. TPOAb = autoantibodies to thyroid peroxidase.  WLE = wide local excision. 
95%CI = 95% confidence interval.  
 
Analyses in clinical subgroups according to age group, nodal status, tumour 
grade, tumour size, type of surgery, ER and HER2 status and molecular subgroup 
showed consistency with the overall effect, with no evidence of any significant 
interaction effects of TPOAb on DFS (Figure 4-5). 
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Figure 4-5: Subgroup analyses of DFS by dichotomized TPOAb 
 
DFS = disease free survival. ER = oestrogen receptor. HER2 = human epidermal growth 
factor receptor 2. HR = Hazard Ratio. NK = not known. TPOAb = autoantibodies to thyroid 
peroxidase. WLE = wide local excision. 95%CI = 95% confidence interval.   
 
Similarly to DFS, there was no evidence of a difference by TPOAb status on 
OS and TTR in both univariate (respectively unadjusted-HR = 0.86 and 0.97, 95%CI: 
0.66,1.11 and 0.78-1.21, p=0.24 and p=0.80; Figure 4-6 panels A and B 
respectively) and multivariable (respectively adjusted-HR=0.89 and 1.02, 95%CI 
0.69-1.15 and 0.82-1.27, p=0.36 and p=0.88; Table 4-8) analyses.  
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Figure 4-6: Univariate analysis of OS and TTR by dichotomized TPOAb  
 
 
HR = Hazard Ratio. OS = overall survival. TPOAb = autoantibodies to thyroid peroxidase. 
TTR = time to recurrence. 95%CI = 95% confidence interval.   
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Table 4-8: Multivariable analysis of OS and TTR by dichotomized TPOAb 
 OS TTR 
 HR 95%CI p-value HR 95%CI p-value 
TPOAb negative 1.00 - - 1.00 - - 
positive 0.88 0.68, 1.14 0.34 1.01 0.81, 1.26 0.91 
Nodal status positive 1.00 - - 1.00 - - 
negative 0.43 0.31, 0.60 <0.001 0.42 0.32, 0.57 <0.001 
HER2 status and 
trastuzumab use 
negative 1.00 - - 1.00 - - 
unknown 1.04 0.76, 1.42 0.81 0.99 0.75, 1.31 0.93 
positive, no 
trastuzumab 1.33 1.04, 1.69 0.02 1.25 1.00, 1.55 0.05 
positive, yes 
trastuzumab 0.89 0.45, 1.73 0.73 1.02 0.58, 1.78 0.95 
Age group <40 1.00 - - 1.00 - - 
40-49 0.84 0.62, 1.13 0.24 0.78 0.60, 1.01 0.06 
50-59 0.93 0.69, 1.24 0.62 0.74 0.57, 0.95 0.02 
60+ 1.17 0.81, 1.70 0.40 0.95 0.68, 1.32 0.74 
Grade G1 1.00 - - 1.00 - - 
G2 1.35 0.76, 2.39 0.30 1.36 0.83, 2.25 0.22 
G3 1.69 0.96, 2.98 0.07 1.64 1.00, 2.71 0.05 
unknown 1.17 0.15, 9.06 0.88 0.98 0.13, 7.42 0.98 
Tumour size (cm) ≤2 1.00 - - 1.00 - - 
>2 and ≤5 1.31 1.04, 1.66 0.02 1.31 1.06, 1.60 0.01 
>5 1.84 1.31, 2.57 <0.001 1.94 1.44, 2.62 <0.001 
Type of surgery Mastectomy 1.00 - - 1.00 - - 
WLE 0.71 0.57, 0.88 0.002 0.75 0.62, 0.91 0.003 
HER2 = human epidermal growth factor receptor 2. HR = Hazard Ratio. OS = overall 
survival. TPOAb = autoantibodies to thyroid peroxidase. TTR = time to recurrence. WLE = 
wide local excision. 95%CI = 95% confidence interval.  
 
4.3.2.2 TPOAb tertiles 
TPOAb+ cases when categorized into tertiles showed no evidence of a prognostic 
effect in both univariate (Figure 4-7) and multivariable (Table 4-9) analyses for 
DFS, OS or TTR.   
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Figure 4-7: Univariate analysis of DFS, OS and TTR by TPOAb tertiles 
 
DFS = disease free survival. HR = Hazard Ratio. OS = overall survival. TPOAb = 
autoantibodies to thyroid peroxidase. TTR = time to recurrence. T1, T2, T3 = first, second, 
third tertile. 95%CI = 95% confidence interval.   
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Table 4-9: Multivariable analysis of DFS, OS and TTR by TPOAb tertiles 
 DFS OS TTR 
 HR 95%CI p HR 95%CI p HR 95%CI p 
TPOAb neg 1.00 - - 1.00 - - 1.00 - - 
pos T1 1.01 0.72, 1.41 0.97 0.94 0.62, 1.41 0.76 1.01 0.70, 1.43 0.98 
pos T2 1.07 0.77, 1.50 0.68 1.02 0.69, 1.52 0.91 1.16 0.83, 1.63 0.39 
pos T3 0.92 0.65, 1.31 0.65 0.70 0.44, 1.10 0.12 0.88 0.60, 1.28 0.50 
Nodal 
status 
pos 1.00 - - 1.00 - - 1.00 - - 
neg 0.49 0.38, 0.64 <0.001 0.43 0.31, 0.60 <0.001 0.42 0.32, 0.57 <0.001 
HER2 
status 
and 
trastuz. 
use 
neg 1.00 - - 1.00 - - 1.00 - - 
unk. 0.93 0.71, 1.23 0.62 1.04 0.76, 1.42 0.81 0.99 0.74, 1.31 0.93 
pos 1.23 1.00, 1.52 0.05 1.33 1.05, 1.70 0.02 1.25 1.00, 1.55 0.05 
pos T* 0.91 0.52, 1.59 0.73 0.89 0.45, 1.74 0.73 1.01 0.58, 1.78 0.96 
Age 
group 
<40 1.00 - - 1.00 - - 1.00 - - 
40-49 0.79 0.62, 1.00 0.05 0.84 0.62, 1.13 0.24 0.78 0.60, 1.01 0.06 
50-59 0.75 0.59, 0.95 0.02 0.93 0.69, 1.24 0.62 0.74 0.57, 0.95 0.02 
60+ 0.94 0.68, 1.30 0.72 1.17 0.80, 1.70 0.42 0.94 0.67, 1.31 0.72 
Grade G1 1.00 - - 1.00 - - 1.00 - - 
G2 1.14 0.73, 1.77 0.57 1.33 0.75, 2.36 0.33 1.35 0.82, 2.22 0.24 
G3 1.38 0.89, 2.15 0.16 1.66 0.94, 2.94 0.08 1.62 0.98, 2.67 0.06 
unk. 0.75 0.10, 5.59 0.78 1.15 0.15, 8.94 0.89 0.96 0.13, 7.32 0.97 
Tumour 
size 
(cm) 
≤2 1.00 - - 1.00 - - 1.00 - - 
>2 -≤5 1.36 1.12, 1.66 0.002 1.32 1.04, 1.66 0.02 1.31 1.06, 1.60 0.01 
>5 1.89 1.41, 2.53 <0.001 1.83 1.31, 2.57 <0.001 1.94 1.43, 2.61 <0.001 
Type of 
surgery 
Mast. 1.00 - - 1.00 - - 1.00 - - 
WLE 0.79 0.66, 0.95 0.01 0.71 0.57, 0.88 0.002 0.75 0.62, 0.91 0.003 
pos T* = HER2 positive treated with trastuzumab 
DFS = disease free survival. HER2 = human epidermal growth factor receptor 2. HR = 
Hazard Ratio. Mast. = mastectomy. neg = negative. OS = overall survival. pos = positive. 
TPOAb = autoantibodies to thyroid peroxidase. trastuz. = trastuzumab. TTR = time to 
recurrence. T1 = TPOAb 6-40kU/L. T2 = TPOAb 41-238kU/L. T3 = TPOAb 240-2000kU/L. 
unk. = unknown. WLE = wide local excision. 95%CI = 95% confidence interval.  
4.3.2.3 DFS sensitivity analyses with dichotomized TPOAb 
2 sensitivity analyses for DFS were performed, based on different 
populations: 
1) 126 node+ patients not treated with radiotherapy, therefore similar to Fiore et 
al. cohort (183). The median time of blood collection after surgery was 12.4 
months (IQR=4.9-21.6; range=0.7–47.2 months).  
2) 123 patients whose blood had been taken after surgery but before any 
adjuvant BC therapy. The median time of sera collection after surgery was 1.1 
months (IQR=0.9-1.4; range=0.5-5.9).  
There was no evidence of a significant impact on DFS by TPOAb status in either of 
the sensitivity analysis populations, with unadjusted-HRs of 1.48 (95%CI,0.68-3.25; 
p= 0.32) and 0.83 (95%CI, 0.35-2.03; p= 0.69) respectively. 
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4.3.3 Thyroid function and breast cancer prognosis 
4.3.3.1 Univariate analysis 
When considering separately FT4 and TSH both as continuous or categorical 
variables in univariate analyses, no evidence of a significant effect for DSF, OS 
and TTR was found (Table 4-10). 
Table 4-10: Univariate analysis of DSF, OS and TTR by FT4 and TSH variables  
 DFS OS TTR 
 HR 95%CI p HR 95%CI p HR 95%CI p 
FT4 
Continuous 1.00 0.96-1.04 0.91 1.01 0.96-1.06 0.68 1.01 0.97-1.05 0.70 
          
Hypo 1.61 0.67-3.88 0.29 2.23 0.92-5.40 0.07 1.80 0.75-4.36 0.19 
Eu 1.00 - - 1.00 - - 1.00 - - 
Hyper 1.08 0.62-1.87 0.79 0.88 0.44-1.77 0.71 1.10 0.62-1.96 0.74 
           
TSH 
Continuous* 1.03 0.94-1.13 0.48 1.03 0.92-1.14 0.65 1.04 0.94-1.14 0.43 
          
Hypo 1.08 0.73-1.59 0.71 1.03 0.65-1.63 0.91 1.15 0.78-1.71 0.48 
Eu 1.00 - - 1.00 - - 1.00 - - 
Hyper 1.19 0.82-1.72 0.36 1.27 0.83-1.93 0.27 1.24 0.84-1.81 0.28 
       * referred to ln(TSH) continuous values 
DFS = disease free survival; Eu = hypothyroidism; FT4 = free thyroxine; HR = Hazard Ratio; 
Hyper = hyperthyroidism; Hypo = hypothyroidism; ln = logarithmic scale; OS = overall 
survival; p = p value; TSH = thyroid stimulating hormone; TTR = time to recurrence; 95%CI 
= 95% confidence interval. 
 
When considering together TSH and FT4 as unique thyroid function categorical 
variable in univariate analyses, absence of evidence of a significant effect was 
confirmed in DFS, OS and TTR (Figure 4-8).  
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Figure 4-8: Univariate analysis of DFS, OS and TTR by thyroid function status (TSH/FT4 
combined categories) 
 
DFS = disease free survival. HR = Hazard Ratio. OS = overall survival. TTR = time to 
recurrence. 95%CI = 95% confidence interval. 
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4.3.3.2 Multivariable analyses 
The multivariable analyses confirmed the absence of evidence of a significant 
impact of thyroid function on DFS, OS and TTR, both when considering FT4 (Table 
4-11) and TSH (Table 4-12) separately or combined into a unique thyroid function 
status categorical variable (Table 4-13).  
Table 4-11: Multivariable analysis of DFS, OS and TTR by FT4 variable 
 DFS OS TTR 
 HR 95%CI p HR 95%CI p HR 95%CI p 
FT4 cont. 1.00 0.96, 1.05 0.83 1.01 0.97, 1.06 0.55 1.01 0.97, 1.06 0.60 
Nodal 
status 
pos 1.00 - - 1.00 - - 1.00 - - 
neg 0.49 0.38, 0.64 <0.001 0.43 0.31, 0.59 <0.001 0.42 0.32, 0.57 <0.001 
HER2 
status 
and 
trastuz. 
use 
neg 1.00 - - 1.00 - - 1.00 - - 
unk. 0.93 0.71, 1.23 0.63 1.04 0.76, 1.42 0.82 0.99 0.75, 1.31 0.94 
pos 1.23 1.00, 1.51 0.06 1.32 1.04, 1.68 0.02 1.24 1.00, 1.55 0.05 
pos T* 0.91 0.52, 1.59 0.73 0.89 0.45, 1.74 0.73 1.01 0.58, 1.78 0.96 
Age 
group 
<40 1.00 - - 1.00 - - 1.00 - - 
40-49 0.79 0.62, 1.00 0.05 0.83 0.62, 1.12 0.22 0.78 0.61, 1.01 0.06 
50-59 0.75 0.59, 0.95 0.02 0.92 0.69, 1.23 0.56 0.74 0.57, 0.95 0.02 
60+ 0.94 0.69, 1.30 0.72 1.16 0.80, 1.69 0.43 0.94 0.68, 1.32 0.74 
Grade G1 1.00 - - 1.00 - - 1.00 - - 
G2 1.15 0.74, 1.78 0.55 1.36 0.77, 2.40 0.30 1.36 0.83, 2.25 0.22 
G3 1.39 0.89, 2.16 0.15 1.69 0.96, 2.99 0.07 1.64 1.00, 2.71 0.05 
unk. 0.75 0.10, 5.65 0.78 1.22 0.16, 9.43 0.85 0.98 0.13, 7.67 0.99 
Tumour 
size 
(cm) 
≤2 1.00 - - 1.00 - - 1.00 - - 
>2 -≤5 1.36 1.12, 1.66 0.002 1.32 1.04, 1.66 0.02 1.31 1.06, 1.61 0.01 
>5 1.89 1.41, 2.53 <0.001 1.83 1.31, 2.57 <0.001 1.94 1.44, 2.62 <0.001 
Type of 
surgery 
Mast. 1.00 - - 1.00 - - 1.00 - - 
WLE 0.79 0.66, 0.95 0.01 0.70 0.56, 0.87 0.002 0.75 0.62, 0.91 0.003 
pos T* = HER2 positive treated with trastuzumab 
cont. = continuous variable; DFS = disease free survival; FT4 = free-thyroxine; HER2 = 
human epidermal growth factor receptor 2; HR = Hazard Ratio; Mast. = mastectomy; neg = 
negative; OS = overall survival; pos = positive; unk. = unknown; TTR = time to recurrence; 
WLE = wide local excision; 95%CI = 95% confidence interval. 
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Table 4-12: Multivariable analysis of DFS, OS and TTR by TSH variable 
 DFS OS TTR 
 HR 95%CI p HR 95%CI p HR 95%CI p 
TSH(ln) cont. 1.03 0.94, 1.13 0.55 1.02 0.91, 1.13 0.75 1.04 0.94, 1.14 0.49 
Nodal 
status 
pos 1.00 - - 1.00 - - 1.00 - - 
neg 0.48 0.37, 0.63 <0.001 0.42 0.30, 0.58 <0.001 0.43 0.32, 0.57 <0.001 
HER2 
status 
and 
trastuz. 
use 
neg 1.00 - - 1.00 - - 1.00 - - 
unk. 0.94 0.71, 1.23 0.64 1.04 0.76, 1.60 0.81 0.99 0.75, 1.31 0.94 
pos 1.24 1.00, 1.52 0.05 1.33 1.05, 1.69 0.02 1.25 1.00, 1.56 0.05 
pos T* 0.91 0.52, 1.60 0.76 0.90 0.46, 1.75 0.75 1.02 0.58, 1.79 0.94 
Age 
group 
<40 1.00 - - 1.00 - - 1.00 - - 
40-49 0.78 0.62, 1.00 0.05 0.83 0.62, 1.12 0.22 0.78 0.61, 1.01 0.06 
50-59 0.74 0.58, 0.95 0.02 0.91 0.68, 1.22 0.53 0.73 0.57, 0.95 0.02 
60+ 0.94 0.69, 1.30 0.72 1.16 0.80, 1.69 0.42 0.95 0.68, 1.32 0.74 
Grade G1 1.00 - - 1.00 - - 1.00 - - 
G2 1.14 0.73, 1.78 0.55 1.36 0.77, 2.40 0.30 1.36 0.83, 2.24 0.22 
G3 1.39 0.89, 2.16 0.15 1.69 0.95, 2.98 0.07 1.64 0.99, 2.70 0.05 
unk. 0.75 0.10, 5.60 0.78 1.20 0.16, 9.30 0.86 0.96 0.13, 7.31 0.97 
Tumour 
size 
(cm) 
≤2 1.00 - - 1.00 - - 1.00 - - 
>2 -≤5 1.36 1.11, 1.65 0.002 1.31 1.04, 1.65 0.02 1.30 1.06, 1.60 0.01 
>5 1.88 1.41, 2.52 <0.001 1.83 1.30, 2.56 <0.001 1.93 1.43, 2.61 <0.001 
Type of 
surgery 
Mast. 1.00 - - 1.00 - - 1.00 - - 
WLE 0.80 0.66, 0.96 0.01 0.71 0.57, 0.88 0.002 0.75 0.62, 0.91 0.003 
pos T* = HER2 positive treated with trastuzumab 
cont. = continuous variable; DFS = disease free survival; HER2 = human epidermal growth 
factor receptor 2; HR = Hazard Ratio; ln = logarithmic scale; Mast. = mastectomy; neg = 
negative; OS = overall survival; pos = positive; TSH = thyroid stimulating hormone; TTR = 
time to recurrence; unk. = unknown; WLE = wide local excision; 95%CI = 95% confidence 
interval.   
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Table 4-13: Multivariable analysis of DFS, OS and TTR by thyroid function status 
(TSH/FT4 combined categories) 
 DFS OS TTR 
 HR 95%CI p HR 95%CI p HR 95%CI p 
Thyroid 
function 
eu 1.00 - - 1.00 - - 1.00 - - 
hypo 1.14 0.79, 1.67 0.48 1.08 0.69, 1.68 0.73 1.24 0.84, 1.82 0.27 
hyper 1.14 0.81, 1.59 0.47 1.16 0.78, 1.72 0.46 1.17 0.82, 1.66 0.40 
Nodal 
status 
pos 1.00 - - 1.00 - - 1.00 - - 
neg 0.49 0.38, 0.64 <0.001 0.43 0.31, 0.59 <0.001 0.42 0.32, 0.57 <0.001 
HER2 
status 
and 
trastuz. 
use 
neg 1.00 - - 1.00 - - 1.00 - - 
unk. 0.93 0.71, 1.22 0.61 1.03 0.76, 1.41 0.84 0.98 0.74, 1.30 0.91 
pos 1.23 1.00, 1.51 0.06 1.32 1.04, 1.68 0.02 1.24 1.00, 1.55 0.05 
pos T* 0.91 0.52, 1.59 0.74 0.89 0.46, 1.74 0.73 1.02 0.58, 1.79 0.95 
Age 
group 
<40 1.00 - - 1.00 - - 1.00 - - 
40-49 0.78 0.61, 0.99 0.05 0.82 0.61, 1.11 0.21 0.77 0.60, 1.00 0.05 
50-59 0.74 0.58, 0.94 0.02 0.91 0.68, 1.22 0.53 0.72 0.56, 0.94 0.01 
60+ 0.94 0.68, 1.29 0.70 1.16 0.80, 1.63 0.43 0.94 0.67, 1.31 0.71 
Grade G1 1.00 - - 1.00 - - 1.00 - - 
G2 1.15 0.74, 1.79 0.54 1.36 0.77, 2.41 0.29 1.37 0.83, 2.25 0.22 
G3 1.39 0.89, 2.16 0.15 1.69 0.96, 2.99 0.07 1.64 0.99, 2.70 0.05 
unk. 0.77 0.10, 5.73 0.80 1.22 0.16, 9.47 0.85 1.00 0.13, 7.59 1.00 
Tumour 
size 
(cm) 
≤2 1.00 - - 1.00 - - 1.00 - - 
>2 -≤5 1.36 1.12, 1.65 0.002 1.31 1.04, 1.66 0.02 1.30 1.06, 1.60 0.01 
>5 1.88 1.41, 2.52 <0.001 1.82 1.30, 2.56 <0.001 1.93 1.43, 2.60 <0.001 
Type of 
surgery 
Mast. 1.00 - - 1.00 - - 1.00 - - 
WLE 0.79 0.66, 0.95 0.01 0.70 0.56, 0.87 0.002 0.75 0.62, 0.91 0.003 
pos T* = HER2 positive treated with trastuzumab 
DFS = disease free survival; HER2 = human epidermal growth factor receptor 2; HR = 
Hazard Ratio; Mast. = mastectomy; neg = negative; OS = overall survival; pos = positive; 
TSH = thyroid stimulating hormone; TTR = time to recurrence; unk. = unknown; WLE = 
wide local excision; 95%CI = 95% confidence interval. 
 
4.3.4 Impact of TPOAb and thyroid function on breast cancer prognosis 
As expected, considering together dichotomized TPOAb and thyroid 
function status in the multivariable model for DFS, no evidence of a significant 
impact was found (Table 4-14). Similar analyses for OS and TTR were not 
performed because they were secondary outcomes. Furthermore, if 2 variables 
(i.e. TPOAb and thyroid function) give negative results when analyzed separately, 
they will give negative results also when considered together.    
 
 
 
 143 
 
Table 4-14: Multivariable analysis of DFS by TPOAb (dichotomized) and thyroid 
function status (TSH/FT4 combined categories)  
 HR 95%CI P-value 
TPOAb status negative 1.00 - - 
positive 0.96 0.77, 1.21 0.76 
Thyroid function Euthyroid 1.00 - - 
Hypothyroid 1.17 0.78, 1.74 0.44 
Hyperthyroid 1.14 0.81, 1.61 0.44 
Nodal status positive 1.00 - - 
negative 0.49 0.38, 0.64 <0.001 
HER2 status and 
trastuzumab use 
negative 1.00 - - 
unknown 0.93 0.71, 1.22 0.61 
positive, no 
trastuzumab 
1.23 1.00, 1.51 0.05 
positive, yes 
trastuzumab 
0.91 0.52, 1.59 0.74 
Age group <40 1.00 - - 
40-49 0.78 0.61, 1.00 0.05 
50-59 0.74 0.58, 0.95 0.02 
60+ 0.94 0.68, 1.29 0.70 
Tumour grade G1 1.00 - - 
G2 1.15 0.74, 1.79 0.54 
G3 1.39 0.89, 2.16 0.15 
unknown 0.76 0.10, 5.70 0.79 
Tumour size (cm) ≤2 1.00 - - 
>2 and ≤5 1.36 1.12, 1.65 0.002 
>5 1.88 1.41, 2.52 <0.001 
Type of surgery Mastectomy 1.00 - - 
WLE 0.79 0.66, 0.95 0.01 
HER2 = human epidermal growth factor receptor 2; HR = Hazard Ratio; WLE = wide local 
excision; 95%CI = 95% confidence interval. 
4.4 CONCLUSIONS 
An association between thyroid autoimmunity (TA) and breast cancer (BC) 
has been debated for years and the presence of circulating anti-thyroid peroxidase 
(TPO) autoantibodies (TPOAb) has been suggested as a favorable BC prognostic 
factor (182-184, 260). Consequently, a common immune response between thyroid 
and BC has been proposed, with TPO the most likely shared antigen involved, as 
discussed in Chapter 3. 
Since around 20% of women are positive for TPOAb (TPOAb+) and currently 
there are few useful blood prognostic markers for BC validated for clinical 
practice, it is important to verify TPOAb positive prognostic role for BC in patient 
cohorts appropriately powered for population size and length of follow-up.  
The present patient cohort is the largest to address this topic to date 
(n=1974), with one of the longest follow-ups (96.7 months). This population study 
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is generally representative of patients affected with moderate-high risk early BC 
receiving adjuvant treatments (both systemic and local). In this patient cohort we 
found that neither the presence nor the titre of serum TPOAb measured with 
standard assays seemed to have a substantial impact on long-term recurrence or 
mortality; similar findings were observed for thyroid status.    
4.4.1 Comparison with results from previous studies 
There may be several reasons why our results do not confirm previous 
findings of a TPOAb+ protective role in BC prognosis. These include the fact that 
previous studies used smaller patient cohorts with shorter follow-ups (182, 183, 
185), considered BC at different stages (185) or provided no information about BC 
stage (182) and may thus be susceptible to bias and random findings. As previously 
stated, the TACT trial is not representative of the whole BC population but of 
moderate-high risk early BC very similar to that analyzed by Fiore et al., who 
recruited women with non-metastatic aggressive BC all treated with 
chemotherapy (183).     
Thanks to the discovery and use of effective treatments for BC, the 
survival of patients affected with BC has increased very much during last decades. 
In particular, the whole TACT trial population had 5-year estimates of 82.7% and 
74.9% for respectively overall survival (OS) and disease-free survival (DFS), very 
similar to the average 5-year OS for BC in UK (82%) calculated in an analogue time 
period (patients diagnosed in the period 2001-2006 and followed until 2007) (328, 
329).  
When re-analyzing the data and preparing the manuscript for submission to 
a peer-reviewed journal, I realised that the analysis population described in the 
present study (TACT patients having blood available) was not representative of 
the TACT population as a whole. In fact the analysed population had a better 
breast cancer prognosis compared with not included TACT patients (without blood 
available); mainly because blood collection was started nearly 21 months after the 
beginning of the study. For this reason the blood was usually taken after 
randomization and consequently early-relapsing patients were less likely to 
provide blood. Furthermore, a higher proportion of patients included in this study 
were treated with trastuzumab: 11.8% versus 6.4% of patients not included in the 
study. The likely explanation is that clinical trials assessing trastuzumab were 
initiated around the same time of blood collection, therefore patients providing 
blood were more likely to receive this additional treatment. This could also have 
contributed to a further increase of the survival among patients with available 
blood. The increased use of trastuzumab in the analysis population group is 
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unlikely to have biased TPOAb and thyroid function results on BC prognosis since: 
1) trastuzumab was given only to a few patients, 2) the “use of trastuzumab” 
variable was considered combined to HER2 expression in all the performed 
multivariable analyses and did not significantly change the results for DFS, OS and 
TTR by TPOAb and/or thyroid function status. 
The longer survival of the BC population analyzed in the present study 
could obscure a minor TPOAb prognostic effect, hypothetically detectable only 
among patients not suitable for standard treatments (e.g. elderly or with medical 
contraindications) and targeted therapies (e.g. triple negative BC). Although 
possible it remains unlikely, since our exploratory analysis conducted among 
different BC subtypes confirmed our negative results.  
4.4.2 Impact of other examined factors on breast cancer prognosis 
The multivariable analysis confirmed nodal status and tumour size as the 
two most important BC prognostic factors (309, 330). Similarly, the better BC 
prognosis characterizing the intermediate age group (50-59 years) confirms results 
of a recent wide cohort study conducted on 4453 women (331). 
The role of tumour size and lymph node metastasis is well-known and for 
this reason they are included as major factors of TNM staging, as described in 
paragraph 4.1.3.1. On the contrary, the impact of age on BC prognosis is still 
debated and contradictory results have been obtained in the literature, likely 
because of the wide heterogeneity of BC and its subtypes, different adjuvant 
treatments and lack of adjustment for other prognostic factors. Many authors 
confirmed a worse BC prognosis among young (332-334) and elderly women (332, 
335-337), not supported by others (338-340). A plausible explanation for a 
worsening of prognosis among young women is that they tend to be affected with 
a higher grade BC, consequently more aggressive, and BC is also more prone to be 
ER negative and therefore less susceptible to treatment with adjuvant endocrine 
therapy (334, 341, 342). On the contrary, BC in elderly women is often ER positive 
(343), therefore responds well to endocrine therapy (344, 345). However, 
although elderly women usually have less aggressive cancers which are susceptible 
to a wide range of treatments, the most likely reason for having worsened survival 
rates is potentially not receiving treatment according to the guidelines because of 
age or comorbidities (331). 
HER2 status and tumour grade were not significant outcome factors in the 
great majority of cases and all the multivariable analyses conducted, respectively. 
The first likely explanation is that the present study has not been powered in 
order to assess the role of these prognostic factors.  
 146 
As expected, HER2 positive patients not treated with trastuzumab clearly tended 
to have a worse prognosis compared with HER2 negative patients and this 
difference reached statistical significance in several multivariable analyses 
conducted.   
Tumour grade, although it missed reaching the statistical significance (likely 
because BC tissues were graded in 104 different centres, without universal 
agreement among tumour grading systems), showed a constant and convincing 
trend of concordance between increasing tumour grade and progressive worsening 
of prognosis. Therefore, all the considered known risk factors for BC showed clear 
or partial influence on BC prognosis, proving that the cohort studied was 
appropriate and the model reasonably sensitive. On the contrary, TPOAb and 
thyroid function were constantly not significant in all analyses, with TPOAb 
tertiles showing no trend at all.    
4.4.3 Principal limitations of the study 
The principal limitations of the present study are principally a consequence 
of its retrospective nature: 1) lack of clinical history for thyroid diseases or 
medications; 2) plasma samples having been collected in most cases during or 
after adjuvant BC therapy.    
In this study cohort all patients were treated with chemotherapy and 
1745/1974 (88.4%) patients were treated with adjuvant radiotherapy for BC. Some 
authors suggested that in some cases the homolateral thyroid lobe can be included 
in the radiation field used for irradiation of internal mammary, supra- and infra-
clavicular nodes (346), with a partial thyroid irradiation more likely to happen 
using fields including supra- and infra-clavicular node chains (347). Both studies 
suggested an increased risk of hypothyroidism after radiotherapy for BC but their 
sample size was small and no previous thyroid history was available (346, 347). 
Other authors observed an increased rate of hypothyroidism in patients treated 
with chemotherapy for BC; in particular, the thyroid function was compared at 
baseline and during/after the treatment, i.e. before the 6th cycle of 
chemotherapy (348) or up to 6 months after completing chemotherapy (349). 
However, Smith et al. evaluated 38’255 patients with BC and found a significantly 
higher incidence of subsequent hypothyroidism in a 5-year follow-up compared 
with age-matched controls, but unrelated to radiotherapy or chemotherapy 
treatments (350). The main differences between studies reporting an effect of BC 
therapy (348, 349) and Smith’s cohort (350) were the length of follow-up and the 
method used to evaluate thyroid function; in Smith’s study the thyroid diagnosis 
was extrapolated from diagnostic codes taken from registers, without direct 
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assessment of thyroid function. A possible explanation for these discrepant results 
could be a temporary thyroid function reduction caused by chemotherapy, which 
would explain why De Groot and Kumar, evaluating thyroid function maximum 6 
months after the end of chemotherapy treatment, observed an increased 
incidence of hypothyroidism (348, 349), not confirmed in a 5-year follow-up as in 
Smith’s study (350). Furthermore, chemotherapy and radiotherapy could act 
synergistically on thyroid tissue. In fact thyroid damaging is known to be caused by 
treatments for head/neck tumours and blood cells tumours, i.e Hodgkin disease. 
Hancock et al. evaluated 1787 patients affected by Hodgkin disease and found 
that chemotherapy associated to radiotherapy was a major risk factor for 
hypothyroidism, because chemotherapy sensitize the thyroid gland to the effects 
of concomitant radiation therapy (351). 
Regarding the therapy with tamoxifen, in this study cohort 1378 ER positive 
patients were submitted to hormonal therapy and in particular 1317 to tamoxifen.  
Some authors reported that tamoxifen may exert a modulation of thyroid 
function, mainly determining an anti-thyroid effect (352-354).  
To my knowledge no studies have been carried out exploring possible 
thyroidal effects (autoimmune and non) of the treatment with trastuzumab.  
Finally, the stress related to the surgical procedure itself has been 
suggested to have a possible immunomodulating effect that could therefore affect 
autoantibodies levels (355). 
In conclusion, a possible influence of various BC treatments on thyroid 
function and autoimmunity has been suggested, with not all authors agreeing and 
contrasting results being produced. Well designed and powered studies are needed 
to definitively address this topic in the future. Furthermore, the impact of those 
treatments on thyroid autoantibody levels has been rarely investigated so far. For 
these reasons serum/plasma samples for the study of thyroid autoimmunity should 
be ideally collected not only before adjuvant treatments but also before breast 
surgery; unfortunately this was not possible in this study cohort.   
However, no clear large-scale effects of adjuvant treatments for BC on 
thyroid function and immunity have been described to date. In addition, the 
sensitivity analysis conducted in a subgroup of 123 patients with plasma collected 
before BC adjuvant therapy also showed no evidence of TPOAb prognostic ability, 
even if the wide 95%CI suggests a lack of statistical power (95%CI, 0.35-2.03; p= 
0.69). For these reasons, the results of the present study are unlikely being 
significantly biased by BC treatments. 
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4.4.4 Conclusions about thyroid autoimmunity and breast cancer 
prognosis 
Our study indicates that circulating TPOAb measured by standard assays 
seem not to have any impact on the prognosis of moderate-high risk early BC. 
However, we cannot exclude a role of different thyroid autoimmunity (TA) 
parameters on breast cancer (BC) prognosis, considering that a positive prognostic 
effect on BC has also been suggested for the presence of goitre (182) or incidental 
TA related 18F-FDG PET/CT uptake (260). Since in chapter 3 differences in the 
alternative splicing of TPO in the breast as compared to the thyroid have been 
suggested, this may result in different epitopes being targeted. This topic will be 
further discussed in the next chapter (5).  
The overall TPOAb prevalence in our cohort was 20.57%, very similar to our 
a priori predicted value. This value reflects TPOAb prevalence among women in 
the general population, reported as varying from 17% (63) to 26.4% (64), with all 
authors agreeing that TAb prevalence increases with age (64-67) and after 
iodization programs (327), explaining why TPOAb+ women were older than TPOAb-
. It remains possible that TPOAb+ rates are higher in the BC population 
(generated, for example, by antigen cross-reactivity) even if they do not predict 
outcome, as this study was not designed to compare TPOAb prevalence among BC 
patients and the general population.   
In conclusion, the present study is to my knowledge the largest currently 
available investigating the impact of circulating TPOAb and thyroid function on BC 
prognosis. In contrast to previous results from small-scale studies, blood TPOAb 
measured with standard assays and thyroid function did not substantially influence 
the long-term recurrence and mortality of moderate-high risk early BC in the 
modern era. Considering the limitations of the present observational study due to 
its retrospective nature, before drawing definitive conclusions it would seem 
appropriate to perform a similar study in a prospective patients cohort, with 
available clinical data about thyroid disorders and treatments and collecting the 
blood samples before any cancer treatment. However, major confounding factors 
in this study due to the effects of BC treatments on circulating thyroid markers 
seems unlikely, even if not 100% excluded. Future studies might also explore non-
conventional or breast-specific immune responses to TPO to determine whether 
other aspects of thyroid autoimmunity may be relevant to breast cancer outcome, 
as will be further discussed in the next chapter (5: general discussion). 
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5 GENERAL DISCUSSION 
5.1 Summary of main findings 
As summarized in chapter 1, paragraph 1.4, an association between breast 
cancer (BC) and benign thyroid disorders (BTD) has been debated for decades, 
supported by many authors (154-158), with others not agreeing (159-163). In 
particular, BC was suggested to be associated with thyroid autoimmunity (TA) 
(157); similarly to BTD this association has not been confirmed in different studies 
(161). More specifically, thyroid peroxidase (TPO) is one of the major antigens 
involved in TA and autoantibodies to TPO (TPOAb) have been found to be more 
common among patients affected with BC compared with healthy controls (166, 
179-181). Furthermore, several small-scale studies observed that patients affected 
with BC and positive for blood TPOAb had a better prognosis compared with 
TPOAb negative individuals, suggesting a possible protective role of TPOAb (182-
184), even if not confirmed in another study (185). BC and thyroid cells share 
similar properties (199), e.g. they both express the sodium iodide symporter (NIS) 
(200) and have a peroxidase activity, TPO in thyroid and lactoperoxidase (LPO) in 
breast (257). In the present study a shared immune activity between thyroid and 
BC tissues has been hypothesized, leading to increased tumour destruction and 
therefore to an improved prognosis.     
The first aim of the present study was to identify the hypothetical shared 
antigen between BC and thyroid cells. Considering that NIS is expressed in both 
thyroid and BC cells, in chapter 2 NIS has been hypothesized as common antigen 
and the presence of circulating autoantibodies to NIS (NISAb) has been 
investigated, expecting a higher prevalence among patients affected with TA and 
BC. NISAb were found to be rare and apparently not related to the presence of TA 
and/or BC therefore, although NIS is present in both thyroid and BC cells, it does 
not seem to represent an important antigen, either for TA, or as shared antigen 
between thyroid and BC cells.  
Considering the higher prevalence of TPOAb among patients affected with 
BC (166, 179-181), in chapter 3 TPO has been investigated as possible alternative 
shared antigen between thyroid and BC cells. The results indicated that TPO, both 
mRNA and protein, is expressed (at a much lower level compared to thyroid) in BC 
and breast peri-tumoural tissues, as well as different tissues, e.g. adipose tissue. 
Therefore, TPO is the most likely candidate as shared antigen between thyroid 
and BC tissue, since even trace amounts could suffice to trigger lymphocyte 
activity. Other unknown shared antigens, e.g. expressed by thyroid colloid, could 
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also be involved, even if unlikely, giving the huge number of studies trying to find 
novel thyroid autoantigens, with negative results. The TPO gene is highly 
subjected to alternative splicing and transcripts for novel TPO isoforms never 
described before have been discovered with this study. Interestingly, some TPO 
mRNA isoforms could be tissue specific, some in particular breast specific, 
therefore if confirmed they could represent possible bio-markers for BC. However, 
despite TPO mRNA and/or protein were expressed in all the BC tissues examined 
in chapter 3, only 1/8 (12.5%) patients was found positive for serum TPOAb (Table 
3-3). Conversely, the prevalence of TPOAb among BC patients should be higher, in 
accordance to data from literature (summarized in paragraph 4.1), further 
confirmed by 20.6% TPOAb prevalence among BC patients observed in chapter 4.  
There are several possible explanations for this discrepancy; first, 8 patients are 
too few in order to validate an epidemiological data (TPOAb prevalence among BC 
patients). Second, thyroid and breast TPO could express different antigenic 
properties, even if preliminary studies seem to exclude this hypothesis (356). 
Third, BC could mainly express TPO isoforms with epitopes different from 
complete TPO protein and therefore generating TPOAb not identifiable by 
standard TPOAb assays.   
In chapter 4 the prognostic role of TPOAb has been investigated in a large 
cohort of patients affected with BC and extensively followed for 96.7 months; the 
prognostic role of thyroid function has been investigated as well. Surprisingly, the 
present observational study clearly indicated that neither TPOAb (measured with 
one standard assay) nor thyroid function seemed to significantly affect the 
prognosis of BC, therefore these results did not confirm previous findings 
suggesting a protective role of TPOAb for BC (182, 183). However, considering the 
retrospective nature of the present study, a confirmation of its results in a 
prospective patients cohort would be needed before definitively excluding from 
breast cancer prognosis a role for TPOAb (measured by standard assays) and 
thyroid function.   
5.2 How do my results compare with those of others? 
5.2.1 Cross-reactivity of circulating TPOAb with different peroxidases 
An alternative mechanism to explain the increased prevalence of TPOAb 
among patients with BC could be the presence of cross-reactivity of TPOAb with 
different peroxidases, in particular LPO, the most abundant peroxidase expressed 
in breast tissue (257), as previously discussed in chapter 3, paragraphs 3.1.1.2 and 
3.5.2.    
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The study of Banga et al. (291) revealed that 40% and 45% of human sera 
positive for TPOAb cross-reacted with native bovine LPO, when detected 
respectively by enzyme-linked immunosorbent assay (ELISA) and western blot 
(WB). In reducing conditions, the percentage of TPOAb cross-reactivity with LPO 
decreased to 25% for ELISA and increased to 60% for WB. Pre-adsorption 
experiments of human sera with human TPO and/or LPO in order to test the signal 
specificity gave poor and satisfactory results in ELISA and WB assays respectively, 
as summarized in Table 5-1. In particular, pre-adsorption with native TPO caused 
the signal to disappear in TPO WB and not in LPO WB as expected; on the 
contrary, pre-adsorption with native LPO was not able to reduce the signal in LPO 
WB. 
Table 5-1: Adsorption experiments with TPO and LPO in ELISA and WB 
 ELISA (Native) WB (Reduced) 
Human serum TPO LPO TPO LPO 
Normal + + + + 
PA with liver microsomes + + + + 
PA with native TPO / / / + 
PA with reduced TPO / / / + 
PA with native+reduced TPO / / / / 
PA with native LPO + + + + 
PA with reduced LPO + + + / 
PA with native+reduced LPO + + + / 
Summary of pre-adsorption (PA) experiments of human serum with thyroid peroxidase 
(TPO) and lactoperoxidase (LPO) in enzyme-linked immunosorbent assay (ELISA) and 
western blot (WB) performed by Banga et al. (291). + = positive signal. / = negative signal.    
 
 TPOAb cross-reactivity with native myeloperoxidase (MPO) was less common, 0% 
of sera tested with ELISA and 15% with WB, however it increased to 70% and 50% 
respectively when using reduced MPO (291).  
Nishikawa et al. further investigated TPOAb cross-reactivity using four 
monoclonal human TPO-Fab (TPOAb’s variable regions only) directed towards the 
immunodominant region of TPO, defined as the region recognized by the majority 
of sera from patients positive for TPOAb. None of the four TPO-Fab cross-reacted 
with MPO or LPO, therefore the authors concluded that circulating TPOAb cross-
reacting with other peroxidases are likely to bind TPO outside the 
immunodominant region (357).  
In conclusion, different patients affected with TA are positive for different 
kinds of circulating TPOAb, some of them cross-reacting with the other 
peroxidases. TPOAb cross-reactivity with LPO could represent an additional 
mechanism to explain why TPOAb are more prevalent among patients with BC. 
However, LPO is abundantly expressed in breast tissue, both normal and tumoural, 
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where it is present as a secreted protein and therefore normally accessible to the 
immune system. As a consequence, the mechanism of antigen unmasking triggered 
by the tumoural process is unlikely to be involved. Different mechanisms are 
needed in order to explain the rise in TPOAb mainly in patients affected with BC 
compared with the general population. An alternative hypothesis could be the 
expression of a more antigenic form of LPO, e.g. with a different glycosylation 
level, in BC tissue compared with normal breast, or a general over-activation of 
the immune system secondary to tumoural processes, leading to an increase of 
auto-reactivity. Considering that TPO is expressed in BC and breast peri-tumoural 
tissue and different TPO isoforms exist, as described in chapter 3, similar 
mechanisms leading to different TPO epitopes being exposed in BC patients could 
be involved.   
5.2.2 TPO isoforms and epitopes 
Lai et al. have already described TPO gene expression in orbital tissue (261). 
The present study (chapter 3) confirmed TPO presence in orbital fat but also 
indicated that TPO is expressed in many different tissues: other depots of adipose 
tissue (abdominal, subcutaneous, from knee), BC and breast peri-tumoural tissue, 
and other cancers. So far, TPO’s role and function in these different tissues have 
not been investigated. Furthermore, it is unclear which TPO isoforms are more 
expressed and if some of them could be tissue specific, as suggested by the 
present study. In chapter 3, a TPO mRNA isoform missing both exons 14 and 16 
was found to be more prevalent in breast and adipose tissue and in BC cell lines; 
similarly, LongRange RT-PCR showed the presence of different TPO mRNA isoforms 
among the different tissues studied (one thyroid tissue, one adipose tissue and 
two BC tissues). Further experiments using a higher number of tissues are needed 
in order to draw substantial conclusions about tissue specificity of TPO mRNA 
isoforms.  
Furthermore, it would be important to establish whether mRNA is translated 
into the corresponding protein; this would be essential to establish if TPO isoforms 
have functional or antigenic activity. In order to be recognized by the immune 
system, TPO has to express certain epitopes and different isoforms may fold 
differently and therefore express alternative epitopes compared with full-length 
TPO. In fact epitopes may be of two kinds: linear and conformational. Linear 
epitopes, mainly recognized by T lymphocytes, consist of short linear peptides (8-
20 amino acids) processed from protein antigens and subsequently bound to MHC 
class II (triggering CD4+ cells) or class I (triggering CD8+ cells) (246), as previously 
introduced in chapter 1, paragraph 1.2.2.1. Many authors identified TPO epitopes 
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recognized by T lymphocytes in the MPO-like sequence (246, 358-361). 
Furthermore, two T-lymphocyte epitopes have been found also in the C-terminal 
part of TPO protein, in particular in the transmembrane region (359, 360) and in 
the intracellular region (359). On the contrary conformational epitopes consist of 
juxtaposed amino acids occurring at intervals in the sequence (or “remote in the 
sequence”) but brought closely together by the three-dimensional folding of the 
molecule (362). TPO epitopes recognized by human serum autoantibodies and B 
lymphocytes are for the great part conformational (242, 246, 255, 363, 364), 
therefore strongly related to tertiary and quaternary protein structures. Only a 
few TPO epitopes recognized by B-lymphocytes are linear: C21 and C2 (365, 366), 
as previously reported in chapter 3, paragraph 3.1.1.  
Therefore, TPO isoforms lacking one or more exons probably fold into a 
different conformation when compared with the full-length TPO and hence may 
lose their antigenic property for B cells and autoantibodies, or expose alternative 
conformational epitopes. Considering that standard laboratory assays to detect 
TPOAb are based on the full-length TPO protein, they are likely to fail in detecting 
TPOAb directed towards epitopes present in TPO isoforms lacking one or more 
exons. This could be an explanation of the negative results obtained in chapter 4: 
TPOAb detected by standard assays (and therefore recognizing the full-length 
TPO) seem not to have any impact on BC prognosis. However, different results 
could be obtained measuring blood circulating TPOAb directed towards alternative 
epitopes present on hypothetical smaller TPO isoforms, whose gene lack one or 
more exons.  
Similarly, the absence of TPOAb influencing BC prognosis does not exclude the 
presence of a hypothetical T lymphocytes common response between thyroid and 
BC cells. 
Finally, metastatic BC patients at diagnosis were systematically excluded in 
our large-cohort prognostic study (chapter 4). Therefore, our findings of an 
absence of any substantial effect of TPOAb on the prognosis of non-metastatic BC 
cannot exclude the presence of a TPOAb protective effect on patients affected 
with metastatic BC, as described by other authors (184).    
5.3 Future directions 
First, it is important to state what I would do differently if I had to start my 
PhD again. During this time I learned the importance of a proper study design in 
order to deliver good quality science and research projects. Therefore, I would 
initially spend more time studying the literature related to my research project, 
delaying the start of laboratory experiments. In fact having a better knowledge of 
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laboratory techniques and work already performed by different research groups 
would definitively save time in experimental optimizations and the identification 
of specific targets and goals. For example, if I had known before that phenol red 
exerts an oestrogenic stimulatory activity on MCF-7 cells, in chapter 3 I would 
have used a different cell culture medium for BC cells experiments and I may have 
obtained more defined conclusions about hormonal regulation of TPO gene 
expression. Similarly, I should have used charcoal stripped foetal calf serum, in 
order to avoid the presence of any hormones that could interfere with my in vitro 
assays.  
Second, the results of the present thesis open multiple possibilities of future 
studies, as detailed below. 
5.3.1 Functional and immunological characterization of breast cancer-
specific TPO isoforms 
First, in order to identify potential tissue specific TPO isoforms, a higher 
number of ex vivo human tissues should be tested with LongRange RT-PCR 
investigating the whole length of TPO mRNA. The following tissues (fresh frozen) 
should be included: thyroid tissue as positive control, BC, normal breast (from 
reductive mammoplasty), adipose tissue from different depots, other cancers 
(from kidney, pancreas, and also different sites) and relative normal tissues 
obtained from benign diseases affecting the same organs. Regarding BC, not only 
different histological types should be investigated but, even more importantly, 
different molecular types. In fact, as previously explained in paragraph 1.3.3.2, 
the clinical behavior of BC is more determined by molecular parameters, e.g. the 
expression of human epidermal growth factor receptor type 2 (HER2) and 
oestrogen receptor (ER) or progesterone receptor (PR). Similarly, it could be 
possible that TPO gene and different isoforms expression in BC is regulated and 
dependent on similar molecular factors. Different forward (F) and reverse (R) TPO 
primers in addition to F in exon 2 and R in exon 17 could also be used, in order to 
investigate for the presence of alternative START and STOP codons in TPO gene 
and therefore to identify TPO isoforms eventually missing exon 2 and/or 17.  
Moreover, the mRNA sequence of all TPO isoforms could be better investigated 
with more recent high throughput techniques for the analysis of transcriptomics: 
RNA-Seq (367, 368). 
Secondly, the corresponding protein should be investigated for the most 
promising potentially tissue-specific TPO isoforms identified. To this purpose the 
development of TPO-isoform specific antibodies would be recommended. For 
example the peptide of the TPO isoform apparently more abundant in breast and 
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adipose tissues, missing amino acids encoded by exons 14 and 16 (paragraph 
3.4.2.2), could be generated by chemical synthesis (e.g. creating a peptide 
composed of sequential amino acids encoded by exons 13, 15 and 17). This 
peptide could then be used to generate a TPO antibody directed towards this 
specific TPO isoform, whose presence in human ex vivo tissues would be screened 
using WB in denaturing (loss of hydrogen and hydrophobic bonds) and reducing 
(loss of disulfide bonds) conditions. This would be essential in order to ensure that 
the peptide does not fold in tertiary structures potentially hiding the linear 
epitope recognized by the newly synthesized antibody. Using this technique, it 
could be possible to test several ex vivo human tissues for the expression of 
specific TPO isoforms that could be then verified by protein sequencing.   
Considering that WB requires homogenized tissues and therefore it is impossible to 
distinguish between different tissue compartments (e.g. breast contains both 
breast cells and adipocytes), additional techniques such as immunohistochemistry 
(IHC) should be used, in order to exactly localize TPO expression within the tissue. 
Different antibodies may be needed for this technique, since with IHC TPO protein 
would be present preserving its tertiary and quaternary structure and therefore 
potentially hiding linear epitopes, while exposing conformational epitopes.   
Similarly, different antibodies and different techniques from WB should be 
applied in order to investigate for the immunogenic properties of tissue-specific 
TPO isoforms, since they may also involve conformational epitopes. In fact TPO 
denaturation and reduction conditions typical of WB cause a considerable 
modification of the antigenic structure of TPO, with loss of many conformational 
epitopes; in the study of Ruf et al. 13 monoclonal TPO antibodies recognized 
native TPO, but only 5/13 (38.5%) recognized also denatured and/or reduced TPO 
(290). Specific monoclonal TPO antibody directed towards conformational 
epitopes of TPO isoforms could be produced by genetic immunization, as 
previously described by Costagliola et al. (369). Briefly, a plasmid DNA harboring 
one TPO isoform cDNA would be inoculated in the anterior tibialis muscle of mice; 
as a consequence, some mouse cells would internalize the plasmid DNA and 
express the TPO isoform and corresponding protein, leading to immunization and 
production of TPO isoform-specific antibodies, subsequently identified and 
purified. Considering that TPO is a transmembrane protein, TPO expression by 
mouse cells is essential in order to maintain the original conformation that would 
likely be lost if immunizing mice directly with the recombinant TPO isoforms 
produced in bacteria, since cell membrane-free. Antibodies produced with this 
technique could then be used in IHC to localize TPO isoforms expression within the 
examined tissues. 
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In order to test the functional and immunogenic properties of these TPO 
isoforms, in vitro assays could be used. CHO cells should be transfected with  
expression vectors like pcDNA3 containing the gene of a specific TPO isoform, so 
that the correspondent protein would be expressed by CHO cells, as performed in 
this study with NIS (chapter 2). The presence of circulating human TPOAb specific 
for these isoforms in the blood of individuals with TA and/or BC, compared with 
healthy controls, could be tested by flow cytometry, as performed in chapter 2 
when searching for autoantibodies to NIS. Considering the presence of aspecific 
human immunoglobulins binding to antigens expressed on CHO cells surface 
(chapter 2, paragraph 2.4.2), it is likely to obtain the same limitation when 
investigating for TPOAb. In order to reduce this aspecific binding, it would be 
advisable to perform the pre-adsorption of human sera with a higher number of 
CHO cells compared to what was done in the present thesis (each 2µl of serum 
wee adsorbed approximately with 9x104 cells: see paragraph 2.2.2.4). In a careful 
analysis of related literature, other authors suggested and performed a 10 times 
higher ratio of pre-adsorption of human sera for flow cytometry experiments in 
order to reduce the aspecific signal: each 2µl of serum were adsorbed 
approximately with 6x105 cells (230). This is an additional example of the 
importance of carefully checking the related literature during the study design 
and before performing the laboratory experiments. If I had to start again my PhD, 
I would perform differently the pre-adsorption step in flow cytometry experiments 
of chapter 2, according to these indications. 
Regarding the functional activity of TPO isoforms, it is likely to be preserved if 
they contain the amino acidic sequence 239-494 AA (encoded by exons 7-8-9), 
corresponding to the catalytic site (247), as previously explained in chapter 3, 
paragraph 3.1.1. In order to test it, specific enzymatic assays based on guaiacol 
oxidation should be performed, as previously described (370).  
If the presence of tissue-specific TPO isoforms should be confirmed, they could 
be used as diagnostic biomarkers and validated in longer prospective studies, as 
later proposed.  
5.3.2 Prospective study 
The results of chapter 4 indicated that TPOAb measured by standard assays 
and thyroid function do not seem to affect the prognosis of BC. However, this 
study has 2 main limitations: the lack of clinical history of thyroid diseases and 
the blood collection performed during or after adjuvant treatments for BC at 
different time-points, that could have affected TPOAb, FT4 and TSH values, even 
if major confounding is unlikely. For this reason, I would like to start a new large-
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scale prospective study enrolling patients newly diagnosed with BC, in order to 
assess baseline parameters in a homogeneous and correct manner. 
v Aims:  
Ø To correlate the expression of TPO isoforms in BC tissue with circulating 
isoform-specific TPOAb. 
Ø To investigate a hypothetical prognostic role of: 1) TPO isoforms expressed 
by tumoural tissue 2) TPOAb measured by standard assays collected before 
any treatment 3) isoform-specific TPOAb if present 4) thyroid function 5) 
thyroid volume. 
Ø To prospectively evaluate the impact of BC treatments on thyroid function 
and autoimmunity. This would represent one of the first principal studies 
in this field. 
v Inclusion criteria: considering that the high BC survival as a consequence of 
highly effective BC treatments could hide a minor positive prognostic role of 
TPOAb, I would include in the study patients affected with BC not suitable for 
usual treatments, e.g. chemotherapy because elderly or having medical 
contraindications, or target therapy because triple negative BC. 
v Materials: 
Ø Accurate clinical history including thyroid diseases, thyroid medications 
and use of drugs potentially affecting thyroid function (e.g. amiodarone), 
familiarity for BC and thyroid diseases.  
Ø Blood for serum extraction collected before any treatment, including 
breast surgery, in order to avoid any treatment-related possible bias. Blood 
would be subsequently collected every year until the end of follow-up 
(initially 5 years, pre-planning a more mature analysis): this would allow to 
document eventual effects of treatments on thyroid function and 
autoimmunity.   
Ø Fresh tissues collected during breast surgery, immediately snap frozen in 
liquid nitrogen and stored at -80 °C. 
v Methods: 
Ø mRNA expression of TPO isoforms: RNA extraction from tissues, LongRange 
RT-PCR, gene sequencing, RNA-seq analysis 
Ø Protein expression of TPO isoforms: protein extraction from tissues and 
analysis with WB using isoform-specific monoclonal TPOAb and protein 
sequencing for confirmation 
Ø Serum would be tested for autoantibodies recognizing specific TPO 
isoforms by flow cytometry using CHO cells transfected with different TPO 
isoforms. 
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Ø The same statistical analyses performed in chapter 4 would be applied in 
order to assess the prognostic impact of: 1) TPO isoforms (mRNA and/or 
protein) expressed in tumoural tissue; 2) circulating TPOAb (both measured 
by standard assays detecting full-length TPO and specific for TPO isoforms, 
when present); 3) thyroid function (FT4 and TSH); 4) additional parameters 
of TA with a suggested role on BC prognosis, such as the thyroid volume 
(182), measured for each patient by ultrasound examination. 
5.3.3 In vitro studies investigating the regulation of TPO expression in 
breast cancer cell lines 
Finally, in vitro assays investigating the regulation of TPO expression in BC 
cell lines (MCF-7, T-47D and MDAMB-231) should be repeated with the following 
modifications: 1) using phenol red-free culture medium and charcoal stripped 
foetal calf serum in order to eliminate uncontrolled hormonal interferences 2) 
trying different concentrations of estradiol and Insulin-like growth factor type II 
(IGF-II). Furthermore, considering that TPO is expressed also in adipose tissue and 
that adipocytes within mammary gland carcinomas seem to be dynamic cells that 
may contribute to human BC progression (274), accurate studies of adipokines 
should be performed in order to add the most important ones to the cell culture 
medium.  
5.4 Summary conclusions 
In the present thesis, a shared immune response between thyroid and breast 
cancer (BC) tissues has been hypothesized, in order to explain the association 
between thyroid autoimmunity (TA) and BC, summarized in chapter 1. Considering 
that the sodium iodide symporter (NIS) is expressed by both thyroid and BC 
tissues, the presence of circulating autoantibodies to NIS has been investigated 
among patients affected with TA and/or BC, with negative results (Chapter 2). 
Therefore, considering that thyroid peroxidase (TPO) is one of the major antigens 
involved in TA and that autoantibodies to TPO (TPOAb) are more prevalent among 
patients affected with BC compared with healthy controls, the presence of TPO 
expression has been investigated in BC tissue, obtaining positive results, even if 
expressed at a much lower level compared with thyroid tissue. TPO expression has 
been found also in different examined tissues, e.g. adipose tissues or other 
cancers and, more importantly, the results of the present study suggest the 
possibility that different TPO isoforms obtained by alternative splicing of TPO 
gene may be tissue-specific and therefore potentially used as biomarkers for BC 
(Chapter 3). Despite the presence of circulating TPOAb being previously suggested 
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as a positive prognostic factor for BC in small-scale studies, the results of the 
present retrospective study obtained in a large patients cohort with an extensive 
follow-up showed no apparent evidence for a significant prognostic role for BC of 
TPOAb measured by standard assays, as well as of thyroid function (Chapter 4). 
Future studies should further investigate TPO isoforms expression in BC tissue and 
their potential as biomarkers, as well as searching for different TPO isoforms-
specific TPOAb, not detectable by standard assays. A prospective study should 
validate the findings of the present retrospective study and also investigate 
whether these alternative TPO isoforms-specific TPOAb, differently from TPOAb 
recognizing full-length TPO, could have a prognostic role for BC. 
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